var title_f34_13_35024="Cumulative risk of death Turner syndrome";
var content_f34_13_35024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Cumulative risk of death from all causes and from circulatory disease observed in the cohort of patients with Turner syndrome and risk expected based on general population rates for females",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 401px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schoemaker MJ, Swerdlow AJ, Higgins CD, et al. Mortality in women with Turner syndrome in Great Britain: A national cohort study. J Clin Endocrinol Metab 2008; 93:4735. file://jcem.endojournals.org/. Copyright &copy; 2008 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35024=[""].join("\n");
var outline_f34_13_35024=null;
var title_f34_13_35025="Extramed hematopoiesis";
var content_f34_13_35025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extramedullary hematopoiesis (paraspinal masses) on CT scan in thalassemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an axial contrast-enhanced CT scan through the level of the chest in a 23-year-old thalassemic woman, showing uniformly enhancing paraspinal hematopoietic masses with no bony erosion (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Georgiades CS, Neyman EG, Francis IR, et al. Typical and atypical presentations of extramedullary hemopoiesis. AJR Am J Roentgenol 2002; 179:1239. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35025=[""].join("\n");
var outline_f34_13_35025=null;
var title_f34_13_35026="Iliac aneurysm repair with iliac branched endograft";
var content_f34_13_35026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Iliac aneurysm repair with iliac branched endograft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKK2PDHhzVPE+oiy0a0e4l6seixj1ZjwB/PtmgDHr07wD8Hta8SpFeagf7L01m6zIfOkXrlEI6HsT9ea9f+HXwk0rwu8d9eEanquAVkkT93A3fYvrn+I88DGOa9SiT5cN1J5PpQBgeD/BegeD4EGkWEUcrcNcON0reuXPOPYYHtXfWt2UiG44wM1ismSi4xjkCtFQGhABx6EUAdCmoQMoR0wfUVFLp9lqAIlTDfwmsZbghCcA+pp8FyYwGRgSDzQBmapokllOwid9oOQD6VTWeSAKJA3txXXw6h5rKswVkzgk9hVq+0aGeIsMKRyO4oA40TbsdhjPNOEKyMSDV7VNFktIlmweeuOn0rJGFGBkknpQBKwJ3KASSaSOcbgGA3DtikMmcZIyO9Q52vu7N14oAvxysHkHOCARSPcKp3MTknris6ad0KsjZCnBBPFRSyLK4GQCfXtQBJfBZA2FBU81yt9Bt2y7htXtjNdTYo7uw64HX61l6umIsDCnqQT1oAzdLaOaVR0wOvetWeHZF8h3egPU/jWFbjy5PNYjr24xT7vU2UAwpkDqT2HrQBZlXzDkABsZqqrnYRt+YE1Skvpml3SZ2HOeMVJZtJvBzujB57570AbDyHLEKMyANyPbn+VXNIuAzsHOcdM9QKzN4xHINxJJX8P8AJqe2YK33cEAEE9x3oA6uMeany9OnFRxyEyCHbls5OPSk024UtgZGRx3xVl2zdMVUfKuc0AOkh3n5hknsODUsEQVSwGeMZxUiTEoDtyTSJIc4IPIzQBHMMuu0ngY/WqUsKsGH8VXbpljXeev86zo3OSzMS5OQPSgC3YxhIyR/EOfSnZJIzjn8aYzeXDgE7j1IpmW4wpbHQ9KAFYYc9cA1ieJfDOjeJ7c22t6fBdoOFZhh0/3WHI/A1tHnPYg80kajPbjn1oA+ZPiH8DdU0hrm+8MFtR09fnFtgm4QZ6AAfPj2wfavGnVo3ZHUq6nBUjBB9K/QfJ+XuMelee/ET4Y6J40/fTD7FqYPF7AoLMMH5XXow6e/AwcZBAPjiiuo8deBtb8F3wh1e2P2eQkQXUfMUo9j2P8AsnB/DmuXoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACinIjSOqIpZ2OAoGST6V9BfCL4LB1g1jxlbblZQ8OnShlIOeDKP8A2U/j6UAcR8M/hRqPitVvtT86w0ggMkm0b5/9wHoP9ogj0zX0l4d0HTfD+npZ6RaJawBvuL1J9Sx5Y+5JrpoLOOFAkUaLEBtVUGAAOmKbPGoICrnoelAFWPcxPYeh4q3GM53HPPSozuLYYc9RkYq7a24ZwMcetAELR7Sm75ferEk6xI4fAB7D+dW7m2O0HZwOnOazLziIq2RjoT2oAccNCHi555wetZpnKyDySQWPepC7pAVQkoOTg1nRfvpsxMRhs5oA0F1GRRtI+c+h4rSh8RTWcIWT5lA+oFZzRxW4DSDcx67e1c3rmpKshijzswQTxxQB0viHx2hsGthgtkHI7Y5qrpGoDU7V3GAQcHb2x2rzmHTp9RnPlZ38Ag88V3fh7Tjp1iYAWyTuJHOaANfbuCnOT0ppiypRT17gZpwVhgEHb7LSlWDDDE8cA8UAV2jZgoYgH2oa1DICycg49yauRyLsUNgeuKQzbQVUBh1GaAFslWMPk7Qea53XnTcVzvBz82a3vOQbRx0P0rk9URplbY+SM8eooA524umWWUHAUDGaTTLjzHVC/DDHP8qrXscihi6Nk4Xgdafp6Bdp28DnAOO9AG/JBbpBiTBcD9PSqsMixzbYeUIyfc0y/uRsbbkgrnisNrpopD1GePlPt60AdwGBtJDuBVGD/wBDVBrvEiID1zgntWXpmoyB/KkcOjErzzkEcfrWR9rk+1KpDDJxj07UAehaZcMzg7jvTjg9q6qwUTwSvn5t2Md6890ySWB1+YnHr+td7oTCeGZo3znDZ/pQBfjVHXHIUU1sREZ4UdzUsaDdluM9vXvVHU7pEhZv4h270AUryUs5OTjr14psWSAeuKol5JFwBjPJq/AreVgHnuP60AWduXAPWn7SSORyMVGQccFsj2qVdoUdeKADYCc5/KnKu35uc1EH+flePX0p8jY+6e3agBXclun/ANakhhAOWA5PekUZ2hjzmpJGO30PYUAUtXsLLVtPmsNRtorm0lG145VyCP8AH36ivmv4r/Be40QTap4USa707czSWmN0luv+yc5dR07sB1zya+m8Ha2BQF3D5vxNAH59UV9PfFn4N2uspLqnhaKK01MbpJrcZCXJx/COitx24Oeeea+Z7u2nsrmW2vIJbe4ibbJFKhRkPoQeQaAIaKKKACiiigAooooAKKKKACiiigAqW3gluZ0ht4nlmkO1I41LMx9AB1NNijeaVI4kZ5HIVUUZLE9AB3NfYHwQ+E8XguEanrKLLr0ybSwO5bZTjKr2z6t+A4JyAZfwX+DEWgx2us+IVSXXMiSKHJ22uRwD6uO56A9M9T7ULfydwcjI7iluJREMZB9zUbXSPb/MxBxnJFADd6KDgL68Gsxm8ycshwTxioDNKzsFfKqcg9DUMNx5pwU5J5C9jQBrWcbSNxjAP1q6GELgBeM84HNVLJwBjGOeualupjCww48w8dOooAtXWpqgAz8rcbcVzup3gWUx/wCsA5JHUVau0ZoNwOH7YPJrBnjkDmV2YMeCePmoAnjvjyqjKjpzxTY5EV2eM89eD3p1taK2FY+nA61ZbTMPuUnBHPNAGXqF3JOAikggZ6kDNYDWE13I2Tkj8ePSuvTSXJCgHaDyQa0ILFfJ2AYcHOfXmgDO8OaZFGUUemWz14rZJhhOByc+tXvs8SQgwD95jnnpWPqCASdcnGT7UAWpLqMxN5YAO7mqzSF8EdW49aLe2B2hmyvcZq3MkcSbdvy9fegCoYjgkrgjnGac8Weuc9ie1TxPGV2dDj9KeJ1YFY+w6+hoApeT9xgjD361zuqWW2aQopWT0PQ11EjyI/AD+xFZGuXAhucuCXZcbT2NAHHakWt4FMiggthhj/PNZKzqIwIsrngD2zW7qstvcXIi5AA+Y9zxWFJpxac/PgDpzigBzGRuoBXgdaqSRlXGRxnP0rRTT5oWIDEkjnPenS25VhuwO+CP1oAzpvkO4ZBUhh6+1SXluHvQwyASH/A80kgKBx15wP8A61XNxe2s5V2lmUxH6jmgDTVgLbIJU4zgGuo8ITutxsV8IwOfyrk4oZmhAVS25Q6hecg9eK2PCtwDdWzIMo+QT+nSgDuJFwSQ7HA5zWbNalzueQH+v4Vbkl3IxOV6iqkkuVwvHGOaAGxW4XJ7irSIpB5GR3quGYxDOQPXNTBwc54OKAJQ2FYAdueKRQTkHP58VGjbj8wOR057VYjG1Rn86AGtHtUDnJHSl2AMBzUpfJG4AnAxQPmYepNAEJBDZznBp0jA/KDjnPFTLFxlhzUTptI5oAgKlyTnjB7VIowgyOKf91Scc0xcMAF4NAEbAl+mBXnfxT+Fll43glvLQpa66qBY7hs7JAP4XA7dsgZHv0r0zysglvTg1IrAKB3z+lAH596rp15pOoT2OpW0ltdwsUkikGCCP5j3HBqnX2h8Wfh9ZeO9MHCwavbKfs1zz36o2Oqn9O2MnPx3q+nXWkapdaffxGK7tpGikQ84YHHB7j0PegCnRRRQAUUUUAFFFFABTkVpHVEUs7HAUDJJ9KbXv/7P3w8jIj8S69Ap3EfYIpFDDH/PU/yGfTPpQB1vwI+F8XhdI9c8R2//ABPHH7iJiGFqp7+zn17Dj1r2SW+UO+WwR0yetFtulg6g7Ov0rPlVGnfe2PT0NAD7qXDiVh8p96huJBJGuMqh68VFNtETeaeMcD2qozoYhEjMcdDQA62b/S5FJPrjircMgeYwqQpYdxzWTHGwud5O58d+1biCN5IpJQBkFfpQBIkjqAvy5HB7fjVa7f8A0gGR8nHGO1Puo4iwZXcHpmqgL5w2SOm7GaAJI2LsGOcr933pssSTjzZWbaeuRgCrkZwFOAy9+OlV9QeNlMJwM8596AG2qOjf6wnHQ5rUg/elV3Lk9qx7RmBAUHGQDjnNaVqUadTuI2n1oAvTwmDg7cfXAqLcQu1VQg9xUGsXf7vJyxHUUulid7bzHG1cbhnrigAa4dBIAU+aqol2u4m27gMZ65pl2Qzugzk/yp1tblo2d0B2nbkigCSzmkbzDGoEfrSX7yzQnaACOp61cWBY4wThBjn0IqvPcrtKBCy4HI70ARwDfa4YEuD69DTUVyVh3YHf6UsDhXKRjrStEyTtKwY4ONpoAmgYrIF5PHU9657xWWU7yjE49OuP85rpWfcFx8mAcg8GsDXMyIUYggj1oA86vJSZNjAg8HcDzzzS2gdWWQSMxVuh70upKY72aCZMdCCO1JavHIMA4ZAcmgDTk1KIJmRiD+VZd/rsazKkYDvj8PrWZr4Cp5gf5DxxxyK5yETXTExuqzFSVBHX2oA7OSeSVCzNGWRcsijnHrUlvdBrGQLtPlOJhjrgdf0rnoRKYo3BYSRYDL3xWppy772KVcBZf3UiDgAkdfpQBu6fJK8c32aXM9mftMILHDqOSv4qf0rft50fXLd7dfKiuf8ASAOoBI+YD8cH8a5DSd9iILwg74H8t09QOxH4kV1+hWyW5uo1O8WRW4tcjlraTr/3ySR+FAHVyyK8RGTwc49aqTEb+N1TjjLcc8+1QtEXfK/dIoAljII75qT7qjoabtdSG5wODzUqK2ASR1oAai4O3oemfWp1l2HqSAKgZm3/AC4PH1p6x5LHI/xoAc8hZsEY9e9OSY5H5Cmlu3JJxnjpQyksMg4zzQBdSVWGMZzTZQOSOR71BIrKc9+oxUfmEtg849aAJGAJwB+VSINkecDNJE2WBIGAaklyQWHAPYUAQSuSPQnj1pkbcEHrjPNOOd2AAD196RVIJBxhuhoAR0LgEkjPpXm3xg+Gtv40037VZJHDrtshEMmQomA/gc459j2J9M16VjJ4PPeglQc9x3oA/P8A1CyudOvp7O+heC6gcxyRuMFWHUGq9fUfx4+HKa/psmuaJAv9sWw3TRoADcx9/T5lHPuBjrivlygAooooAKKK2fCHh+68UeIbPSbLIknfDSbSwjT+JjjsBQB1/wAGvAh8U6ub7UI/+JPZMDIGB/fN2Qe3c+3Hfj6x0+OOK0VVCoFGABwAOwA9KzNE0Sy8N+H7bS9LjC2tum3OBuc92bAGWPUmrtnMUVfl+XoeKAN3TnXLvLwQO3cVlaqyiUoWwjcirQmBl+QBTjBx/OqN+rrOhYbx2Pt6UAQ3XmNGiEH2J6EUyCJEcA5DMeRjtVkXMhYoy9+vcUI20kkZbtg0ARiNVfjkHpVqVtqqvYcYFQvOwRiFZivTio2drhApIVgOlADZXlSJ1B3HOVNSWjhoR53yt1xUEQOxgeMc47fnSKV9DuyB9aALrzMgKxkFT+lVXYu53ZJwOMUz5wzAKSQe9XYIQCJMLk5Bz2oAS3hMKlieD2qQxgfMcDPOc0924VSvQ9+lNddyrsx/SgCMyDzNjDjP8QzWtJKkdvG7NlFHIrLQbo8sPnH86tvFHPadlx74/CgCjHdR3J2RxqvzcMTV+JmhGxy5U9PSqNhCkc3zkcHj2q9csqKDyB69qAI7md2jMYyy44z1rMjuCFIHKH+LHI9qnlvW2nG1cdT1IqkJAZDtwSRjjvQBt2wh+TH3sYwPWpbiIiMuWOT0XNUtOtgsm4PhyM596iv7gQAveSrsBzknFAFxEaTaS29R68VieIZEwI+hVck45qnL4nXzm+xJLcNjC7RgCsa5s9U1KcS3V4kCE/cU5OKAM3XDFtS5eSPI9T1FcfN4ks/+EktNGjtbu4u7zHleTHkZOcAdzyPSvRItB0+FlEqNO3q/TNcZ8SpToM3hrXbeNIm0zUI2YxjBKhg2PxAIoAkvtF1KaeW0a0nhePgpMCpU4p1v4Uuodsty6xrt5CHkGvYviNpjz6/BewFhDdW6tuUdSOP5FayINBkO12bbER3Gc0AcrH4R/tC3WDTNXTTr0rmKe7j8yNmHRXPYHkZ96z7DR7uAv9pEHnr/AKzyG3R716hSeoPOK9MtdLjRAsigLnHHT8qq6jpotZChRfJflSvTFAHMXVgn26V4xlZkWQn++p7/AFBFaejXEcAtJ5IwZrYtBJj+KBzyD9GOfxpLxPJghV8kRsUV17BhkH6ZBFVI5/st6GVd0cnIB7/3lNAHWWwZVMJPMbbRn07VPu2gcHPas/TpPOj4wHjzEy56r95WA79SK00jCoOfmoAiCkuM425qw2NmFbJ68VGXAI9hg80sWApPfvzQARKxzgj6VJtxuySO+aXPXB69MimFCUCk/MeTQAqL85IycdPepYU3HBz9PWiMrFgkZx1pzkKA4AxQAS4C7mJxUEQ3FvrTJHLyE4PAxipUwB82fQ0AO+6xCHnrU6MHXnG4dvSqwyCfc4p5bABxg+tACmP5s/pTWyDz+fSpxhlJx8xokG0cEGgCoMLnGcnmnMeOD7nFOeN9q7c+1N8pnYAqcHtQBE2OPX+VfMvx/wDh2ukXj+I9Gj26fcv/AKTAo/1Uh/jXA4VvTsc9jgfUKwhCc7fYVV1GwttRsprW9gSe1nXZJE65VlPYigD8/wCiuu+J/g6XwV4pm08NJLZOPNtZnHLxnsTjBYdDj64GcVyNABX1b8DvBZ8KeHvtmoKP7T1ELI4A/wBVHj5Uz3Pc+5x2yfIPgR4PXxH4mN9fwh9L0/Dvu6PIfur79CT+HqK+qZFBjIXoOmKAHXGPK4zUFsu5ckH6U/erQle5HU0+w27Vx29qAJlDuhOce3pTJmDxFJT8wOOB2qaVcAkDAwDVGYEMc9DyPagCS45gDRhSFHI71BbDEoL9CODmozlDvLHjt2NLHJ5jMjNt46UAWgflbY5BzgKx4NI1tIrqsi7Wb0Iqv5L+XvRsj3qx9rLW/wC8GdnPzDPFADlUou0sNreg/nUE8YWQlSME9/WpEmjm2hM7OvNOba7quMnoCe1AD4VDqGPGf0NXQgEWQcAVXQjGxgQBkEj1oBJASRuPSgCeIZDbgR7VEgVg5bhumBxmktWKyHaSRjAz2qOWQpKDwFJwcdKAFjZVOzcevBNTKDkgng89arEnz8grg84Ix+VT7QV5GCOooAqssseWQjtwRmo7yaSZBGODng1cDYiyxAO7AqpczRqQdqgerUAQNGykF15z1Ap3mQQYkdlQAcn0rJ1XWIY1MUDHcesZOSfpWRBHNqMwSTIRQCQDwo96ANfUNa3S4sNzsepHAFVf7OkuI0n1SVnXso/+tVy2gjjysUYDDuDV5Y1FuWn/AHYHGKAM2PZbjy4ECKRge/tUsdtLcONy/uwOc8Uya9CoRbRBf9tlzT7RpzIolOVfn/8AV+dAE14ltbMolk8zHOE9aLS9s0gDQ20ckh6GUZ5Hek1Gzmmi2RxkH+9jHFGhWRAUSgnHcc4NAHVyavd6jbIl6Ubb90KmMcYojjYJzwAMYHpioVtP3RflWH4VOGZoQ54boee1AFWXIlwfTBOcUsW24ja3nz5bH5HHJjbHDD19xUc21yNrbuxzTmYiNtjeWV5OAO3agDD1e0nitbm2njjSYIWURklSyjcCvsRn6GudgeGZEW5z9nlQMxU/MpyeQfauj1y/SO5dwA6wnzBg8gA8j8ia4m7uFtbmSAHKRyMFH+w3zLQB02mTqLh4Zy5ntvkcrweOQR9Rg108UwuIyVJJRircdxXDvPIY7bVUAKwhbe5PQlSfkf3wcgn6V1FhcuzA4+XPlMR6Y+Q/0oA0o87egPH0xTRhSGJ+bvTlB7cdvr3oaQKOgO6gCe0YybjxnHWnsTnpg9M1HE5SLAHJximSyMqk456UAOll2MFzweaZkZ2k5GePpVVWaTO/O7tSxxNvDOx6cUAXECk/OOp4qbAzgEg/So1HAJzgDpUnnqzrEFwcZoAdGN5JyODinBO5zjtik3hV7c0nOCWOAPxoAccIvPU5p8ZDEsarySKIqiVzIvyttz60AaD3EKrhcZFVpZmZ8qcdqrKu1sSZf0qcqFGSOKAGbiCd2fan+YOg6+lRFlDEH8OKiebso5PTFAHKfFfwYnjXwtNYIyx6hE3m2kjDIEg/hPsw4z2znnGD8X3VvLaXU1vcoY54XMciHqrA4I/Ov0I0uCea4GYmKjqccV87ftU+AP7LvbfxTptsEtbpvJvdv8Mp5VyPRgCM+oHqKAPT/APhmLwp4Ws9LiIMqL5kzcfNI33j/T6AV0EUhK4IwankwDwcgjvVeRGB2r1oAkkhBQEZzg9O9VbCUpIyk8g96mDyqmO3Tp0qjc747kP6nOMUAdChV4QD97FQXMPG6P73Wo4JCyg5981K0/ucfzoAqSRtlQRn8KjVfnIK8AYDHrWnEyOMEDLfpTHgXGVyaAKMe5LccE7SeD3p9uUkP7w4I/hxUsoZU4BPbNQpblJjhsHsR0oAljtkjJCkAdqtJb5XJ71EqZUADnrnFTtIQq85wKAGtAygbQWXnPtUTjPXGcVKZjjHOcdc0xpMLkY57gUALAcKT0JPeoZz5jqrevpUkZTcBJzntUwCNuUDOOOlAFdYiuAvTGMYzmpkwg6dutSkoqg8nnmoTLlW568dOlAFS5Yq4Yn5W5zXOajPvm8uEF5DkbWHStDWr1i4giYM45JH8NU7O03zFEJ80jLue1AFTTtJLysWYM45aQjIX6Vqi3REMcKgRqeX9fqavr5NraYHypjP+8fasK6lnuX8pdyQjoo/mfWgC6JyBixUO+QDKRxViKxeXcZnbzjn6CnadbtHbREgZ6k1dW5JzhDuPGT2oApHT/LcOFHT8604LAJGJVG7HQDtVdpSNvOSRkj0qyl5JD+7UgdwDzQBPI6iyxJ9/JHFUtLiNvMSq5VzzVxCZJH+0LwfSp0MCEquN2MjngUASy3ARNr/AHsdKz5pgwAPBA5xS3NwjN/td+az5ctyGPPHFAEqSrls5Ck0GdDBPlstsaqiKxbdjAz39abLbtKjnBBYHjPU/wCcUAcvrt2jalJCMYkQKMd8riuZ1SZZbS1vR97b5MmPVW4z+Bq/rcLrfRyKzEhFznrkZrLhiN1bX0EagLIvnKoPKuOoFAHR6JMktoI5SFt5VaCX2B5B/A1vaBKw22s7D5x5JYdj1U/mK4/Rwy2Ug+8GAI9iO1a+nXLM6vtJdGVhtPUZ6/hQB30LM6JkYk6MPQg1fiij4coT9BmrWjaWJZxMozFIgfPoeM/mMGukhtbZVwwCnqOelAHNxIGbmNsdMlaq6iixZTGAe5GK6eee3UbSpXvnGKy724tLmM7sZBxz3oA52GMeaR94jNWyuASRjParv2CNctCcHHNZ8jMxKuNpBoAeW2gDFMCgYI4brz2pS21OR1pofPUd+eaAFkGSOeMcZpG3KNqcgcHNSxrkc0ShVPyj68UAQ9c7s9Oc0qKwbgcA4ApWJ24OM4xTGbnAb5jQAsrYPOBn8MVZSKabbgfKfWrmm6SzkSXWD3we1a6yRI+2NQQO9AGTb+HpLjBkkb1wBWxZ6Jb27jdtDHucVNLqBihzuIJ6c/pVS0mkvLgru6DJoA37eO3iAWLb+FYXj7RbHxH4X1HSb9cwXMLRNgdM9CPcEAj6VtWUPlj5hzVfWmCWzAYBIPWgDzzb5ifu2B4BK9x+Hp70wj5ue9QYYMHhJVl5wDg/ge1WI7hJiVmASTOBIF2qc9Aw/gPv90+x4oADxxnj1qlqMbFFbaDxjOatzOsMrJLlCvBBBBz9KhuWV0AHI9qAI7Z8op745NWdwwvPTrVSP92dxzg8dasqNrKQQR1+lACqWyTzweOasJKcYbOOmajXrlT3pDyMNgn2oAe0oyFbkdqV9hYnByR1zVOYbyu1jgHoKmYjClSM560AWFk2Lj09BUe8q+CMZ/KkVmBODnPNKqkLyBjvg0AIGK9fXjrUbSNn5RvX1FSu3z4AOCOo5pgBXG4ZHXpQAwMowT1HQ5qKW8jTJL9ew71U1O4jjY7OnQ1im8LgmTkjjigDdbU0UN9/ae27rWfe6xII9kAIeT5Qv9TWZczBYt4I2dOD1pulwP8ANJP95uxPQelAE9qjxgksWkbqSep6VrR3UWnWpab7zYz/ALVQ2aKiPeSDbGnCA96x7t3vZiX4JJCj0oA1ZLk3c+ZTlCPlBPAFaVlaqy42DAyPWsXS7aZiEAUlTyT0roYt0G2MZO3kn+tAEyLtcr2AwfQVHDld27cCD1HenHPnF1b5mHPGKdC3zHepx29zQA54iFLM3HTg0m5FkUYxzgk09UYqeDu9KRYGZRu6Zzx2oA0UaNoc56j61mSHO4Kct7GnoTAMryOlVpjsIYMQCe9AERLbthJHuRyamkZUiDKPmU9PUUgJlI2qTjpzUZY/MBQA4Iz7mB4I70+PcsYIB4GT+dLCWUEFRtPB7GmszZZc7SVKgn6UAcJ4jQreFY2Dx/wn2ySK5zSotMSY31zdPHqVtOoiTDFJY2BDgjpkV6FfaWkhEkjKFC4IrzmfTL+e/lt9Js3vbkFpFiLbN6jk4J/lQBvxobe5eEHBSTgeo/8A1V0OiwJE4LqCvQg1iTOrxWd2VbzHi2lTwdy9QffH8q2NKvoC6oGJkkQOoPXpz+P+NAHpug3kq6fHHHkKq7cnuAeD+Rx+FT3l4QCj8j19awfDUsg/eb28tSFK54AJGf1xW3cRW7EszcAZ60AZdxdMcBD8ue5zTIImdt3RR2P86Ht90gMZOzPTuKv+agj8tlycA0AMhkMY3NxUV0A4Zhw/POOopzugRsntVCe5wQQdx6YoAarndyPu+9Krcllx/Oo+HbJJ25qRVVW4JA7igCxG5EZDdT1pigo5JyU570mACvr65qRkLpsXnPGKAGHMzERDnpWjYWSQP5sxztGfbNLBFHZxruHzYyR6VG87OQ2cgnOKANCa7aRMIdoBwMVEjFVLHrVUTAOE74zSmUEDnJ9KAFuZzwc5Hp6Vq+Gk+R5CPvnj2FYLYLdMnNddpyBIUC4GBQBsL90VzviC4yzAYwBitTUZWhsCRwTxXH3l0WUhsk4IoAw1G5d3fPPeiWIOFdTiQcqSMjHoR3B7jvSqMBiMY74680K+WBQ5IGDmgBliPtTLZ3IVSihYduQVI/gz3X+6eo6elMuYHjLqRh06D1puoKRD9piBMsIzsB+8O4rSu2juoYriBy6uBz6gqGB/EEUAc/FMJCUOM9K0YXLJ8x6Cs7UbUohkjX5/QDrSaVcOMJMAsnrQBqjIJ24CjrzRPjyxjqaCQSw7euaicgAKSBQBIFChF55Gc4qJsF0UAEjoSO1SlwWABxx07VDIdkqP1yMZoAn4Un8+KJXUlsZ/w71GArS5P3QODmpSC2c4oAjRtj4OCpOOeuararcGGHdxuPQk1a4IBBDe3rXMeJbvG5EO1cd6AKdzfDJ3tzxwSKz5Lg+ZwwBPUjpWdJMTKiMRggDPb8KYSChxwCMHvzQBrW7G4uVDZaKLngfxdq6CGA3EkcEf8WS+T0XvWZolp5dur7ugyxrq9NsmisGucgS3WQAeqp/9egDC1W5WWYRxqVtojtQAdTim2Fm08ik4yOQT6VsPp8YwAMtxwR1p8SCDlVG0fmaALdtbJGVWMBcj5sjg0+WZVVVVCT0Jp7F3CnaV3evalQqjESEHPU46UAN84dFGOvUdKlt5GUNuCkeoonCbEI+Y9OnFCRuVAYc44A6UASbizhozkY6jsaaH+XcDx6Gp4ZDb4RlDc96bNdQp1Qqp9R0oAYD5nKqDx6VC8JIYFCccEE5q9BPFInUcnjBqNpsPtjbp+tAGZGDGx4GecYqnJv8ANIUdDz7VtSMeGOGIGDTYVjDbhtyeee1AFNVZF+bI3c570vGAW5/pUt7KhXCqSSfwFUIyWjKk/Pzn360AR6hHG6I7seSYwfQ4yOPzrlxay2Fy95azSRS27Fg6noD6V1vkl4XRidygOo9x/wDWqnqUBjtnlcDYQAR6A8Z/MUAcdcXInsrmB3BnRhOhxnkfeH5UtlBI+lRXi7R9mlDY24JR/lJ498VyHiLU9Z0nxRZadoWlnUrqOM3UyLGzt5GduMA9+fzFd3oMMpkvbG+DQuN9sycgg9sj24oA6LS9R2xyRK2dyOOfUDP9K6KG4d1O5gRgYFcFoLl54FcYk3+W49G2up/lXUWU77EY4AZR29hQBuW0xbJyQBxzT2nDgueo5rOkdfJwsijPPXmo3nVUYKeAOaAJL26AyF6tx9arhgwyQcmqby+dIemanUgtg5z60AX7OXa4BP3u/pVqVeQM9ec1l5KuADitC1l3Ls6sT69qAHDPmkHPOOK1ba3MMQmbrnIzVCAlJhvAOT+daEzkJt5IxxQBHIPOkOeTzVeTEY24+b0oZzGQUbBNVy7STF5BzQAy5lCgSc5U8/SpIbhGTKMC/Q5ppkRkwxAwcHNRrpxuG3Q5TAyXPSgCdpRGoZsAAg5rpbbWbZI1aN8nH4Vw11DOjFJGDxDoxFU0uZYk+cbFB+Ukfy9aAPR31uO6IgDqc8txzWXrZjSMlVGe2Kw9DjSMlnLNK3JzWsWV4n39D0oAwP3incjE+2cEfQ9vp09qsRyJcYBAEvHQYyfQ+h/Q1G+AQRgZ6VE8W7DLy3TqeR6UATltoKkHjjGKTS226JHjJUIuPbEkyj/x0LTHujPbm3JT7WciN2POfR/cDkN0I9+toRCz0a2gP+sKAlT1AHT8ep/GgCnco5B25x1xis+/j+7Ip6kDHcVozDKHa2D1DYqIW7MoLMMfzoALS5EqANjcKWT52U8YBz+NZkwks5C2TtP3avWV3DIpJdVbvk0AXHQFMj7w/X6VE5y2w9W6ilWaGUsscqybfQ9KIB5kpY8DsDQAICoUY2ipiQVOeh60wtllyMenehwcEcAketAEUrhIXPQBTXE6iTM7EnPsT710+qy7LYgZGTg+9cpOf7xG38aAM6VcDEY3A9xxU+nwCW6TIJVTlgfamNtJwoP0rV8P2hI8w9GPf07UAbFpAJZUhZRtbqR2HUnNb0c/2gHy9uxeEGOgHFZUKlLed+d+fLU9/etezhMdsgGATyfb60ASLGW75z6U/wApEU/LmrFvsAySefbrVsrviOMbc9D1oAzxEWAz8pHI5qGSLYrsW3tjlR2rQMfOc4xzVZ1O5lY5Y8EHvQBVALIqgY53e9Sw3JVQccDg4pzKqfNng89elRiTcrfLuJ9aAJBdRSgk56YFRyNHKmxhnvwar+VuIVcgfyqU5I3bfmAA29OlABGUiZtuCO3tVacshLk/L7Hipo1y52jOOoPasHxfr91o0ul2+naLJq0uoSNHgS+UkOBklmwQPx9KALst1J96IFs/jUYNzIfnVifdaZbanErpb6layaXdkZWOdlaN8f3JR8rfTg+1a5fCNgDKmgCggcDa+RxwCOhqxaRYfc3QDBoWQOWLRnj9M1IZAAccZGeBQBNG6C6XcAR3HtVTVlgINqrN0aHJB9Qyn9ajkuCLgOo34GQPT3NVr+9aRBNG5Vs7WA9eef1H5UAc54LkT/hKNXW2kD3Wq+ILTSkkC4Zbe2TzpgPY4IP4Ua3eF9Xv9WtuY7y4lDexV8ow+q10uj6TpPhjw9eakNWtrzXZjc3NvGCN0c84CnI9hgfga5KOOSbR7633KJI0EsIQdSn3l/ECgCK0lm/taW4Qfu5LhJMdRknn+dXdOvby6ZFETbRlD6Ag1e0y2tBp0d3ECTIgO3HA961NKtvk8wfeZiT+JoAs2unSSW+ZJNr5wQtTNZBUKc4zzWpHb5hUqcHJ5xUbQMhILdB1x1oAy1tUUELk+lSJEAwPJq4Iir5PTHekkGCMemaAKF8WWMsvGOn06/0qzpc+ZlAB49+KpXzbYJMk7VHBFR6bIXMbA859aAOmMbsy4A4Oc0+6vdkZjH3gKqT3DR4OMbu2elMVWdmdxjOcfSgCePcyhiDzSo2SxxkH1pNwwqE4HqO1NldQhRMjjmgCZLTfKqjBDYLCtaZ0ithCowAepFZGnX8druiJAn7k9hWn9rt7m2b5Q0i9FHU0AVJI4mjMlwdsePzrLmg85xcOo8scRpjgVfmU3Dgy8KvAj7ClduAvVf5UAZSmSOTKkgdcjtWjDcb4xxyefaopVBDBeOeKqgsAVB4PA9qAGSMx4KnIYn1pY47hh8oGPU4X+ZpxOGye3FIilHGMbd1ACSWqwSGYPHNNGdwTnDn0Y8cewH41amn/ALRhNyEdCRu5PO0kjB91IKn6A96ryAM7t65NJokph1Oayk/1dwzbMdmaMt+pjoAaYwYyNwPelTgAY4HbFOZQrEYxjrzTMHuevQUAOuIkkj2SgnNc5qGntFkZyAeMV04wQo+Ye9ZutKwiDDAzxmgDL0iCSHc0jgEn5QK24iVT5Qc4zzVK1j3QJwxAP1rQXCcL93tQBHIWyrH7w7Cp/wDWRHIwR0psqKydeR+VIjhVUEhRnBJPWgDM1o/u0APbJxXKXpAcxljjHNdRrMgxmFxu28kYrlrkZ5JyR196AKsQJkVR0Py/Suus8RW+FHIHSue0+H/TEA6qckf1rprSAPNGpXlfmJFAGsINkEaFRhF5JHU96vWx4K+wNRZVxjJ2445oU+WRnOPc0AX0jDEsR1q4yARYJAJ5qnaukijDYHpmrUk6gbenrQBBM5UEcDis2eUhslgMVbuJF3jYc8Vm3jDynIXtxQBdjdHjwSCe/tTJFAkUZBJrFgvCHUnqMg8VpBQyiRTk4NAFhG2begbpxTkw4yARk81DDwg39BViNggyucdOT1oAiaMK74IyOKWFpoXzB95eQw6YpzMgY7eD7elM3naQh+U8AkUATzW1lqMAhmWK2c8PHIm+2l/3k/h+ornbnSNU0S4JtLbZaEHFpJMZIX9DDMeVP+y3H0roc7VUkgkDtRYX9xaGRItpjc/NE43Rt9RQBg6NqVrqUciQO0dxEP3ttMuyVPqD1HuMirF0RHGzk4TqQK3Jn0s2M7QaWkOoSYTzC24RjgnaTyBx0Fclqs5RccEZOAR+HFAFCWVjc7ixyRjB4IFVZLkDciM+R3zyfcVDG5F6iFsk9CT09KfLGRIqhGKYwRx2/wAmgCRlEy+XiQt1O0dc1HpyGzmBI2YfdtI5K9xWho1m0jqUm2jePMHqD0/WpL2J1uPMXarnOMDuOooAqQJLC91ZW8fmRWz7hg4PlN8wIHfHI/CujsNmyPy2DIecVTkuoy1hfCPBx9nmx/Ep5X+RH5VO8Y069VLYg2so8yLn7p7j+ooA6a2QvD8pB7cVHMjD5SOMd+1QWl/iH5SM5yTU4uBKjcgseMUAQvjB2DPoDVKYYIHTFaGwoo3Dn+VUr2ZUUscM2Og7UAYmqSDyli6tI3Sr2lWIRlkH3eox6+lVokE8vmOoJHQCtzTSsKFMcHmgAnXchyCB1GaVGAVhnjJAqSSRZiQuSuMdareQyrgNnvQAzdncMgEDr61qWFusFu00oyxHGe1Z9vCJbhUbPArYvSyxrGp+XAJoA5LXoWlmQ2wYTZ429+a19HdLZFwQZhw3ual+zoiNIR856nFZ1xGTIXjJB6NxQB002y8TevEg689az3XafeoNOudjIGOD0zWm0azqcAlvbvQBnMvPy559qh+6duPSr72sigYBB/lVG4LK2xxtb1xQBUOVPXp3ojbjLH3ocspKn+XNMV8gjGMHHtQBL2AwcE8HNRogOt2zbiCpSUk+itj+TEU4ybtu3k56VHpTGfVpeCFi8uMt26l2H4CMf99UATOhWWQluMnqetJGOScAEUkzqGZydoJ6mqNxexREbHLN6UAaZKkg+nWsvUyWCrzxyeap3/iKO0kj8zaqPyOeTU7SmdgyZO75hx2oAuachEO7oAatNGA/B49KSFNqBe+KkCnABwSOaAImAQs+OF556Vwmv6xKs7YzyeAOgru7sGSB1C/MQR9eK8l8Q7kuJEOQwzkdwc0APg1eUTDDfJ09R+VbIcypvRAFbqB2rlNOsp5ZFDArGTnOMZruolWO1LeXtUDg+uBQA7Rosu7A4wcZPPGK3LPjJjzvzt6dPWs/S4la2VlJU5JratoWVVyOcc49aALVuqxgAElgORUp+YKdpGOlRQjORyBUjYLAEngZ60AOifyyGOAeOnFTRxvM5zkJ654qK2gEjMd2FBzVozLt2JwDQBFM0acKAV65xnNUbqRGUrsAz3BqZgcfMxz/ACrPuv4upx29aAKXlASkBup79q0bMMsZD8YP4VlsxMhwPetvR3WUMOQQMggZFAEysFO5BkY6dqcSjFtuA3pipJpAg5CgdRgVTe4VIvnIxjI4zigB7FcNzgnGafCQ4IAyAeSvasO68Qpb7lCJtPryaSy11XLE28pDDqiZFAG+4R3Zd2B15NSRxKQDuBHasdbqRmDC23Ieh3gA0651BFwxRYkbIOJct+Xb60AWr+fyoXRAD/ePTA9Pc1yt7IZHdSVIPQKfu0t7fF2TbEduRjGePc+tUWnk3NiMKx592oAltl/fIDhTyMMev0rSlsHdkjV9p53N1NZds4E0ZjXJU9W4xXZaNYNcBXK8HDM2eAAaALGh6asdpJ5i7WnGzOOQPX86zNWjJbcwCuTyB0Dj/JFdPcZVj/d6DHasXV7f7RISp4lXJx/eHX+hoAytOthcJcWxI2Tx5T2IOR+RrT0iD+0NPa2kOyaP95Ec/p+efwzWXHvt7lJc/NE2WHoeMj+R/GtRZBb6yxhHysPtEf8AtKeHX8DzQBdEMZiDKm3Jwy91PemSRiMKxJwB61sYWYmePHluOf8AeHf8R/Ks26jHmMc/IR0HQUAULiXKkF3wOmTVZYZJDubG0dBV9oxv+6DkVKBt24UY7igCC2t/LG/+I9/SpWQsD0J9OlPKY7cYzjvTThgAP/1UAOijWIcdO+aj8h8/LJ8nXr0qwRx3NNZxhjwB3oAt6NbPuaVznsPetK+iV/LckDI5FZNlqaxABeT6fjU9xercsFDKMc4oAiuCrKQGGfY1Xe2BGUOc8c1MLdyGZs4PUelTwxwYwzru9M0AZyWJJ3nIx2rd0yTbtWTgZwDSeQOsIB+lOUIRkEAjtQBrSW6uM4BYDr61gajBhmDDbitSG/EACMSVP6U3Uo1nRnQgj1FAHGsCwIO761DtwTtHXnr3qdCEU4OW5/nUbEb+wHpQBG8xgLMVyQDgdyal01WgsJJWYb5Wcgj+I9GP04x+dVooze6isCOy5+UOoyEwMs5/3QPzK1V8V34tEjjtPkgjxHGvoo6ZNAFbU7kr/rnVR2XvWJPdyMW8jcfei2ikupWknfcB/DW3pVihQzSKAvQACgDlRp89/OjXUREakH5j09q6uGVkCo2RtUAVoyWy3CjylCkcD/69UZraSKMiRRxzQBr29wJEBQgjoQKm3EHhscVzEE0sbEh2Bz6Yp730xRgX5PrQBsXl/DbqSzZYds9a4a+UXV68skSlyxO4jgVpSSszYbkcfWmx2rzTbUU7WoApWdsZJlwc+3rW9qVvHFZJCAN4zmtLSdNS1UNIAXPYdqzLxSdRCsc/N60ATWNv5JijDYTP6Vv2zDyyw4bPUd6zook28DDAHmrNkSkR3DjPFAGgcAb2I46YqGQpIwUMoJ96hmuACRjOf1os7dp5zJI21FoA0HdYkES4BA5qvubbkHHPPNNnRS5O/DHvmq+1wSwbI+lAFssDHzgMPWqcycktkKRjJ5pwkBPzhgR+PFTrJGASBg54OaAMqWMB8lAVzxV/SW8uQsgwCMYHanyRbkGHUH2otSAnlkDGeWI7/lQBPPMu/HGOmCP1rn9ZJ2sEbAHI9q2ZrKNiCEd274Y7T+HaobvTY1t2ZVd2xwpORQBwVyGVxI2XU+/eq0Ny4nDKrLjqoJrpZYjGjIbcL7dax5tsZzHkAc4Ixx6UAOh1ARIqGdkKklGzwfamfazJcHerLu6E4IqhND5khXy8c5A/wrSWyeMJtbIYZwR/KgBztJuDFyUBz8uTn2pqRiZ18pmkznBPY+9W7PT/ADflBYsTgOP4Sfatyw0ZXZFWANt5LE9PUk0AZ2mWElzIFV13dRuHf2r0DSdkFqsIZWYffxxWesNvb24FugD5IZx/Sst7toLhQchfyzQB012u4Boxxiq8MO+J4iBvY5TPZv8A64qSwl86MMGBUilJMbjuBQBh6naEFi6vE+3a6sDz6GqMxkXTFkB3XNk4l47xnAb/ABrpZ8yOzzHdkd6yy0Ud1vIHlPmNx2KtwaANDRLj7QdsjfK3IA7Crl5b7SQoBB5rmdOeWzuJbSRts1vIY8joR2P0wRXSKxNqrvIZSuWU7cY/vD8ufwoAytxQ7XUk1IGBQADPOCSfWpLuNS2Rj5uRgZzUcYBynRj396AHBcsMHnuOtOAAJ2njrTGyoOAOPTrTo+FBx7UABYkjqBVTUGKxMM4YnGB3qycFfl44P4mqV+UWOPc3OcUAZ8UbR3YMrHaR6960POWGQODyOlZsr+YOMbutVGvS0qkjIzQB00eos+VkYetRFyZCyn8apxRC4UIvyswxx2q9bwCIEOSWPf2oAsW1+VkwxwPatNJ1kHXJP8QrEuIIwu8E5Az1osrzy2UFhjOOvSgDdmRgBkEr1zUUN/t3RkdR3q3ZzJNCVcA46HtWNq1o6TrLE5CD7woAzmIOAuQd3aoboSMuxfvEd+3uamkX5iApySBmjakOQTlyAeT1OP5D0oAdHJHptmxXPmSrhiey9f1PNcnqEjXkjFgGjPTnGKsajeF2ERycNg57ioLWDMuwjOenagBun28wfagbZ3JFb0W8qI1TCd+KsWFvHBBtIHPUgZq0MJ8uRj2GKAI4lKJgAcUy6UPATkZHerABCncwI9ay7648z5EzjpxQBnzbZGxwT0yvWmm1kblAz49ua07KyLsJJVP0z14rUiiiQYRQM0AYVvpbSDMhIJ9cVsW9tFAvyj5sYzU7KuduCB2PWk8uQcgbgfwoAA21cYyawbmER6pnGRgsPx4rcPBPrjpVK+TMkcrd1K0ANjOFJ67u1SWd2JhsYjg1RupNquCQAOlZdjK8bhweAeM0AdTHF5s4EanJ7kcCtEhYIfLPJ74pLd1W1hderrmmEkkhmw3bNAEBCvyRg+tRlQSFBKknBqUoTzgjPYdaWADzQDuB56/SgCJ7dMc5wMjqaheEqcr1A45q3JuA4YgVCoctubB96AKbeaG38mq7apHHOIpGAPv0/MUaze+WskaAjBJOOM157q2q5bcnUckjigD0w3rqg8vAU45UnBq9HclYl3Ku44zXA+ENYaZiJXyFHy564robjU3IJVEyByaANV5opC24oMHgNWFeWtvcSNyI2GQfQ1WS6Zi3mHOetTZEpxjI9qAI10l/NCqYlZSCGZwoIPvXRaZ4eEz5mu4BGBgiPLflWdp8SmZFYjBOCOuPxrohMtmFRF4bpx096AJntNPt04V5pQBt3YUD8BUUk2YcPhUHRV6VTlnIcseXJpjSGQ7WIH9KAFluJB8sY4JJqCSFpyfMA9eD0NS7DuXcCT0zVoRjg9hQBQ0ueS3u/LduOuK3p3+XcDkNzmsOZQl/G+OibTV03sYhIBJUDgH1oAkeVmJV/mUnrVS9YIHTklBhfpjj9eKRbkOM9M9u45p05WSIMPvr8pOOcH/6+D+FAGTfyu72V/kASA2s4HRZByp/EV0GiXyuzwtglsSKD3P+f51gCza9N3pwIH2lMxkHGJVOU/UYqnpd6wjguBwycOMcjnkfgaAOvutsY2Rkja3y5/u9R/hUKqTh884HWopbjzzDKnzKRgke/wD9f+dTbtuQRkj+dAEkbAR4IH19abKOcj0AxTcM38PX9KfIGjHfBPSgCCVjEnAxnke1YWqzHYq4O4HtW9IDLERkFu1ZF7EXDAjnGDQBmQzlgeexxVNpAckdQaseU8Dtu5X161jXMpt3lDZA9etAHYaVKD+83YZeOK03keUEgjcPQ1w2l6oInA+8GHSteLWIlV5CxBHFAG6swaFvOx8gIJrDEoZyEPJPFZeoa8pDCI4D5B96i0y73yoeuOpoA9F0GSUR7HOOOKk1JwFbJ4IxisrTr3YDgngYFVmuJbu6wc7BnIoAsltq5YgkdvSs27ciNgTkj9RUmXZj79ferD2wkt9xwGHHTHNAHPT27Fy23OT/AJNbFlZ7FSTO1vQ81MkSGHIwW6cipYGBAVicg8UAWVGwjAyCalDCPjGSeoqpJdRQ7vNkAI/hHNUrjVkRsRjcT+VAGhdufKZxg46jsK56K5Q3LBmHJx61Bq+r3D25ji+QHrt6mszSEmkvowBuHvQB38WFReOfYU7Pov8A9ag8cE/XikBxzjg0APBXHP481GD6E/XNKMs3WpBGBnPAxzQAISfvfMO1MuAJYcccNnOPSpDtXAyB60hOy2kPBwGwSaAOX1U+VayEgliOTWVZSggkLyeg+lauvALC59cAVk2UTPKqnlmI59KAO5sZd1jbIV24XmpVlXcdxAYmoEG3YqngACpVjhyCwJb60ATMwUknJHYkVB8rY52jrUpQFMIxx6GozD3YnGO2aAIjMyuQcHHTNQyzBY3JOOKlMKljv6Dpk1FLDCPvBWGc564oA5e/uElVlZnbPYYJrj77SJ3k3kFoj2A5/GvRb+1gZsx7UPrjHP4Vi3Ed0gIaBCv98HJIoAxdFhMOQpClQPlPetJblldvlPzcEE5qIqFfaFbeSOB1/WrXkArl0II6ZIGfxoAW2ffI5BLfUdK1LW280jCY+nQ1lRXC2vSNRjrznNW7XWZGJ/csq9B2xQB0ACWargZI6HvSy3YuyjqcBeMjsaxpZfNU7hgt1FT2ClGKoPlYfWgC7C58w7gWyKvQQ7gCBgk9h70kcaog3DDHjFTIxHyqNwAoAkmwMAjHHWg9MAnGM4FM3NJwwGPrS5IGNucfyoAidMvnrnrVKe0DocNjnkYq5KRyST0/KhZAUJADfh1oAzzEyYAzjscVZicB8M52uNpNDkfx8dgKrM5Vm4zjtQBW1NpIW3rlJY2D7h6jv/X8aytQm+z6wzQKv2XUk+0KB0ST/lov5gH8a2b2WORGMgJlIxtPOax0ic6fPGo3zQN9piGOT/eH5UAdD4eXNtMjuF39Cw46c1o4Gdwwf0rO0Nkaxj2kESgNkHrV+QfOODg+/SgC5DhVLnrnpUVxc4OAAWzjFRtvWMgHBABGKYqcbgO+ORQACUgZBH5d6bMhfLKvP86k2/Lle3UYqRMbAWzkcc0AY97ZlgzbcKw5rmNYsZSu6NdwH3h3rvDGZeQ2AaqTWQc5RSR0zigDy3y2RnKAjvtYZH4UsUsxUK4J3cHPau8v/DySMXhxuI5U9D9Kx59Fuonx5TFehxzQBzYsndkwMkH5vStXTLdYpn4PPHHIzVpdIu3BCjatdJpOhxwwBpSSTwRQBHC48tYoBuc+3StWC3S3GAwZyASalitYYwBGgU44NGxVlJfJHagCuqKsuCetWIGQxyB+hIIxUJIyBnAxkfnVa4vBEiFQATwKAEu5hay70wVYZA9DmsW8vJOzYDcfQ1emmNxAp4PGfp61WisTcxuuCvPUigDOMrysxDEt3BpEidpPlB9/rW1bWUNuxaQbm9xWpaQRqM7Fz2xQBz8GkzSsN6/L6nite306OzQSxDMg65OKvMo3LkfKOmKGQnCoffBoAIJ1kGAVDY5BNPCFvU00QhsNwGHc96likO3y5F+hx1oAesZBOSO1PYbQOvTtQQAMYyajJySPzzQA1geCT170sy7LP0yaOACeDn07Ul4cQW6f3iT+QoA5rXI98eCAMkcfnUejWwa6Qv2O7r2qbXAVKKAeT0/CptBjLSMzfwj/ACKAN7k/KmNlM2Yzg5waB05znNDMOcUASfwnn5hTJJHT7xI7YqKWcL0IJPvVfLPJkE8UAFzcMMhSVB96zpJ2d2CZyT1q1eKpIUHp1qWytFc7pFyAeAO9AFJIWbGckmtE2StGGfAJ69/0q0Y+AFGBTVjbjJBFAGPdWsH3mQuo/h7/AJ1Wkj05FxHZsG6ljMx/rW1cLsbhcg9jVG8svMw6tg9wO1AGNPFG2SiFATyCcgVDbq4IPUE+laLWsgbDAnNTW9jI5wMIvvQBC0bywhOPXkVPpZa3lztGT2xxWvFbJFAyock1Tt8ecO3PQUAaTL5h3DhgOh5/KmNuKlRxxnjvU6noysMjnmpSN3zbeBk0AUUL4O4cg9TTnm28nGMYJ6VMVG8qT8hzkZxzUUyIrNu5AzigCKOcEZOSDxTfNADdQD0FPIj2AY5xVd4nkGcdD0oAjluERtvzfUDNVC7yvgcZ6E1pizDJycfWpFsUjIbBY0AZix4HA2k8AmoLbdBeRTlTlWz/ALw6Gui8oFJEAO3GQfoRWdexqtxlAAMEYxxmgCCyR47ue0iIQA+ZCSONjc/pyK10fIUOPnQ4bHrWaF823guy2Htm8mUjvG3GfwNaEaMCQ7AtyjHHUqf6jFAFjnAwc8de1IFbkdBRhlIBB2kdu1LuPBUkAnGKAFQCPqQMihioBbJUA8juaZgnAyDipGA2KGxmgB8bLIPkJ2/0qZdoYErj3zioAm1RtPHpTCcxnOcjIFAEpAY5Jzg1HcHZAFBxk0pwF5YDNQTEliOoHTmgBqRbuSOnU1OQdpx9aSJtsYHUk8Uuc5Vic+/SgBQQo5AIH51DO4H8J9cUrYCk59x/hUKbnY5yeKAKdzM0bBckgDj25rLmJdAecHkirdwAXPODnp681Jb24lYbhwDgH1oATSbYvkOOM4xV1EEchGMADjnvU67Uwq8AHj3pLpNy7lx8pzQBSulVpgrA+p96txvhApx+FVxsmfg++eeKm2nZgg5HUigCaNwoOencGnxgNygGO9VojgA9R61cWMhQ6dSPzoAR1XBAxxz1piLkc5x1zSsecttz70CQgbVK49RQAPIR8pz9aRiFGM8+tI/zLtY5J5piv8rAZGOtADgSSSOme3pUl6MeSmBxGWx+OKZ/DjoMYzS3v/H1GhI+WBSfxJoA5vV8tcInJ4yfatPQ49sDEjnIz+Wazr9sXSKCSu3rjnOa17RGit1IwNwBPpQBbl2pGxzlu1Vi4Cbj1J61OQpDFzkkcYrOmlKMQ4AHQUAPVQ7YAOOman8oJCRnGe9RW53qW2kDOKluWYRZB4oArxwhmXnvyTV7ARRgjp2qvbrk5IxnoatkYB4OKAAP8pzk9wPekzlhnAHfPFJtO3KnrT2TB+bv3NAEM0e7G7r1FV3LBipOfw5q6FyD+lVbnKg56igBiy44PLdKlOMbsYA688ioI0Lk8cZ4PY8VZEPTd0NADYX3uSudueKoEGO45xkdq0wgTAXk/Wq13bksD3PpQBZRyygjge1TxkFGwDz71RtJCnyNkn19Kug4HB9CaAEKIjMTkg9PamjAOcZyMkZ7U7IIwMk9TTHG8tuBHToKAHEhvT8qF27sEkLnPT9Kch3DAA6Z6UL8rZbOOlAAzAtxwuDikPI4IK+tKEJZiwwOxoVcH07cUAPhB8wD+HGMexrJ1DhWHO9PmA9cHFam44JyOOhqvqKAy4b5d6nn1yMZ/OgDOs3/AHs1vIAUmQg/SrdqGQzR5BaPbKM/7Pyk/kRVC2fa1tKcZJCNx3rSMojSzuHPEcxs58D+F+FJ/ECgC7Ky9Qct+mKTJLEFlGOoHaooUfYDIfmXKsMdCDg/yqQfdxgj370AKGGcAbj3A6U9WO8gg7TUe1s4x2+lSquASWI6nnmgBrZVQN350oJKY59OaE+/z1p21cthuP5UAQNt+bvgcmqw+d8dh1OamuMD5U6Zye1Mt15PXJoAlDKoUgZx3pjPkZAIAp5jIBClqr3GSNqk89aAEJZ32gZU9atIvUDnA6UkEZRAx5OMdalAwRxjnrQBiSKXcMgq3BGVRQBwfShEzyTgE459KkkOEYrwQMDHrQAfLuy3AHr0qQOFyAAc8euRVAJcEne+Q1WrTAJMg46dKAIYQBnI6N+lWBjhjz7UzaDI+3kipD/CcfKRQA1AOoOOemKnD7YwAeagKkH5Sf8ACpclh0+bvxQA3fupVII59eD6VDkpIcjGDmpiQTwvXnIoADnpjnvSFSMPgml2kdST7gUccUALG27IwPoRS6iR9um74RAB+FMAIcEdMgY/Gl1MD+0Lo4/5aAH8hQBjSx7rt8L6cVr2YK24RuoHWsWeT/SiexArZtWzEu7n3oAJM9Og6VRY5crndz0rRnUAMQPf6Vksf3gIHT360AaUPCjIG2kmCsMAE5p0Z4HQnHUUqhdw6+uKAK8RMcoGO9W1OfunjoaiuIwfmXHrio4W2OSSDj1NAFnB69qfncDgd+c1G7+Yo2896cq9cGgBH5bNVZVDkjPB7CrT4XnJx0xUajnryaAEjjAIwTx2NSuAwwMgihMnk8Z5p0nXOBxQAzaOw59KUrvXJw1Pxnp0IpOc4bpnp6UAZ8mYzhR0PSrkTFoh8vOeaZeL+9DDuOeO9Jav87YBwOg9aAJsZVT0JNKjHI3MMjIxnildM4GKTaoHzdz2oAFYo3zAhT19qeoDfKeRTCRxn7p71JHwMfL1x7mgBBndwTx1wOtIUVmGWJ+tOxlsEFflOOelINzY9x3NACEANtDYH060l0GZInJ3EAr/AFA/I09oiJCATg96kEZkhmh/5aH50+o/xGaAMCTpdqBgg+aoHbo38iau2oWZ7m3nx5V7b4znow6H6ggVDc8yRygAI6mKQtxt9D9MH9KhtvMkggUEo8JDA56gjBoA0rOWSZn3AiXguuOhI5/lUxBQ4Yg4B+oqorKGs7wt/rV+zS4PG8cqfxq+eSeSw9u31oAYhBbJJz05NSsSMBQCtQbRk/Lg9Tn1p+NpOTgZoAeB6nPuKZOyqhyRSMwSHdlhjnmqTSmRhyvfp/KgCVf3j8HPqas7CAdvbj6VBCgC5IBbtxU+1sk9umM0AK/7tB0z0+tVoY97g+nP1qScgMBk5FS20a7QRkHOetAEyrzwDjPTFDKN/vzxTnIUDDcGo2JJx29aAKAAKkMcc8U4oSpww9cZpi/f2n1zUgYfeIwR796AI/mBJZdxAycc4oJU8kBT7mpkYBTnP0p2UdD5gGP1oArKxLkHGT3zUoz8rYwRUE9v5TiWJiQOwqQNvwUHIoAkGOvDD09KUAZyhx7U0AfNgH345pY2CtjHXvQBGcFvmWl27MjtT5MFQQOenFMXIHNACkgcZyM9aD0yRzikAwARgqR1pVJ3ZfPsaAJLcfvUAPBYdfrUV8c3t0QTjzD+PSpYMfaoQvQOM5qvLl3uSeB5r4/M0AZLf6+TAGM/0rXtcrAq9CetY4yZZQD0J4rWteY8N6d6ALb/ADIBwT0rGmG2VuD161scBF56+tZ98p4dMAH8KAJrV8w85FSgZbJOB64qlYv+8IGCKuYwMHj2oAd3IznPtUFxECPlGCOtTADG4nPanjcVyCAR0JoAr2zgcE8VYBJZSe9Upcxy4wMnAPNWY+Y8jBxxQBI53KdwyMVCrYOOcHr7VK+CcYzkY9BSKBtBbP8AhQA9T8gIGT1pcnIzkn61GchvlJHekV3VjjGAMUAWA2X5GPqaWM/MScYqIyAgfKQemKcoYDj6UARzkNGSAOvGe9Q2zENk5xU8qnym45HPNVYWO9Q3TPIFAF3lMMepHftTvlyWYdf1ppBXGRx6Zp6E46cmgBGHQZGfYUzb8+cnIOaVVYnkkcVIFAwRx3we9ACLlVwSCDTsBcDBwe9IPvfNyB3p4I8scZHQ85oAQhQ43cHr+tKjusgIG11PHNNLKVIxkgZxTBhRyCPTB/SgCrebg5Zhuzz9TWVM/l7j3J5/z+Nbdw/7tgDwecCsGcNn5emevrQBZs2WdZbSfCRXA25J+645VvzFallOZIMsMSKdkgHGGHB/xrnwNgDYzzjJPNaBuDDcR3f/ACyuQElwOkijGfxFAGqxPynPPccmmlt3AIODj61GZCSGU4H1pSkgXIBXscUAV7tmQFW3YxnBP8qbZwKxBYnnqMD9abcvIZcFsY9qs2rARnzEGT0I5zQBYwqHIICY5pTlVJGOOTzmmghlGAMjAwTUdzIQoUqPmPXNADE+eQ7umP0NXM7AxUdRxg1XtFzyM47VYdyBhiM9hQApBYg9+nNBBw2RxTBMx5UDJ6jPGaYZ2ZTgY560AV1BG7OOR3puCFPt1p3B2leTyDSOwCjj72PbFADmG/H92lxgjbzn+E1CoLEdscelKUYgZbmgCV2yRtIDZ6ZpzJyG4VsdulRlOQpHz/yp2M5UkjHf1oAFBY7WHPQGlO77pHPrQeQOuB1oZiUPfFACjhwOmOxpG55XsORSqccde3SkwAT7d6AGnnI7dxTSpC464qRtu5XUdetNbHGBwPWgBbMk3Uec8NkAVE2GEnY726fWpbUETBlPeq6YMRI6gn+dAGcnMjEgfe61q23KZGSeOKy0PXHrmta1I8peg78UAPc5Ube5wM1FcJvhI59qmX5mGeB2pGOSwJwBQBkxYjfapx9a1FIcHI9+Kq3EOxvlywqS1f5eSfYUASoMn8O9KQVIyc+uKcT3P40MFIO0n8aAK86bucc/yotWPlkc1J/Ew7VFDhm2kYJNAE6nacg+596eMlegxSAZJ4wB70mPlILEGgB2SS2MDpxTifm6DPrioweBkcAY4p4bLZzjPrQArjI6fjTQWUnb0oOAehPfPrT88jHJoAR87evJ/LgVTjZRKdo+bvmrpHDEtj1+lUIgA4+vSgDRwD90Zzz16mhAxBAABzSxbR0GCKQuCOwHtxQBI20DDsM9x3phbaepI9aRdpJytGCxOQTg4oAdvHAJBJFLv3IMAZ9KjZgWBwAP5U9WHpz70AJt+YkYAJ6nmmMh2Esc49+KlUnI9MdD3pRkg5wDQBFt5AIAI7Y61T1KBEG/bhm9BWgSq8E5yOMdqikO9CuDjoCaAObllC8YB7dOKltHS8iexLbDNyjr/C45Bp+oWRjc8sVPTtmq1pZT3M/l24IkA3HL4Cr65oAs6XfyeTufIlUlJEx0Yda6K2SSW0kuZmWKJVLAucF/YDrWNcm0tLv7XZ4laYhXlIO0SAdQPeoJrmXeZGlZ3xkkn/OKALokWQq+7IcAg/WtFIlVFDZHuKxNNwl0YGXdEcyxe47r+BrXSQF8YwSeAaABoTg7Vzjoe9UZXzKA/J6c1pA4JDEAetVAqzOORnpkUAWYj5aLgYXA6U9mDIc/eB5qIp5bgYbaepp9vInzDaaAGRqXHAHXFKyqmCCeT09aI7htu0L846im8cs7Zf8AlQBAmScNjqc004M2Dj1rA+H/AIkh8VeFrLVYgBI48udc/dkH3h/UexFb5UAkjvQA/qSBx9abLI4AMYDE+/SnFScfMCQM0h+TjOR7UACMwbLrk989KlOXHTGe1MPGR0+nehG4ORznvQA4krjI+Y8YprMkasXcIgwcn+VJdOsWBgu7YKoOWNMijzIstyA7jBSMchT/AFNAE+xnhEqggHnBGGA9cUh5III57Vcy1okm47rmZdrY/gX0+tUyNuMcnPSgBgYrwDkGndiRgGmt97kgYp3qFIPrQA62+WQED0B/E1nsx+z5Q84b8+a0IGw4xwSwFZ0qkWw5xywP50AV4F3c846c1qxqFUcjgZ5qnboQAwBPcCrikE4xjNAEqkEEkd6jc5cnjrUiAEk5xjoTUJz5nse9ACTKTHkdO1VUYIM7jnP51oYAQD0NUp4gvPTntQBcQhh/D+VIDlMk9B61HbyHBAwPbFOmcCPIIyeuaAIJXJfjjjtS2m5nLfwjPNNDB2+U/pVuKNFXGQD9KAFQnGDnHU+1LzkbgMeopGJ/hznsaCecEGgA75bOKOBnDAgcmlwCO4/qKRdvYjgelACsRs4GP60q4zxnpUbYXoeR+tPLnBA60AKrZQLgcjHWqDqFkJGeufrV1QMjHrVW6AWTjjPWgC4vIHr3p4C8liBniq8TKyDIzxj61PjK4wQuOc0ALghvvAg0jnGDtyx9+nvQBkj5gD/On7RnqTQAhGSelKFOVAwCelNYqF6Hnt+NDMTtxxzmgBxGAA/PFM3ZzjAwPzpGJZhu5A6ZpfvAZ6ZzigAGN3Tkd6VTzjdnHtwaXoCMZAGKaAeq7WoAbNGrqVfGOM1lTxSWlwJIAOmB6H2rVBJQnPPQj0xSSx+dEEz8w6ZoAzZ0RoDGDmG5XchPVG9D7g8Vjq7sxVzh1O11A7itTymaNrRhtZ+Y26Yf0/Hp+VZ11Hi4juzlPMYRzLjG1wMA/jQBdijM0QWJ/wB9H88Jz/F/d+hHH41oWUyXUCkMCSOnce1YhmCYESjOeuau6fM0dy0g4ifknoN3fHrQBqSrKsfynk9jTrNCxY/d9vQ1D9o8/ouCDjFTqcLgkj3oAuYAUBmB/CoyI1OVXBJ6etQeZklSpPpQuAm4k59TQA9iEY4wXJprg7iSBx2qI5bk8gDJrO8QatBoWiXuqXxIgtozI3vjgAfXgUAfM3wK8Zf8I14lNjeS7dM1AhH3dI5B91/bqQfqPQV9Thg6+pxwa+C6+rPgh41Pinw59jvcf2ppwWNyD/rY8YV/Y9j7jPfAAPSM/Nx2pSQ2OBSHHHXd2FNZiWO44PtyaAJAyKp3OFHvUas8g/drsU/xMP5CgRgPucbmH97tVmKHzl8xtqRqfvnp/wDroAiigIbbCGaVzyW5Y/8A1qugRWgBjPm3HQt/Cn09T70xpVRGjtwVQgAsR8zf4D2qvHk8Dn+lADy37xlJPIzk0cq3JJ9wKa5LNHu64xmlwF3ccigBHHzKGHXnGKaRjlTwfSnhicE9AOlNZcDPNAD4gdqEdS9Z5LNCo7ZxitKIcQn/AGsnH1qhH8wQcY3E0ATRDCrzRIdjEj9aAw3MMfN2pV+bIJGM0AAfjnnPUUZzznr29Kr3LFAAoAb37VLagsm5hnnA5oAsBTtwOvWorpdyZBJPrin5wSQO2KjlLBCM4oArxMN4Azz1qaYBu33aqLJgjJ6fmauJhsD19qAGWsO1m64PQ+lWQSOVOT9adtwoJ59iOlCruHuenNAAG7MCMcU4EDAB9jzTX4BzjPtSFflyw4/zzQAoAycnOB3pvQbifwpTkLwf8+lGSBzjIGKAHR8nJ+7SFThj68D6Uz1JJ9qkLY68DFAAMbScYNQMC74XkAVICTgMeBTI8Kfm+b69qAIElaLsVFXVPBbk57etV5od43IDnPrRDK0ZG7mgC1kqvQYzzTuQP50zO5S38J9+lP6wsT+FADVOWIGevf3oXAbI6CmpnrninKCzAk8HvQA3dk4I4NL0xyPy60oHORjPXNPUDauR83YUAM4wzc5xxQFBOT09jS7vlYHGTRgDdyRkcH0oAQjbgpkt0+tDZzkk5z17fSlLEEEgLnjr+dNdiCRxt680AQ3lqJ1IY4bGQwNZt7bPczukjH/TU2sQPuyr/F7AnB/Otlgny5O0Enj3pPIL5ViOTgN6HsaAOQtY3G6KbCzwsYnUDGGH+c1oRn720/K4xkknPPTjk/QYqXxBCkcsGolTmVha3YHIEg+4349M1AGG4jgDJzkn/wDWfoKANLTTsJDZznHPUVpsCeCc+lZEMoATbksow4YdB24HAHP1NaJmVgCfxxQAMwAJJyT3HWmn1xk+vWmsNxLKRwenrSnOc8jJwe9AABwCOuOxr50/aM8ZC+vovDdhNm3tm827Knhpey59FHUepHoK9b+KXi9fBfhie9VFkvpf3NqjHgyH+I+yjJx3xjjOa+PLiaS5uJZ53LzSsXdj1Zick0ARVseE9eufDWv2mqWeS8DZaPcVEifxKSOxFY9FAH3D4c1yz8RaLbanpcge3nQMF43IepRsdGHQitMKTwQS3seK+Vfgt47/AOEV1sWWoyAaPeMBIzE/uG7OPbOAfbntz9UJMsih4nVoyAQynKkHvmgC0nlg7jtkbrt7Uk0rPncQMYIAHAqAE4yMEHmpDk8jpQAfQU2PIbPpSZ2tUcDkvI0pBIcqFHQAHFAFmT76Y6VGh3v8pDEcNippk6OuChHQdqz7RvLUxkYZGx0oAvHAR2Y42jkU20kaflwqqeQP8amlG+Hd3I+YetZ1ixRNjAkq2BQBpzoYWjAHI55/Os61RcK+0sSSSx+taDT7thcEOmOvesyFDGSpGFySCPrQBduE2OCOhGQ1RoMEZ6Ugd3jK7iVPv/nFMEeeSG56HOaACcQkgMy++TTkljChVB2r0KjNCrg/InzAcYNObOz5iRnnnjNADUklYY2sQe5FSOpKkOOfXFNwSD6Z4HpTkcqfl5B/hxQBRlAEmOoq7akFck49CaivYeFkjOVbsexpLQlfkJyCOKALb9BjH8qUj5dvApuM89MetPYfKD1z7UAKCflBxnvTGBbG0ZGMCl/g7Zz0PpRkjnuKAGn5WxwaZjg+vXFPPJ6gCkzxgZxkc0ADH5TkYPXNO6YOMkd6RiQ+QPrntSHJ+VeeOpoAUswA4A4OaRQQMjv3zSbTn1PtUnGAeg9TQAgbAySPrUdxGvzvgjAzj8qnGOU49QcUjqQm08ZNAEMRyuO47elWnwIBz1P51SwFlIxjPT3q2x+VF9DjNADCwGVI5znpSHPOT2zjPWgHDZGeR/WlUEnIwcdz3oAEwcANtXqc80p5ZvQHGBScjIBwCefSkOcEEgcdAc0AKDllH8XWgZ3fMePrwKM7QBsxn0pSMhsdD6cYoAFG4L2A/LrSFgdyg9/ypdr8gjg9x0NNA2YGO2aAFCMBluvp/hRk84yDnpinAK2Pm5oPynK5JHc0ANljguY3huuYLlPJlJP3T/Cw9wfSuWhSeEvaXg2Xlu5il7bsdGB6kEYPFdWmHJ3AYPBFUNWtmnuIrpCxmC+RJjgso+6fWgCrZoROVKjjplc49wvQH3PNaEeV5I79SajjTylGOAByAPephwOhHoDxmgBCFwMEf41DeXdtp9nNd300dvaxKXklkOFUDuasjG35gRjn2r5s+PfxCXV7x/DujuDY2z/6TOh4mkH8K4PKj17n2GSAcL8TPF8vjPxRNqG2SKzT93awueUjHcjOAx6nH05xmuToooAKKKKACve/gL8QwIl8M65cAAfLYTSEAAcfuj/ME+uOwrwSnIzI6ujFXU5DA4INAH3lGO2/Deg5pVYAZbGfUcV5F8E/iUuvwx6Hr9wTrCA+VM4C/aFHQZHVgM/UDPJya9cH32A6YHWgCR3z8uB9cVTRNkkmCAjEH5R0qZsZ4xupQAV+VQG68UASJKY0Kj5lPY9qgCL5hkLBWbuadhyvDDb9cU5RkjccKD36UAOJ6AfdxnANRjgFWx+HGaehIOBQ4+bkk/XtQAm4bRz24waRd3AVhzzyKdkYCjGQD0HGKCBuPyjd6+npQAwAoeB8oFP2gsMg9MgD1pDnb2zjgetCje+F4Pb2oAHba3dv6+9Bbn5umcZzTwOOODjnA61JHBIwJSNj9KAIhk8K/wBQRkUiMRwWPPfBqYwsrDzWjjH+04z/AFNG2FSf3mSePkTt+OKAHRxl7edGwCBuB9MVmZKPu5yOcVqmVVi8qJSFY5dmPJqpOFcdQWHr3oAdFJuABOakyQcDGc1RU7ORUwmPTaD9KALA5ViTg9qdyFAOQfWoFmVjyCD/ACqXIYdcEUAIxIAHfvQ2AuMAk/pSA7sE9T60oHXPXFACHLEHHGMcU5Rgkg/X2pcgEn9aAcAnk0AKD9csME0u3OcHPv60gO4nBIzxihiBgYOe/wBaAFGQhAAweAaZJxyOO1P5RMHLDpk0FAYyOeRmgCORVDoeCByadE+SvHTJ602QbY9pIyKLTHmN3BH6UAPG35QQeh57U3gAgA5HaiQbV9BnkUpGXH91qAAYwAzYpDxhV6kdSacq4A+bvxuFAADHB4NAC9MEg49BSOFBzzhuvNKv3WGAcUmflx09OaAFLAMCdrH2FB+YnC9fU0mW4IHHXpxTs+oG0+1ADNmGO4sMcUEYHLHNPJ3BjkAjrmo3wGwSd3oBQAmNoyGwB7daGXPBOD3H9aG+b+HjtmggZzgZPPHNAEYILYCgDPHNKoDEkgDPbNJjjocdABXnXxd+IUPhDS2tLORG125jPkKoDeQOnmMDx9AepHQjNAGV8cPiKNC0+XRdEuB/a1yNs0iEE26d+o+8w49QDnrivmSp767uL+7mur2Z57mZi8kjnLMT1JNQUAFFFFABRRRQAUUUUAOjd4pFkjZkdSGVlOCCOhBr6k+EHxJj8WQ/2dqbpFrcSbsAbVnUdWHYH1H4jjOPlmpIJpIJklgkeKVDuV0Yqyn1BHSgD7vVtrDcASeB3xQoJ55H1ryP4QfFOPXkg0fX5Amsk+XFKBhbjjjPYP7dD2r1s5RgTn/GgCTYWAOMD0py9fugZH1pmQTxwBg5qRTlc446cCgB53PwcBe3amMg85EDnBqT5uo5B6Z9aSMgTB2/g4A9TQAkkQWYpuJXOOR/WoowzMRuAVTgZ5zUkpZpcnnBBqGJmdSwXv8AlQBZEUB+80jN/sgLT5fLjjzBGSvcMSf5VAjnvj6VKj8bSeG4/GgBFunXhMJ3IVQP1qOSQyN80jNz3JNPZUb73yv0yO9MMbISOq9jQBXlUF+Rz2NPiU4AbvSMCW5B9KkA+XP8qAA556ZpJFDKMUqd+ORzTivGBQBVaLAPqOlTQ4A29PWnoOWHeoGUBySTjPFAEjRg5AJ9cmmqzA4GcrT8Z789aRs5+ZSD05oAerbgOPqc80EHGSQc89MVEsm35c5GemKsclfwoAaDlRknApwOFIbgetBXK98Dgg0nOCB+AoAXIQ9cnGeKMnd1GOec0m0buvXrQVTkkEk9KAAsedxGaXPGVBI9hSIUXJ2dvSpA/wAvzA7SOf8AGgCNtpDEYJxyDUdtgOD2AIFOVk2MOCR+tR2+FcMOR6GgCz98Y7EfrUYOSFzxjvTwGDtwAD3weKYSQ4x0bvjFAErAkE5+X16fhTDjgAc0hcEYAwR/CSaczL2Jz70AA5ByetCjnH4/jSL93cpB/HFOOWGPuMeh96AFxhMH04z3Haj5eVOcHkUisWf5m+bp/kU1jk7eRQAoyuWBAHb1qIlQxx34J9qcxAxjnHUUh3BTjafqMZoAbnBzgDHOaRSCScH2zSqxwoH3ujAV518V/iXZ+ELeWysmW41x0BjiYZSPP8T/AIcgd6AL/wAUfH1n4K0pfuzatcKfs9v9P429FH69uhx8latqFzq2p3V/fymW6uZDLI57knPTsPbtSanqF3ql9NeahcSXF1MxZ5JDkk/57VVoAKKKKACiiigAooooAKKKKACiiigByMyOroxV1OQQcEGvefhT8YUCQ6R4wmwFULDqEjMxY5wBIfx+8fx9a8EooA+8o5FdS0Tbo2G5SvQjtUynAzjGfX1r5T+GvxW1DwsFsdU87UNHACpHuG+Af7BPUf7JOPTFfS3h7XtN1/TlvdHvIrq1Y43oSCD6Mp5B9iBQBttKoXjrjng9aSBGZWkABVeSc1ASBy5LenNTQyeUkuCRux04zQAbwJPuknPSoogwXgEcnv1FOYnduznPpSbj5e3d3zzQBKPu8rn3NNYLgFSc0nmb8DHA7etG4duPagBzk7geBgelKr8AHkHnio2bcmC2OnOKTcxXHP8AKgB86qRkHD+maiUHP3cEe+acePvAEHuaFUKvyoD/AIUAAyrY29fWngseSDjHHfNRnKscN0460jPzzjg847UAOPBz0x7UrYKY4z27UhZcDkc9s05twyFVuPfpQAiZHDYB9KAcI3Cn60m/awAyMdeMUjk5yScdwP60AIV3dOG9BUgYInQnjuKZu6fuxt6Ug4bBz9CKAH5YjgD/AAoTB3DC9M53UzcAPvAD69acR04J9ABQA5SUGMkg8560pIIORj0yf8KRSBySAew9aZJ8xHGWxn6UAOygUqc4/KlWTao2AZ9SaaOcANx3pxwFO5sbeOtAAw5yCmT2FRRr84IILe3WnsmFz1B9scU1eTwec9etAEu9iOFPPAxSsx2fMuQfWo1BDgMcE9Mdqc3AJ3DOM9KAEPHO04PHpSKSoIIYr25/rQwJ744ye1NA7HGAOtAE2Ruxu5pSTjDHGO4PWoxynTI6E57/AEpfM27RnaPb0oAA/QKvPfHFITk4B9xQ78Z37u/uRTSv94EJ3OfWgBzAgdM9uOooduOcZNVNW1Gz0qxlvdRuo7a0iBZ3kYAD/E+3U186/E/4w3GsCXTPCzTWdhkpJdg7ZLhfbjKL+RI645FAHY/FP4vW2jpLpfhmWK61E7kmnXJS3OOx6M304GPXivnG7uZ7y5kuLuaWe4kbc8srlmc+pJ5JqGigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK2fC3iXVfC+pC90W7e3m6OvVJB6Mp4I/l2waxqKAPqr4efFrSPFDpZX6rpuqkALHI37uZu+xvXjoeeRjPNemLtIHbFfBNeneAfjBrXhqOKz1Ef2ppikfLM5Msa9MI57D0OR24oA+pWJYBTwMnp1pcFR/eOe1c/4U8XaL4sgMuh30csirmSBhtkj+qnn8eR710WTkj09D0oARs8D7o9M0uBnpk44xSjnGOw7jvTQQh74Py8daADAyAvHrinNkEbucj1oLfMCvyqPXmmttOCH75+tAChQ2cE9sHFO5A5wD35podgfb069qTgY6ggflQAuPmXhQTxx60oxn5ip4yaFIOR3IxSBgwIJ6HGaAEXB29BzxzQc5JK9QRgH9aUHDNuJyP50cMuc4z26/lQAhP3dvAPGT/jSjA3c5Y447U4EFCMDp0pjFPmxnHSgBRwRls+2cClDkYUAk9MU3PA55BxwKUAA8YyOlACF8jG0be/1oGB1+Yjnr7Uqth/nGG44A6+9CEhvmBwOelACNnPTbx3pdwKDs1BBxwMAdM//XpWADYXHPVc0AH3QSoyD3oi27jk8E5II6U7gJt43k+lMYhV5428ZFAAdpGVHIoADAFhgjr1p+0nbsA7Ec9KamPu8HnNADgNr5GAPQdaYiqeecjgc9aQjsuOvUd6dndwOAoPUgCgAQ4xngZzk0OcdSOfToDSBNy+56d6V8ckH5sZP1+lACg7CVO0jORtPSkQAnrx/OlO4A56noDWR4l8RaT4bsRda1fRWsZPyhjlnPoqjlu3SgDVbKj+9xxXE/ED4maL4NQQSsb7Uif+POBuVHq7dFHt15HGM15B4/8AjZqeqmex8Ng6fYE7RcgkXDj1BH3Pw5968gdmd2d2LOxyWJySaAOk8b+NNY8Y3/n6rPiBCTDax/LHEPYdz7nJ/lXM0UUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Common iliac artery aneurysm repair with an iliac branched endograft device (Zenith&reg;). The endograft extends into the internal and external iliac arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35026=[""].join("\n");
var outline_f34_13_35026=null;
var title_f34_13_35027="Penicillin G procaine: Pediatric drug information";
var content_f34_13_35027=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin G procaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12661?source=see_link\">",
"    see \"Penicillin G procaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/10/32931?source=see_link\">",
"    see \"Penicillin G procaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pfizerpen-AS&reg;;",
"     </li>",
"     <li>",
"      Wycillin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in this age group should be avoided since sterile abscesses and procaine toxicity occur more frequently with neonates than older patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Congenital syphilis: I.M.: Patient weight &gt;1200 g: 50,000 units/kg/day once daily for 10 days; if more than 1 day of therapy is missed, the entire course should be restarted",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12661?source=see_link\">",
"      see \"Penicillin G procaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: I.M.: 25,000-50,000 units/kg/day in divided doses every 12-24 hours; not to exceed 4.8 million units/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Congenital syphilis: I.M.: 50,000 units/kg/day once daily for 10 days; if more than 1 day of therapy is missed, the entire course should be restarted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: I.M.: 0.6-4.8 million units/day in divided doses every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     When used in conjunction with an aminoglycoside for the treatment of endocarditis caused by susceptible",
"     <i>",
"      S. viridans",
"     </i>",
"     : I.M.: 1.2 million units every 6 hours for 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurosyphilis: I.M.: 2.4 million units once daily for 10 days with probenecid 500 mg every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension: 600,000 units/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"     <b>",
"      Do not give I.V., intra-arterially, or SubQ",
"     </b>",
"     ; procaine suspension for deep I.M. injection only; inadvertent I.V. administration has resulted in neurovascular damage; in infants and children it is preferable to administer I.M. into the midlateral muscles of the thigh; in adults, administer into the gluteus maximus or into the midlateral muscles of the thigh",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in refrigerator",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderately severe infections due to",
"     <i>",
"      Treponema pallidum",
"     </i>",
"     and other penicillin G-sensitive microorganisms that are susceptible to low but prolonged serum penicillin concentrations",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Penicillin G procaine may be confused with penicillin V potassium",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Wycillin&reg; may be confused with Bicillin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F207809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Conduction disturbances, myocardial depression, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS stimulation, confusion, drowsiness, myoclonus, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia, neutropenia, positive Coombs' reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site, sterile abscess at injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions, Jarisch-Herxheimer reaction, pseudoanaphylactic reactions, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin, procaine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, hypersensitivity to cephalosporins, or history of seizures; modify dosage in patients with severe renal impairment. Avoid repeated I.M. injections into the anterolateral thigh in neonates and infants since quadriceps femoris fibrosis and atrophy may occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some formulations contain sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Penicillin crosses the placenta and distributes into amniotic fluid. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal and hematologic function tests with prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetration across the blood-brain barrier is poor, despite inflamed meninges; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1-4 hours and can persist within the therapeutic range for 15-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal clearance is delayed in neonates, young infants, and patients with impaired renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Paryani SG, Vaughn AJ, Crosby M, et al, &ldquo;Treatment of Asymptomatic Congenital Syphilis: Benzathine Versus Procaine Penicillin G Therapy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(3):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35027/abstract-text/8071762/pubmed\" id=\"8071762\" target=\"_blank\">",
"        8071762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12688 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35027=[""].join("\n");
var outline_f34_13_35027=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049271\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444111\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049263\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207757\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207741\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049274\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049267\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049273\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207811\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207809\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049277\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049262\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049261\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299842\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207750\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207753\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720603\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049270\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049260\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049276\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12661?source=related_link\">",
"      Penicillin G procaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/10/32931?source=related_link\">",
"      Penicillin G procaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_13_35028="Lidocaine and tetracaine: Pediatric drug information";
var content_f34_13_35028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine and tetracaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?42/57/43924?source=see_link\">",
"    see \"Lidocaine and tetracaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/34/31267?source=see_link\">",
"    see \"Lidocaine and tetracaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1181967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3300077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F3300088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/57/43924?source=see_link\">",
"      see \"Lidocaine and tetracaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Children &ge;3 years and Adults:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Venipuncture or I.V. cannulation: Apply to intact skin for 20-30 minutes before venous access",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Superficial dermatologic procedures: Apply to intact skin for 30 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maximum dose: Current patch removed and one additional patch applied at a new location to facilitate venous access is acceptable after a failed attempt. Otherwise, simultaneous or sequential application of multiple patches is",
"     <b>",
"      not recommended",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1182001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Synera&reg;: Lidocaine 70 mg and tetracaine 70 mg  (10s) [contains heating component, metal; each patch is ~50 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3362805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3300089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Do not use on mucous membranes or the eyes; apply to",
"     <b>",
"      intact skin",
"     </b>",
"     immediately after opening the pouch. Do",
"     <b>",
"      not",
"     </b>",
"     cut or remove the top cover of the patch as this could result in",
"     <b>",
"      thermal injury",
"     </b>",
"     .  Do not cover the holes on the top of the patch as this could cause the patch to not heat up. Avoid contact with the eyes due to potential irritation or abrasion. If contact occurs, immediately wash out the eye with water or saline, and protect the eye until sensation returns. Wash hands after handling patch. The adhesive sides of a used patch should be folded together; used patch should be disposed of immediately.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3300085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3300079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical anesthetic for use on intact skin to provide local analgesia for superficial venous access, including venipuncture, and for superficial dermatological procedures, including excision, electrodesiccation, and shave biopsy of skin lesions.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11394984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F1181980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic:  Application site reactions (contact dermatitis, rash, skin discoloration); blanching, edema, erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylactoid reaction, angioedema, bronchospasm,",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3300081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lidocaine, tetracaine, local anesthetics of the amide or ester type, para-aminobenzoic acid, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5048986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients who are more sensitive to the systemic effects of lidocaine and tetracaine, including acutely ill, debilitated patients. Use with caution in patients with severe liver disease, pseudocholinesterase deficiency, and patients receiving class I antiarrhythmics and/or local anesthetics (systemic toxic effects may be additive or synergistic with lidocaine and tetracaine).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3300082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Since the heating element in the patch contains iron powder,",
"     <b>",
"      remove patch before",
"     </b>",
"     magnetic resonance imaging.  Do not cut patch or remove the top cover since this could result in the patch heating to temperatures that can cause thermal injury.  Keeping a patch on longer than recommended or applying multiple patches simultaneously or sequentially can result in systemic absorption sufficient to cause serious adverse effects due to the local anesthetic components. Transdermal patch may contain conducting metal (eg, aluminum) which may cause a burn to the skin during an MRI scan; remove patch prior to MRI; reapply patch after scan is completed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Topical use prior to cosmetic procedures can result in high systemic levels and lead to toxic effects (eg, arrhythmias, seizures, coma, respiratory depression, and death). Toxic effects may occur particularly when topical anesthetics are applied in large amounts or to large areas of the skin; left on for long periods of time; used with materials, wraps, or dressings to cover the skin after application; or applied to broken skin, rashes, or areas of skin irritation. These practices may increase the degree of systemic absorption and should be avoided. The FDA recommends that consumers consult their healthcare provider for instructions on safe use, prior to applying topical anesthetics for medical or cosmetic purposes. Use of products with the lowest amount of anesthetic and applying the least amount possible to relieve pain is also recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1181984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1181983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1181972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1181973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3300090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain assessment",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3300086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lidocaine (amide-type local anesthetic) and tetracaine (ester-type local anesthetic) block sodium ion channels required for the initiation and conduction of neuronal impulses. Heating element enhances delivery of the local anesthetics",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5048987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 20 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3300087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Lidocaine crosses the placental and blood-brain barriers; lidocaine is excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Lidocaine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neonates: 2.75 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 1.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Lidocaine: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lidocaine: Metabolized in the liver by cytochrome P450 CYP1A2 and partially by  CYP3A4 to inactive and active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tetracaine: Hydrolysis by plasma esterases to primary metabolites para-aminobenzoic acid and diethylaminoethanol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Lidocaine: Adults: 1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Lidocaine: Excreted in urine as metabolites and parent drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F3300091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/34/31267?source=see_link\">",
"      see \"Lidocaine and tetracaine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chewing or ingesting a new or used patch may result in toxicity. Avoid inadvertent trauma (rubbing, scratching, or exposure to extreme heat or cold) since application of the patch may lead to diminished or blocked sensation in the treated skin.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5048989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains CHADD&reg; self-warming heating element which facilitates drug delivery (when used appropriately, the patch is designed to increase skin temperature by &lt;5&deg;C); patch is latex free.  A used patch will still contain large amounts of lidocaine and tetracaine (at least 90% of the initial amount).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Sethna NF, Verghese ST, Hannallah RS, et al, &ldquo;A Randomized Controlled Trial to Evaluate S-Caine Patch for Reducing Pain Associated With Vascular Access in Children,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2005, 102(2):403-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35028/abstract-text/15681958/pubmed\" id=\"15681958\" target=\"_blank\">",
"        15681958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13027 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35028=[""].join("\n");
var outline_f34_13_35028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181967\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300077\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300088\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1182001\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362805\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300089\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300085\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300079\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11394984\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181980\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300081\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5048986\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300082\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181984\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181983\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181972\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181973\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300090\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300086\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5048987\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300087\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3300091\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5048989\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13027|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/57/43924?source=related_link\">",
"      Lidocaine and tetracaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/34/31267?source=related_link\">",
"      Lidocaine and tetracaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_13_35029="Ofatumumab: Drug information";
var content_f34_13_35029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ofatumumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/54/18276?source=see_link\">",
"    see \"Ofatumumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9524862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arzerra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16053099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Arzerra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9525628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9609714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with acetaminophen, an antihistamine, and a corticosteroid 30-120 minutes prior to treatment (see Administration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      CLL:",
"     </b>",
"     I.V. Initial dose: 300 mg week 1, followed 1 week later by 2000 mg once weekly for 7 doses (doses 2-8), followed 4 weeks later by 2000 mg once every 4 weeks for 4 doses (doses 9-12; for a total of 12 doses)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9609715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9609716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     When studied in patients with creatinine clearances ranging from 33-287 mL/minute, baseline creatinine clearance did not have a clinically relevant effect.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9609717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infusion reaction: Interrupt infusion for infusion reaction (any severity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grade 1 or 2 infusion reaction: Resume at one-half of the previous rate; may increase (see Administration) based on patient tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grade 3: Resume infusion at 12 mL/hour; may increase (see Administration) based on patient tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grade 4: Do not resume.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9609723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arzerra&trade;: 20 mg/mL (5 mL, 50 mL) [contains edetate disodium, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9609609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9609718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Do not administer I.V. push or as a bolus.",
"     </b>",
"     Premedicate with acetaminophen, an antihistamine, and a corticosteroid 30-120 minutes prior to administration. Administer with an in-line filter (supplied) and polyvinyl chloride (PVC) administration sets. Do not mix with or infuse with other medications. Flush line before and after infusion with NS. Begin infusion within 12 hours of preparation. The final concentration of dose 1 is 0.3 mg/mL and final concentration of doses 2-12 is 2 mg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Premedication:",
"     </i>",
"     Premedicate with oral acetaminophen (1000 mg), an oral or I.V. antihistamine (eg, cetirizine 10 mg orally or equivalent), and an I.V. corticosteroid. Full dose corticosteroid is recommended for doses 1, 2, and 9; in the absence of infusion reaction &ge;grade 3, may gradually reduce corticosteroid dose for doses 3-8; administer full or half corticosteroid dose with doses 10-12 if &ge;grade 3 did not occur with dose 9.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Doses 1 and 2:",
"     </i>",
"     Initiate infusion at 12 mL/hour for 30 minutes, if tolerated (no infusion reaction) increase to 25 mL/hour for 30 minutes, if tolerated, increase to 50 mL/hour for 30 minutes, if tolerated, increase to 100 mL/hour for 30 minutes, if tolerated, increase to 200 mL/hour for duration of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Doses 3-12:",
"     </i>",
"     Initiate infusion at 25 mL/hour for 30 minutes, if tolerated (no infusion reaction) increase to 50 mL/hour for 30 minutes, if tolerated, increase to 100 mL/hour for 30 minutes, if tolerated, increase to 200 mL/hour for 30 minutes, if tolerated, increase to 400 mL/hour for remainder of infusion.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9609706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9525630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory chronic lymphocytic leukemia (CLL)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9525626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ofatumumab may be confused with omalizumab",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9609619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (20%), fatigue (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (18%), nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (&ge;grade 3: 42%; grade 4: 18%; may be prolonged &gt;2 weeks), anemia (16%; grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pneumonia (23%), cough (19%), dyspnea (14%), bronchitis (11%), upper respiratory tract infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (70%; includes bacterial, fungal or viral; &ge;grade 3: 29%), infusion reaction (first infusion [300 mg]: 44%; second infusion [2000 mg]: 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (9%), hypertension (5%), hypotension (5%), tachycardia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Chills (8%), insomnia (7%), headache (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Urticaria (8%), hyperhidrosis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (8%), muscle spasm (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (8%), sinusitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Sepsis (8%), herpes zoster (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, angina, bacteremia, cytolytic hepatitis, hemolytic anemia, hypoxia, interstitial lung disease (infectious), laryngeal edema, neutropenic sepsis, peritonitis, pharyngolaryngeal pain, pruritus, rigors, septic shock, throat tightness, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9609615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9609616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hematologic toxicity: Severe and prolonged (&ge;1 week) cytopenias (neutropenia and thrombocytopenia) may occur. Monitor blood counts during treatment; more frequently if grade 3 or 4 cytopenias develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion reaction: May cause serious infusion reaction; reactions may include bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac ischemia/infarction, back pain, abdominal pain, fever, rash, urticaria, and/or angioedema. Premedicate prior to infusion; interrupt infusion (and institute appropriate treatment) for reaction; may require subsequent rate modification.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intestinal obstruction: Small intestine obstruction may occur with treatment; evaluate if suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Progressive multifocal leukoencephalopathy (PML): PML may occur with treatment and should be considered in any patient with new onset or worsening neurological symptoms. If PML is suspected, discontinue and evaluate promptly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatitis B: Reactivation of hepatitis B (including fulminant hepatitis and death) has occurred with CD20-directed monoclonal antibodies, including ofatumumab. Patients at high-risk for hepatitis B should be screened prior to treatment initiation. Hepatitis B carriers should be closely monitored for signs of active hepatitis B infection during and for 6-12 months after completion of treatment. Use in patients with active viral hepatitis has not been sufficiently studied; discontinue (and institute appropriate treatment) in patients who develop viral hepatitis or reactivation of viral hepatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Live vaccines should not be given concurrently with ofatumumab; there is no data concerning secondary transmission. The ability to generate an immune response to any vaccine following treatment is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9659666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9609610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9609611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenicity was not observed in animal reproduction studies, although prolonged depletion of circulating B cells was observed in animal offspring. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9609613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9609614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if ofatumumab is excreted in human milk. However, human IgG is excreted in breast milk, and therefore, ofatumumab may also be excreted in milk. The effects of local GI and systemic exposure are unknown, therefore caution should be used in nursing women receiving ofatumumab.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Arzerra Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (5 mL): $542.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg/50 mL (50 mL): $5425.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9609721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, hepatitis B screening (in patients at high-risk; prior to therapy initiation); signs of active hepatitis B infection (in hepatitis B carriers; during and for 6-12 months after therapy completion); signs or symptoms of infusion reaction; signs of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arzerra (AT, AU, CH, CZ, DK, EE, FR, GB, IE, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9609707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ofatumumab is a monoclonal antibody which binds specifically the extracellular (large and small) loops of the CD20 molecule (which is expressed on normal B lymphocytes and in B-cell CLL) resulting in potent complement-dependent cell lysis and antibody-dependent cell-mediated toxicity in cells that overexpress CD20.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9609709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 1.7-5.1 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Between dose 4 and dose 12: ~14 days (range: 2-62 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Lepretre S, Pedersen LM, et al, &ldquo;Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(3):1094-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35029/abstract-text/18003886/pubmed\" id=\"18003886\" target=\"_blank\">",
"        18003886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagenbeek A, Gadeberg O, Johnson P, et al, &ldquo;First Clinical Use of Ofatumumab, a Novel Fully Human Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Follicular Lymphoma: Results of a Phase 1/2 Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(12):5486-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35029/abstract-text/18390837/pubmed\" id=\"18390837\" target=\"_blank\">",
"        18390837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kipps TJ, Osterborg A, Mayer J, et al, &ldquo;Clinical Improvement With a Novel CD20 mAb, Ofatumumab, in Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Also Refractory to Alemtuzumab or With Bulky Lymphadenopathy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15s):7043 [abstract 7043 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Non-Hodgkin&rsquo;s Lymphomas,&rdquo; Version 4.2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osterborg A, Kipps TJ, Mayer J, et al, &ldquo;Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, is an Active Treatment for Patients With CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of an International Pivotal Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(11):328  [abstract 328 from 2008 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wierda WG, Kipps T, Mayer J, et al, &ldquo;Activity of Ofatumumab, a Novel CD20 mAb, and Prior Rituximab Exposure in Patients With Fludarabine-and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15s):7044 [abstract 7044 from ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9523 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35029=[""].join("\n");
var outline_f34_13_35029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524862\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16053099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9525628\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609714\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609715\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609716\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609717\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609723\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609609\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609718\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609706\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9525630\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9525626\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609619\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609615\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609616\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299781\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9659666\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609610\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609611\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609613\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609614\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322753\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609721\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962018\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609707\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9609709\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9523\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9523|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/54/18276?source=related_link\">",
"      Ofatumumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_13_35030="Piperacillin: Drug information";
var content_f34_13_35030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Piperacillin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/24/31107?source=see_link\">",
"    see \"Piperacillin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/10/33956?source=see_link\">",
"    see \"Piperacillin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3000477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Piperacillin for Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: 2-3 g/dose every 6-12 hours; maximum: 24 g/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 3-4 g/dose every 4-6 hours; maximum: 24 g/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Burn wound sepsis:",
"     </b>",
"     I.V.: 4 g every 4 hours with vancomycin and amikacin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cholangitis, acute:",
"     </b>",
"     I.V.: 4 g every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Keratitis",
"     </b>",
"     <b>",
"      <i>",
"       (Pseudomonas):",
"      </i>",
"     </b>",
"     Ophthalmic: 6-12 mg/mL every 15-60 minutes around the clock for 24-72 hours, then slow reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Malignant otitis externa:",
"     </b>",
"     I.V.: 4-6 g every 4-6 hours with tobramycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Moderate infections:",
"     </b>",
"     I.M., I.V.: 2-3 g/dose every 6-12 hours (maximum: 2 g I.M./site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint",
"     </b>",
"     <b>",
"      <i>",
"       (Pseudomonas):",
"      </i>",
"     </b>",
"     I.V.: 3 g every 6 hours with aminoglycoside",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Pseudomonas",
"      </i>",
"     </b>",
"     <b>",
"      infections:",
"     </b>",
"     I.V.: 4 g every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.M., I.V.: 3-4 g/dose every 4-6 hours (maximum: 24 g/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infections:",
"     </b>",
"     I.V.: 2-3 g/dose every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Uncomplicated gonorrhea:",
"     </b>",
"     I.M.: 2 g in a single dose accompanied by 1 g probenecid 30 minutes prior to injection",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F210331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/10/33956?source=see_link\">",
"      see \"Piperacillin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Infants and Children: I.M., I.V.: 200-300 mg/kg/day in divided doses every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystic fibrosis:",
"     </b>",
"     I.M., I.V.: 350-500 mg/kg/day in divided doses every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjust dose for renal impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: 1-2 g every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: 2-4 g every 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F210311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 6-8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderately dialyzable (20% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemofiltration: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F210288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels. Give at least 1 hour apart from aminoglycosides. Rapid administration can lead to seizures. Administer direct I.V. over 3-5 minutes. Intermittently infusion over 30 minutes. Do not administer more than 2 g per I.M. injection site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F210355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS, SWFI, bacteriostatic water;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, allopurinol, amifostine, aztreonam, bivalirudin, ciprofloxacin, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, famotidine, fenoldopam, fludarabine, foscarnet, gallium nitrate, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, IL-2, labetalol, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, midazolam, milrinone, morphine, multiple vitamins, nicardipine, oxytocin, pantoprazole, propofol, ranitidine, remifentanil, tacrolimus, teniposide, theophylline, thiotepa, verapamil, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, amphotericin B cholesteryl sulfate complex, filgrastim, gemcitabine, sargramostim, tobramycin, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Anakinra, cisatracurium, fluconazole, ondansetron, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, heparin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible infections such as septicemia, acute and chronic respiratory tract infections, skin and soft tissue infections, and urinary tract infections due to susceptible strains of",
"     <i>",
"      Pseudomonas",
"     </i>",
"     ,",
"     <i>",
"      Proteus",
"     </i>",
"     , and",
"     <i>",
"      Escherichia coli",
"     </i>",
"     and",
"     <i>",
"      Enterobacter",
"     </i>",
"     ; active against some streptococci and some anaerobic bacteria; febrile neutropenia (as part of combination regimen)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, convulsions, drowsiness, fever, Jarisch-Herxheimer reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalance, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Abnormal platelet aggregation and prolonged PT (high doses), agranulocytosis, Coombs' reaction (positive), hemolytic anemia, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myoclonus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis, acute renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to piperacillin, other beta-lactam antibiotics (penicillins or cephalosporins), or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Particularly in patients with renal impairment, bleeding disorders have been observed; discontinue if thrombocytopenia or bleeding occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukopenia/neutropenia: During prolonged use, leukopenia and neutropenia have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cystic fibrosis: An increased frequency of fever and rash has been reported in patients with cystic fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment, due to sodium load and adverse effects (anemia, neuropsychological changes); dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5719723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Piperacillin crosses the placenta and distributes into the amniotic fluid. Due to pregnancy induced physiologic changes, some pharmacokinetic parameters of piperacillin may be altered. At term, the apparent volume of distribution of piperacillin is increased and peak concentrations are significantly lower. Total clearance is normal to increased at term. These changes continue into the early postpartum period.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F210317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5707585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of piperacillin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering piperacillin to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F210294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g: 1.85 mEq",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F210282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs and symptoms of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avocin (ES, IT);",
"     </li>",
"     <li>",
"      Cypercil (PH);",
"     </li>",
"     <li>",
"      Isipen (CZ, HR, PL);",
"     </li>",
"     <li>",
"      Ivacin (DK, SE);",
"     </li>",
"     <li>",
"      Pentcillin (JP);",
"     </li>",
"     <li>",
"      Peracillin (KP);",
"     </li>",
"     <li>",
"      Peracin (TH);",
"     </li>",
"     <li>",
"      Picillin (IT);",
"     </li>",
"     <li>",
"      Picillina (TW);",
"     </li>",
"     <li>",
"      Pipcil (BE, LU, NL);",
"     </li>",
"     <li>",
"      Piperac (AR);",
"     </li>",
"     <li>",
"      Piperacillin (PL);",
"     </li>",
"     <li>",
"      Piperilline (FR);",
"     </li>",
"     <li>",
"      Piperzam (ES);",
"     </li>",
"     <li>",
"      Pipracil (HK, IN, MY);",
"     </li>",
"     <li>",
"      Pipracin (IL);",
"     </li>",
"     <li>",
"      Pipraks (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pipril (AT, AU, BG, CH, CZ, DE, ES, FI, GB, GR, HN, HR, HU, IE, PK, PL);",
"     </li>",
"     <li>",
"      Pipril &rdquo;Orifarm&rdquo; (DK);",
"     </li>",
"     <li>",
"      Piprilin (PT);",
"     </li>",
"     <li>",
"      Prisutomycin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F210290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: 70% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~16%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Not well absorbed when given orally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (dose dependent; prolonged with moderately severe renal or hepatic impairment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 1-5 days old: 3.6 hours; &gt;6 days old: 2.1-2.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-6 months: 0.79 hour; 6 months to 12 years: 0.39-0.5 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 36-80 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 30-50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine; partially feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Capellier G, Cornette C, Boillot A, et al, &ldquo;Removal of Piperacillin in Critically Ill Patients Undergoing Continuous Veno-Venous Hemofiltration,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(1):88-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/9428548/pubmed\" id=\"9428548\" target=\"_blank\">",
"        9428548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani, and Nightingale CH, \"",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, \"Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JA, Korth-Bradley J, Milisci M, et al, \"Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41:979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/11549103/pubmed\" id=\"11549103\" target=\"_blank\">",
"        11549103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, \"Inactivation of Aminoglycosides by Penicillins,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs PC, Stickel S, Anderson PH, et al, \"",
"      <i>",
"       In Vitro",
"      </i>",
"      Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(1):182-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/2014975/pubmed\" id=\"2014975\" target=\"_blank\">",
"        2014975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halstenson CE, Wong MO, Herman CS, et al, \"Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(9):1832-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/1416875/pubmed\" id=\"1416875\" target=\"_blank\">",
"        1416875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hitt CM, Patel KB, Nicolau DP, et al, \"Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(23):2704-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/9408514/pubmed\" id=\"9408514\" target=\"_blank\">",
"        9408514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keller E, Bohler J, Busse-Grawitz A, et al, &ldquo;Single Dose Kinetics of Piperacillin During Continuous Arteriovenous Hemodialysis in Intensive Care Patients,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1995, 43(Suppl 1):20-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/7697932/pubmed\" id=\"7697932\" target=\"_blank\">",
"        7697932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konishi H, Goto M, Nakamoto Y, et al, \"Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):653-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/6223576/pubmed\" id=\"6223576\" target=\"_blank\">",
"        6223576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau A, Lee M, Flascha S, et al, \"Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients with Normal Renal Function,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 24(4):533-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/6651279/pubmed\" id=\"6651279\" target=\"_blank\">",
"        6651279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Placzek M, Whitelaw A, Want S, et al, &ldquo;Piperacillin in Early Neonatal Infection,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1983, 58(12):1006-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/6559060/pubmed\" id=\"6559060\" target=\"_blank\">",
"        6559060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prince AS and Neu HC, &ldquo;Use of Piperacillin, A Semisynthetic Penicillin, in the Therapy of Acute Exacerbations of Pulmonary Disease in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1980, 97(1):148-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/6445961/pubmed\" id=\"6445961\" target=\"_blank\">",
"        6445961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russoe ME and Atkins-Thor E, \"Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,\"",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(4):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/7237864/pubmed\" id=\"7237864\" target=\"_blank\">",
"        7237864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tan JS and File TM Jr, &ldquo;Antipseudomonal Penicillins,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1995, 79(4):679-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/7791416/pubmed\" id=\"7791416\" target=\"_blank\">",
"        7791416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thirumoorthi MC, Asmar BI, Buckley JA, et al, &ldquo;Pharmacokinetics of Intravenously Administered Piperacillin in Preadolescent Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 102(6):941-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/6222169/pubmed\" id=\"6222169\" target=\"_blank\">",
"        6222169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson MIB, Russo ME, Saxon BJ, et al, \"Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1982, 21(2):268-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/6462107/pubmed\" id=\"6462107\" target=\"_blank\">",
"        6462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viollier AF, Standiford HC, Drusano GL, et al, \"Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(5):597-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/4008387/pubmed\" id=\"4008387\" target=\"_blank\">",
"        4008387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterspiel JN, Feldman S, Van R, et al, \"Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(9):1875-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/1952861/pubmed\" id=\"1952861\" target=\"_blank\">",
"        1952861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/13/35030/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9775 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35030=[""].join("\n");
var outline_f34_13_35030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000477\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210349\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210309\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210331\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210310\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210311\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210288\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210355\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210287\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210347\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210291\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210272\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299883\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210277\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5719723\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210317\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5707585\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210294\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210282\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038768\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210271\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210290\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9775|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/24/31107?source=related_link\">",
"      Piperacillin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/10/33956?source=related_link\">",
"      Piperacillin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_13_35031="HSG showing endometrial polyps";
var content_f34_13_35031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67493%7EOBGYN%2F80816%7EOBGYN%2F60263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67493%7EOBGYN%2F80816%7EOBGYN%2F60263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram showing multiple filling defects due to endometrial polyps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram showing multiple filling defects due to submucous myomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram showing a filling defect due to synechiae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35031=[""].join("\n");
var outline_f34_13_35031=null;
var title_f34_13_35032="Clinical features, diagnosis, and course of placenta previa";
var content_f34_13_35032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and course of placenta previa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Karen Russo-Stieglitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35032/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/13/35032/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa refers to the presence of placental tissue that extends over or lies proximate to the internal cervical os. Sequelae include the potential for severe bleeding and preterm birth, as well as the need for cesarean delivery.",
"   </p>",
"   <p>",
"    Placenta previa should be suspected in any woman beyond 20 weeks of gestation who presents with painless vaginal bleeding. For women who have not had a second trimester ultrasound examination, antepartum bleeding after 20 weeks of gestation should prompt sonographic determination of placental location",
"    <strong>",
"     before",
"    </strong>",
"    digital vaginal examination is performed because palpation of the placenta can cause severe hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review including 58 observational studies of placenta previa, prevalence ranged from 3.5 to 4.6 per 1000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence is several-fold higher early in gestation, but most of these cases resolve before delivery (see",
"    <a class=\"local\" href=\"#H1783334\">",
"     'Ultrasound presentation and course'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Purported risk factors, some of which are interdependent, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/2-12\">",
"     2-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous placenta previa",
"     </li>",
"     <li>",
"      Previous cesarean delivery",
"     </li>",
"     <li>",
"      Multiple gestation",
"     </li>",
"     <li>",
"      Multiparity",
"     </li>",
"     <li>",
"      Advanced maternal age",
"     </li>",
"     <li>",
"      Infertility treatment",
"     </li>",
"     <li>",
"      Previous abortion",
"     </li>",
"     <li>",
"      Previous intrauterine surgical procedure",
"     </li>",
"     <li>",
"      Maternal smoking",
"     </li>",
"     <li>",
"      Maternal cocaine use",
"     </li>",
"     <li>",
"      Male fetus",
"     </li>",
"     <li>",
"      Non-white race",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1783986\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of placenta previa is unknown. One hypothesis is that the presence of areas of suboptimal endometrium in the upper uterine cavity due to previous surgery or pregnancies promotes implantation of trophoblast in, or unidirectional growth of trophoblast toward, the lower uterine cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ]. Another hypothesis is that a particularly large placental surface area, as in multiple gestation or in response to reduced uteroplacental perfusion, increases the likelihood that the placenta will cover or encroach upon the cervical os.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1829329\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental bleeding is thought to occur when gradual changes in the cervix and lower uterine segment apply shearing forces to the inelastic placental attachment site, resulting in partial detachment. Vaginal examination or coitus can also disrupt the intervillous space and cause bleeding. Bleeding is primarily maternal, but fetal bleeding can occur if a fetal vessel is disrupted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1783334\">",
"    <span class=\"h2\">",
"     Ultrasound presentation and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;One to 6 percent of pregnant women display sonographic evidence of a placenta previa between 10 and 20 weeks of gestation when they undergo obstetrical ultrasound examination for assessment of gestational age, fetal anatomic survey, or prenatal diagnosis (see",
"    <a class=\"local\" href=\"#H1398189\">",
"     'Diagnosis'",
"    </a>",
"    below). The majority of these women are asymptomatic and 90 percent of these early cases resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/14\">",
"     14",
"    </a>",
"    ]. Two theories have been put forth to account for resolution of the previa:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lower uterine segment lengthens from 0.5 cm at 20 weeks of gestation to more than 5 cm at term [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/4\">",
"       4",
"      </a>",
"      ]. Development of the lower uterine segment relocates the stationary lower edge of the placenta away from the internal os.",
"     </li>",
"     <li>",
"      Progressive unidirectional growth of trophoblastic tissue toward the fundus within the relatively stationary uterus results in upward migration of the placenta. This phenomenon has been termed trophotropism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Placental atrophy may explain why the portion of the placenta that sonographically appeared to cover the cervix resolves.",
"   </p>",
"   <p>",
"    The later in gestation the previa persists, the more likely it will be present at delivery. In one series of 714 placenta previas, the previa was present at delivery in 12 percent of those identified at 15 to 19 weeks, 34 percent of those identified at 20 to 23 weeks, 49 percent of those identified at 24 to 27 weeks, 62 percent of those identified at 28 to 31 weeks, and 73 percent of those identified at 32 to 35 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distance the placenta extends over the internal cervical os is the best predictor of placenta previa at delivery. However, available data correlating gestational age, millimeters of extension over the cervical os, and outcome are insufficient to make precise predictions. Based on available data, at 18 to 23 weeks of gestation, a distance of at least 14 to 15 mm appears to be associated with a 20 percent risk of placenta previa at delivery, and when the distance is at least 25 mm, 40 to 100 percent of previas will be present at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. In the third trimester, a distance over 20 mm is highly predictive of persistence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/20\">",
"     20",
"    </a>",
"    ]. An anterior placenta previa appears to resolve more often and more quickly than posterior placenta previa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524431\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the second half of pregnancy, the characteristic clinical presentation is painless vaginal bleeding, which occurs in 70 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. An additional 10 to 20 percent of women present with both uterine contractions and bleeding, which is similar to the presentation of abruptio placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In approximately one-third of affected pregnancies, the initial bleeding episode occurs prior to 30 weeks of gestation; this group is more likely to require blood transfusions and is at greater risk of preterm delivery and perinatal mortality than women whose bleeding begins later in gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. An additional one-third of patients becomes symptomatic between 30 and 36 weeks, while most of the remaining patients have their first bleed after 36 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. About 10 percent of women reach term without bleeding.",
"   </p>",
"   <p>",
"    For an individual patient, it is not possible to predict whether a bleed will occur, nor the gestational age, volume, or frequency of bleeding. Authors have reported that placentas that cover the os bleed earlier and more than placentas that are proximate to the os [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/26-29\">",
"     26-29",
"    </a>",
"    ], placentas near the os have a greater risk of bleeding if the placental edge is thick (&gt;1 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/30\">",
"     30",
"    </a>",
"    ], and identification of an echo-free space in the placental edge covering the internal os [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/31\">",
"     31",
"    </a>",
"    ] or cervical length &le;3 cm are predictive of hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Although the magnitude of risk may differ according to previa characteristics, all patients with placentas covering or in close proximity to the cervical os are at risk of significant antepartum, intrapartum, and postpartum bleeding. Further study of patient-specific risk factors for bleeding is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa has been associated with an increased risk of several other pregnancy complications. The most serious and best supported of these complications is placenta accreta.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Placenta accreta",
"      </strong>",
"      &mdash; Placenta accreta complicates 1 to 5 percent of pregnancies with placenta previa and an unscarred uterus. The presence of placenta previa and one or more cesarean delivery scars places a woman at very high risk for placenta accreta and need for cesarean hysterectomy: one previous cesarean birth (11 to 25 percent), two previous cesarean births (35 to 47 percent), three previous cesarean births (40 percent), and &ge;four previous cesarean births (50 to 67 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/35-37\">",
"       35-37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one large series, composite maternal morbidity in women with placenta previa and zero, one, two, or three prior cesarean deliveries was 15, 23, 59, and 83 percent, respectively, and almost all of the excess composite maternal morbidity in women with a prior cesarean was related to complications associated with placenta accreta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1398279\">",
"       'Exclusion of placenta accreta'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preterm labor and rupture of the membranes",
"      </strong>",
"      &mdash; Antepartum bleeding from any cause is a risk factor for preterm labor and premature rupture of membranes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathogenesis of spontaneous preterm birth\", section on 'Decidual hemorrhage'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"       \"Preterm premature rupture of membranes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Malpresentation",
"      </strong>",
"      &mdash; The large volume of placenta in the lower portion of the uterine cavity predisposes the fetus to assume a noncephalic presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/39-42\">",
"       39-42",
"      </a>",
"      ]. Noncephalic presentation at delivery is also related to the increased risk of delivery before term, when noncephalic presentations are more common.",
"     </li>",
"     <li>",
"      <strong>",
"       Intrauterine growth restriction",
"      </strong>",
"      &mdash; An increased risk of intrauterine growth restriction has been reported by several [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/8,22,43-46\">",
"       8,22,43-46",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/24,25,43,47-49\">",
"       24,25,43,47-49",
"      </a>",
"      ], investigators, and remains controversial. If a reduction in fetal growth occurs, it is likely to be mild or due to confounding factors.",
"     </li>",
"     <li>",
"      <strong>",
"       Vasa previa and velamentous umbilical cord",
"      </strong>",
"      &mdash; Vasa previa and velamentous umbilical cord insertion are uncommon, but when present they are often associated with placenta previa. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/18/20775?source=see_link\">",
"       \"Velamentous umbilical cord insertion and vasa previa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Congenital anomalies",
"      </strong>",
"      &mdash; Population-based cohort studies have reported an increase in the overall rate of neonatal congenital anomalies in pregnancies complicated by placenta previa, but no single anomaly or syndrome was associated with the disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/8,25\">",
"       8,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Amniotic fluid embolism",
"      </strong>",
"      &mdash; A large population-based cohort study reported a strong association between placental pathology, such as placenta previa, and amniotic fluid embolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398189\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa should be suspected in any woman beyond 20 weeks of gestation who presents with vaginal bleeding. For women who have not had a second or third trimester ultrasound examination, antepartum bleeding should prompt sonographic determination of placental location",
"    <strong>",
"     before",
"    </strong>",
"    digital vaginal examination is performed because palpation of the placenta can cause severe hemorrhage. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The diagnosis of placenta previa is based on identification of placental tissue covering or proximate to the internal cervical os on an imaging study, typically ultrasound. Transabdominal ultrasound examination is performed as the initial examination; if it shows placenta previa or the findings are uncertain, transvaginal sonography should be performed to better define placental position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398236\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398243\">",
"    <span class=\"h3\">",
"     Transabdominal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal ultrasonography is used for initial placental localization. The sonographic diagnosis of placenta previa requires the identification of echogenic homogeneous placental tissue covering or proximate to the internal cervical os (a distance greater than 2 cm from the os excludes the diagnosis of previa). Sagittal, parasagittal, and transverse sonographic views should be obtained with the patient's bladder partially full.",
"   </p>",
"   <p>",
"    Specific points that should be appreciated when performing sonographic examination for placenta previa include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An over-distended bladder can compress the anterior lower uterine segment against the posterior lower uterine segment to give the appearance of a previa (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76545 \" href=\"mobipreview.htm?15/36/15938\">",
"       image 1",
"      </a>",
"      ). The diagnosis of placenta previa should not be made without confirming placental position after the patient has emptied her bladder. Care should be taken to not make the diagnosis of placenta previa when the lower uterine segment is contracting, which commonly occurs after a woman empties her bladder.",
"     </li>",
"     <li>",
"      A previa can be missed near term if the fetal head is low in the pelvis since acoustic shadowing from or compression of placental tissue by the fetal skull may obscure the placental location. In these cases, the cervix may be better visualized by placing the patient in Trendelenburg position",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gently pushing the fetal head cephalad.",
"     </li>",
"     <li>",
"      The sonographic diagnosis of a complete central previa is readily made since the placenta is centered over the cervix and placental tissue is imaged anterior and posterior to the cervix. Complete noncentral previas, particularly when lateral, are more difficult to confirm. Transverse views at and above the internal cervical os should facilitate an accurate diagnosis.",
"     </li>",
"     <li>",
"      The placental location may also be obscured by a hematoma or a lower uterine segment contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall false positive rate of transabdominal ultrasound for diagnosis of placenta previa is high (up to 25 percent), so the diagnosis should be confirmed by transvaginal ultrasound unless the previa is clearly central [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398250\">",
"    <span class=\"h3\">",
"     Transvaginal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and prospective comparative studies have established the superior performance of transvaginal sonography (TVS) over transabdominal sonography for diagnosis of placenta previa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/39,53,54\">",
"     39,53,54",
"    </a>",
"    ]. Transabdominal ultrasound examination is performed as the initial examination; if it shows placenta previa or the findings are uncertain, TVS should be performed to better define placental position. TVS generally provides a clearer image of the relationship of the edge of the placenta to the internal cervical os than transabdominal ultrasound. In one study of 100 suspected cases, sensitivity, specificity, and positive and negative predictive values of TVS for diagnosis of placenta previa were 87.5, 98.8, 93.3, 97.6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TVS can be performed safely in patients with previa since the optimal position of the vaginal probe for visualization of the internal os is 2 to 3 cm away from the cervix and the angle between the cervix and vaginal probe is sufficient to prevent the probe from inadvertently slipping into the cervical canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Translabial (transperineal) ultrasound imaging is an alternative technique that provides excellent images of the cervix and placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/57\">",
"     57",
"    </a>",
"    ]. The use of three-dimensional (3D) ultrasound may also improve accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1829588\">",
"    <span class=\"h4\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa is best documented by using transvaginal ultrasound to describe the distance (millimeters) that the placenta covers the internal cervical os if the previa is complete or the distance (millimeters) between the internal cervical os and the inferior edge of the placenta if it is not complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other descriptors have been used; the following terms represent an older, imprecise system for classifying placenta previa by ultrasound findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Complete placenta previa",
"      </strong>",
"      &mdash; The placenta completely covers the internal os (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74665 \" href=\"mobipreview.htm?40/60/41923\">",
"       image 2",
"      </a>",
"      ). A central placenta previa occurs when the internal os is approximately equidistant between the anterior and posterior edges of the placenta (20 to 30 percent of cases).",
"     </li>",
"     <li>",
"      <strong>",
"       Partial placenta previa",
"      </strong>",
"      &mdash; The placental edge appears to cover part, but not all, of the internal cervical os.",
"     </li>",
"     <li>",
"      <strong>",
"       Marginal placenta previa",
"      </strong>",
"      &mdash; The placental edge is adjacent to or at the margin of the internal os, but does not cover it (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55703 \" href=\"mobipreview.htm?35/47/36596\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Low placenta",
"      </strong>",
"      &mdash; Low placentas are associated with an increased risk of bleeding, and possibly other adverse perinatal outcomes, but the risk is less than with true placenta previas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An apparent placenta previa in the second trimester, or",
"     </li>",
"     <li>",
"      A placenta that lies in the lower uterine segment, but the exact relationship of the placenta to the os has not been determined, or",
"     </li>",
"     <li>",
"      A placental edge in close proximity to the internal os. There is no universal standard; a common definition is a placental edge &gt;0 but &lt;2 cm from the os.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398257\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is well-suited to the assessment of placental-cervical relationships because of the differing magnetic resonance characteristics of the two tissues. However, it is not used for diagnosis of placenta previa because of its high cost, limited availability, and the well-established safety and accuracy of transvaginal sonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/59\">",
"     59",
"    </a>",
"    ]. MRI is most useful for diagnosis of complicated placenta previa, such as previa-accreta and previa-percreta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link&amp;anchor=H3939754#H3939754\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398271\">",
"    <span class=\"h1\">",
"     POSTDIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398279\">",
"    <span class=\"h2\">",
"     Exclusion of placenta accreta",
"    </span>",
"    &nbsp;&mdash;&nbsp;When placenta previa is diagnosed, the possibility of placenta",
"    <span class=\"nowrap\">",
"     previa-accreta/percreta",
"    </span>",
"    should be considered. The normal interface between the placenta and bladder is characterized by a hypoechoic boundary that represents the myometrium and the normal retroplacental myometrial vasculature. When placenta accreta is present, this hypoechoic boundary is lost and the placenta appears contiguous with the bladder wall. On ultrasound, intraplacental sonolucent spaces (ie, lacunar flow) may be observed adjacent to the involved uterine wall. The diagnosis of placenta accreta is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1398554\">",
"    <span class=\"h2\">",
"     Follow-up ultrasound examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two to 4 percent of pregnant women display sonographic evidence of a placenta previa between 18 and 24 weeks of gestation, but many of these early cases resolve (see",
"    <a class=\"local\" href=\"#H1783334\">",
"     'Ultrasound presentation and course'",
"    </a>",
"    above). We do not perform follow-up examinations of placentas that are proximate to, but do not cover, the cervical os before 20 weeks of gestation. For those that do cover the os, we suggest a follow-up ultrasound examination between 28 and 32 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/20\">",
"     20",
"    </a>",
"    ]. We repeat the sonographic examination at regular intervals as long as the placenta covers, or is in close proximity (within 20 mm) to, the internal cervical os.",
"   </p>",
"   <p>",
"    As discussed above, extra vigilance is needed when the fetal head is low and visualization of the lower uterine segment is limited. (See",
"    <a class=\"local\" href=\"#H1398243\">",
"     'Transabdominal'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1830439\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1830447\">",
"    <span class=\"h2\">",
"     Maternal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa increases the risk of antepartum (RR 9.8), intrapartum (RR 2.5), and postpartum hemorrhage (RR 1.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/63\">",
"     63",
"    </a>",
"    ]. For this reason, women with placenta previa are more likely to receive blood transfusions (12 versus 0.8 percent without previa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/42\">",
"     42",
"    </a>",
"    ]) and undergo postpartum hysterectomy,",
"    <span class=\"nowrap\">",
"     uterine/iliac",
"    </span>",
"    artery ligation, or embolization of pelvic vessels to control bleeding (2.5 versus 0 percent without previa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/42\">",
"     42",
"    </a>",
"    ]). The risk is particularly high in those with previa-accreta. (See",
"    <a class=\"local\" href=\"#H524431\">",
"     'Bleeding'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Associated conditions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid, significant loss of intravascular volume can lead to hemodynamic instability, decreased oxygen delivery, decreased tissue perfusion, cellular hypoxia, organ damage, and death. The maternal mortality rate associated with placenta previa is less than 1 percent in resource-rich countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/64\">",
"     64",
"    </a>",
"    ], but remains high in resource-poor countries where maternal anemia, lack of medical resources, and home births are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1830454\">",
"    <span class=\"h2\">",
"     Neonatal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal morbidity and mortality rates in pregnancies complicated by placenta previa have fallen over the past few decades because of improvements in obstetrical management (eg, antenatal corticosteroids, delayed delivery when possible), the liberal use of cesarean delivery, and improved neonatal care. The principal causes of neonatal morbidity and mortality are related to preterm delivery, rather than anemia, hypoxia, or growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective cohort study of live births in the United States (1989 to 1991 and 1995 to 1997) included over 61,000 singleton pregnancies complicated by placenta previa and delivered by cesarean birth after 24 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/66\">",
"     66",
"    </a>",
"    ]. During this period, the neonatal mortality rate was 10.7 per 1000 live births with placenta previa compared to 2.5 per 1000 live births in non-previa pregnancies (RR 4.3; 95% CI 4.0-4.8).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1830461\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa recurs in 4 to 8 percent of subsequent pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35032/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/20/6466?source=see_link\">",
"       \"Patient information: Placenta previa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placenta previa should be suspected in any woman beyond 20 weeks of gestation who presents with painless vaginal bleeding. For women who have not had a second trimester ultrasound examination, antepartum bleeding after 20 weeks of gestation should prompt sonographic determination of placental location",
"      <strong>",
"       before",
"      </strong>",
"      digital vaginal examination is performed because palpation of the placenta can cause severe hemorrhage. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Previous placenta previa, previous cesarean deliveries, and multiple gestation are major risk factors for placenta previa. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The distance from the placental edge to the internal cervical os is the best predictor of placenta previa at delivery, but available data correlating gestational age, millimeters of extension over the cervical os, and outcome are insufficient to make precise predictions. (See",
"      <a class=\"local\" href=\"#H1783334\">",
"       'Ultrasound presentation and course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic clinical presentation is painless vaginal bleeding, which occurs in 70 to 80 percent of cases. An additional 10 to 20 percent of women present with both uterine contractions and bleeding, which is similar to the presentation of abruptio placenta. In approximately one-third of affected pregnancies, the initial bleeding episode occurs prior to 30 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H524431\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some conditions that may be associated with placenta previa include placenta accreta, malpresentation, preterm labor or premature rupture of the membranes, vasa previa and velamentous insertion of the umbilical cord. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of placenta previa is based upon identification of placental tissue covering or proximate to the internal cervical os on transvaginal ultrasound examination. (See",
"      <a class=\"local\" href=\"#H1398189\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/1\">",
"      Faiz AS, Ananth CV. Etiology and risk factors for placenta previa: an overview and meta-analysis of observational studies. J Matern Fetal Neonatal Med 2003; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/2\">",
"      Ananth CV, Smulian JC, Vintzileos AM. The association of placenta previa with history of cesarean delivery and abortion: a metaanalysis. Am J Obstet Gynecol 1997; 177:1071.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. NIH Consensus Development Conference: Vaginal Birth After Cesarean: New Insights. March 8&ndash;10, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/4\">",
"      Lavery JP. Placenta previa. Clin Obstet Gynecol 1990; 33:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/5\">",
"      Ananth CV, Demissie K, Smulian JC, Vintzileos AM. Placenta previa in singleton and twin births in the United States, 1989 through 1998: a comparison of risk factor profiles and associated conditions. Am J Obstet Gynecol 2003; 188:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/6\">",
"      Demissie K, Breckenridge MB, Joseph L, Rhoads GG. Placenta previa: preponderance of male sex at birth. Am J Epidemiol 1999; 149:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/7\">",
"      Yang Q, Wu Wen S, Caughey S, et al. Placenta previa: its relationship with race and the country of origin among Asian women. Acta Obstet Gynecol Scand 2008; 87:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/8\">",
"      Rosenberg T, Pariente G, Sergienko R, et al. Critical analysis of risk factors and outcome of placenta previa. Arch Gynecol Obstet 2011; 284:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/9\">",
"      Iyasu S, Saftlas AK, Rowley DL, et al. The epidemiology of placenta previa in the United States, 1979 through 1987. Am J Obstet Gynecol 1993; 168:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/10\">",
"      Macones GA, Sehdev HM, Parry S, et al. The association between maternal cocaine use and placenta previa. Am J Obstet Gynecol 1997; 177:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/11\">",
"      Rasmussen S, Albrechtsen S, Dalaker K. Obstetric history and the risk of placenta previa. Acta Obstet Gynecol Scand 2000; 79:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/12\">",
"      Gurol-Urganci I, Cromwell DA, Edozien LC, et al. Risk of placenta previa in second birth after first birth cesarean section: a population-based study and meta-analysis. BMC Pregnancy Childbirth 2011; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/13\">",
"      Rose GL, Chapman MG. Aetiological factors in placenta praevia--a case controlled study. Br J Obstet Gynaecol 1986; 93:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/14\">",
"      Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol 2006; 107:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/15\">",
"      Dashe JS, McIntire DD, Ramus RM, et al. Persistence of placenta previa according to gestational age at ultrasound detection. Obstet Gynecol 2002; 99:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/16\">",
"      Mouer JR. Placenta previa: antepartum conservative management, inpatient versus outpatient. Am J Obstet Gynecol 1994; 170:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/17\">",
"      Becker RH, Vonk R, Mende BC, et al. The relevance of placental location at 20-23 gestational weeks for prediction of placenta previa at delivery: evaluation of 8650 cases. Ultrasound Obstet Gynecol 2001; 17:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/18\">",
"      Taipale P, Hiilesmaa V, Yl&ouml;stalo P. Transvaginal ultrasonography at 18-23 weeks in predicting placenta previa at delivery. Ultrasound Obstet Gynecol 1998; 12:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/19\">",
"      Rosati P, Guariglia L. Clinical significance of placenta previa detected at early routine transvaginal scan. J Ultrasound Med 2000; 19:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/20\">",
"      Oppenheimer L, Holmes P, Simpson N, Dabrowski A. Diagnosis of low-lying placenta: can migration in the third trimester predict outcome? Ultrasound Obstet Gynecol 2001; 18:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/21\">",
"      Cho JY, Lee YH, Moon MH, Lee JH. Difference in migration of placenta according to the location and type of placenta previa. J Clin Ultrasound 2008; 36:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/22\">",
"      Cotton DB, Read JA, Paul RH, Quilligan EJ. The conservative aggressive management of placenta previa. Am J Obstet Gynecol 1980; 137:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/23\">",
"      Silver R, Depp R, Sabbagha RE, et al. Placenta previa: aggressive expectant management. Am J Obstet Gynecol 1984; 150:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/24\">",
"      McShane PM, Heyl PS, Epstein MF. Maternal and perinatal morbidity resulting from placenta previa. Obstet Gynecol 1985; 65:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/25\">",
"      Crane JM, van den Hof MC, Dodds L, et al. Neonatal outcomes with placenta previa. Obstet Gynecol 1999; 93:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/26\">",
"      Tuzovic L. Complete versus incomplete placenta previa and obstetric outcome. Int J Gynaecol Obstet 2006; 93:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/27\">",
"      Oya A, Nakai A, Miyake H, et al. Risk factors for peripartum blood transfusion in women with placenta previa: a retrospective analysis. J Nippon Med Sch 2008; 75:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/28\">",
"      Dola CP, Garite TJ, Dowling DD, et al. Placenta previa: does its type affect pregnancy outcome? Am J Perinatol 2003; 20:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/29\">",
"      Bahar A, Abusham A, Eskandar M, et al. Risk factors and pregnancy outcome in different types of placenta previa. J Obstet Gynaecol Can 2009; 31:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/30\">",
"      Ghourab S. Third-trimester transvaginal ultrasonography in placenta previa: does the shape of the lower placental edge predict clinical outcome? Ultrasound Obstet Gynecol 2001; 18:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/31\">",
"      Saitoh M, Ishihara K, Sekiya T, Araki T. Anticipation of uterine bleeding in placenta previa based on vaginal sonographic evaluation. Gynecol Obstet Invest 2002; 54:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/32\">",
"      Zaitoun MM, El Behery MM, Abd El Hameed AA, Soliman BS. Does cervical length and the lower placental edge thickness measurement correlates with clinical outcome in cases of complete placenta previa? Arch Gynecol Obstet 2011; 284:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/33\">",
"      Ghi T, Contro E, Martina T, et al. Cervical length and risk of antepartum bleeding in women with complete placenta previa. Ultrasound Obstet Gynecol 2009; 33:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/34\">",
"      Stafford IA, Dashe JS, Shivvers SA, et al. Ultrasonographic cervical length and risk of hemorrhage in pregnancies with placenta previa. Obstet Gynecol 2010; 116:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/35\">",
"      Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/36\">",
"      Clark SL, Koonings PP, Phelan JP. Placenta previa/accreta and prior cesarean section. Obstet Gynecol 1985; 66:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/37\">",
"      Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/38\">",
"      Grobman WA, Gersnoviez R, Landon MB, et al. Pregnancy outcomes for women with placenta previa in relation to the number of prior cesarean deliveries. Obstet Gynecol 2007; 110:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/39\">",
"      Sunna E, Ziadeh S. Transvaginal and transabdominal ultrasound for the diagnosis of placenta praevia. J Obstet Gynaecol 1999; 19:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/40\">",
"      Sheiner E, Shoham-Vardi I, Hallak M, et al. Placenta previa: obstetric risk factors and pregnancy outcome. J Matern Fetal Med 2001; 10:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/41\">",
"      Gemer O, Segal S. Incidence and contribution of predisposing factors to transverse lie presentation. Int J Gynaecol Obstet 1994; 44:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/42\">",
"      Olive EC, Roberts CL, Algert CS, Morris JM. Placenta praevia: maternal morbidity and place of birth. Aust N Z J Obstet Gynaecol 2005; 45:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/43\">",
"      Brenner WE, Edelman DA, Hendricks CH. Characteristics of patients with placenta previa and results of \"expectant management\". Am J Obstet Gynecol 1978; 132:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/44\">",
"      Varma TR. Fetal growth and placental function in patients with placenta praevia. J Obstet Gynaecol Br Commonw 1973; 80:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/45\">",
"      Newton ER, Barss V, Cetrulo CL. The epidemiology and clinical history of asymptomatic midtrimester placenta previa. Am J Obstet Gynecol 1984; 148:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/46\">",
"      Ananth CV, Demissie K, Smulian JC, Vintzileos AM. Relationship among placenta previa, fetal growth restriction, and preterm delivery: a population-based study. Obstet Gynecol 2001; 98:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/47\">",
"      Comeau J, Shaw L, Marcell CC, Lavery JP. Early placenta previa and delivery outcome. Obstet Gynecol 1983; 61:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/48\">",
"      Harper LM, Odibo AO, Macones GA, et al. Effect of placenta previa on fetal growth. Am J Obstet Gynecol 2010; 203:330.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/49\">",
"      N&oslash;rgaard LN, Pinborg A, Lidegaard &Oslash;, Bergholt T. A Danish national cohort study on neonatal outcome in singleton pregnancies with placenta previa. Acta Obstet Gynecol Scand 2012; 91:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/50\">",
"      Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol 2008; 199:49.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/51\">",
"      McClure N, Dornal JC. Early identification of placenta praevia. Br J Obstet Gynaecol 1990; 97:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/52\">",
"      Oppenheimer L, Society of Obstetricians and Gynaecologists of Canada. Diagnosis and management of placenta previa. J Obstet Gynaecol Can 2007; 29:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/53\">",
"      Smith RS, Lauria MR, Comstock CH, et al. Transvaginal ultrasonography for all placentas that appear to be low-lying or over the internal cervical os. Ultrasound Obstet Gynecol 1997; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/54\">",
"      Sherman SJ, Carlson DE, Platt LD, Medearis AL. Transvaginal ultrasound: does it help in the diagnosis of placenta previa? Ultrasound Obstet Gynecol 1992; 2:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/55\">",
"      Leerentveld RA, Gilberts EC, Arnold MJ, Wladimiroff JW. Accuracy and safety of transvaginal sonographic placental localization. Obstet Gynecol 1990; 76:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/56\">",
"      Timor-Tritsch IE, Yunis RA. Confirming the safety of transvaginal sonography in patients suspected of placenta previa. Obstet Gynecol 1993; 81:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/57\">",
"      Dawson WB, Dumas MD, Romano WM, et al. Translabial ultrasonography and placenta previa: does measurement of the os-placenta distance predict outcome? J Ultrasound Med 1996; 15:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/58\">",
"      Simon EG, Fouche CJ, Perrotin F. Three-dimensional transvaginal sonography in third-trimester evaluation of placenta previa. Ultrasound Obstet Gynecol 2013; 41:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/59\">",
"      Thurmond A, Mendelson E, B&ouml;hm-V&eacute;lez M, et al. Role of imaging in second and third trimester bleeding. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215 Suppl:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/60\">",
"      Predanic M, Perni SC, Baergen RN, et al. A sonographic assessment of different patterns of placenta previa \"migration\" in the third trimester of pregnancy. J Ultrasound Med 2005; 24:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/61\">",
"      Magann EF, Doherty DA, Turner K, et al. Second trimester placental location as a predictor of an adverse pregnancy outcome. J Perinatol 2007; 27:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/62\">",
"      Warshak CR, Eskander R, Hull AD, et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol 2006; 108:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/63\">",
"      Crane JM, Van den Hof MC, Dodds L, et al. Maternal complications with placenta previa. Am J Perinatol 2000; 17:101.",
"     </a>",
"    </li>",
"    <li>",
"     Clark, SL. Placenta previa and abruptio placentae. In: Creasy RK, Resnik R (Eds): Maternal Fetal Medicine: Principles and Practice. WB Saunders, Philadelphia 1999. p. 616.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/65\">",
"      Salihu HM, Li Q, Rouse DJ, Alexander GR. Placenta previa: neonatal death after live births in the United States. Am J Obstet Gynecol 2003; 188:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35032/abstract/66\">",
"      Ananth CV, Smulian JC, Vintzileos AM. The effect of placenta previa on neonatal mortality: a population-based study in the United States, 1989 through 1997. Am J Obstet Gynecol 2003; 188:1299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6772 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35032=[""].join("\n");
var outline_f34_13_35032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1783986\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1829329\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1783334\">",
"      Ultrasound presentation and course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H524431\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1398189\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1398236\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1398243\">",
"      - Transabdominal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1398250\">",
"      - Transvaginal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1829588\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1398257\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1398271\">",
"      POSTDIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1398279\">",
"      Exclusion of placenta accreta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1398554\">",
"      Follow-up ultrasound examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830439\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1830447\">",
"      Maternal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1830454\">",
"      Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1830461\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6772|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/36/15938\" title=\"diagnostic image 1\">",
"      Overdistended bladder mimicking placenta previa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/60/41923\" title=\"diagnostic image 2\">",
"      Complete placenta previa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/47/36596\" title=\"diagnostic image 3\">",
"      Marginal placenta previa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/20/6466?source=related_link\">",
"      Patient information: Placenta previa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/18/20775?source=related_link\">",
"      Velamentous umbilical cord insertion and vasa previa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_13_35033="M-mode echocardiography in cardiac tamponade";
var content_f34_13_35033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiography in cardiac tamponade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode sweep in panel A is from the left ventricular (LV) cavity to the aortic root (Ao) in a patient with a large pericardial effusion (EFF) and cardiac tamponade. Right ventricular (RV) narrowing is seen in the minor axis; only minimal cavitary expansion occurs with inspiration (IN), although it becomes more marked toward the right ventricular outflow tract (RVOT). With inspiration there is a reduction in the dimension of the left ventricular (LV) cavity, seen by the more posterior position of the interventricular septum (IVS) (black arrow); there is also a reduction in the E to F slope of mitral valve (MV) movement during inspiration, a result of reduced volume and flow from left atrium to ventricle (red arrows). After pericardiotomy (panel B), the pericardial effusion has disappeared, the RV is decompressed, and there are no changes in LV or RV volume with respiration. Note that the M-mode sweep after pericardiectomy goes from Ao to LV cavity.",
"    <div class=\"footnotes\">",
"     ARVW: anterior right ventricular wall; CW: chest wall; PLVW: posterior left ventricular wall; LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35033=[""].join("\n");
var outline_f34_13_35033=null;
var title_f34_13_35034="Clinical features, laboratory manifestations, and diagnosis of multiple myeloma";
var content_f34_13_35034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/13/35034/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35034/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/13/35034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35034/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/13/35034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/13/35034/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/13/35034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma (MM) is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, osteopenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pathologic fractures. The diagnosis of MM is often suspected because of one (or more) of the following clinical presentations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone pain with lytic lesions discovered on routine skeletal films",
"     </li>",
"     <li>",
"      An increased total serum protein concentration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of a monoclonal protein in the urine or serum",
"     </li>",
"     <li>",
"      Systemic signs or symptoms suggestive of malignancy, such as unexplained anemia",
"     </li>",
"     <li>",
"      Hypercalcemia, which is either symptomatic or discovered incidentally",
"     </li>",
"     <li>",
"      Acute renal failure with a bland urinalysis or rarely the nephrotic syndrome due to concurrent primary amyloidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to distinguish MM both from other causes of the clinical presentations above and from other plasma cell dyscrasias for the purposes of prognosis and treatment. It is also important to evaluate patients suspected of having MM in a timely fashion since a major delay in diagnosis has been associated with a negative impact on the disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, pathologic features, diagnosis, and differential diagnosis of multiple myeloma are discussed here. The pathogenesis and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27977?source=see_link\">",
"     \"Pathobiology of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma (MM) accounts for approximately one percent of all cancers and slightly more than 10 percent of hematologic malignancies in the United States (US) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/2\">",
"     2",
"    </a>",
"    ]. The annual incidence in the US is approximately 4 to 5 per 100,000. A similar incidence has been reported in the South Thames area of the United Kingdom and in Europe in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence appears to be stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. While some reports have suggested an increase in incidence over time, this more likely reflects the enhanced availability and use of medical facilities, especially by older persons. Our database from Olmsted County, Minnesota has documented a stable incidence from the 1940s to the early 21st century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MM occurs in all races and all geographic locations. The incidence varies by ethnicity; the incidence in African Americans and blacks from Africa is two to three times that in whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In contrast, the risk is lower in Asians from Japan and in Mexicans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. MM is also slightly more frequent in men than in women (approximately 1.4:1).",
"   </p>",
"   <p>",
"    MM is a disease of older adults. The median age at diagnosis is 66 years; only 10 and 2 percent of patients are younger than 50 and 40 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small but unknown fraction of cases are familial. The risk of developing MM is approximately 3.7-fold higher for persons with a first degree relative with MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/12\">",
"     12",
"    </a>",
"    ]. MM has been reported in clusters of two or more first-degree relatives, identical twins, and in four members spanning three generations in one family, with an incidence of approximately 3 familial cases per 1000 patients with myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/12-27\">",
"     12-27",
"    </a>",
"    ]. In one report of 15 families with MM clustering, 10 occurred in siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/22\">",
"     22",
"    </a>",
"    ]. The same IgG kappa monoclonal pattern was present in all cases in seven families. In addition, a genome wide association study that genotyped 1675 patients with MM and compared them with 5903 control subjects suggested that persons with a common variation at the 3p22.1 or 7p15.3 genetic loci are at a higher risk of developing MM (odds ratios of 1.32 and 1.38, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/28\">",
"     28",
"    </a>",
"    ]. While intriguing, such cases would be expected to account for less than 5 percent of familial risk. The low hazard ratios indicate that these markers do not have any direct clinical implications, and reflect the complexity of the disease and the etiologic mechanism involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with MM present with signs or symptoms related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. As an example, a retrospective analysis of 1027 sequential patients diagnosed with MM at a single institution found the following symptoms and signs at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia - 73 percent",
"     </li>",
"     <li>",
"      Bone pain - 58 percent",
"     </li>",
"     <li>",
"      Elevated creatinine - 48 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Fatigue/generalized",
"      </span>",
"      weakness - 32 percent",
"     </li>",
"     <li>",
"      Hypercalcemia - 28 percent",
"     </li>",
"     <li>",
"      Weight loss - 24 percent, one-half of whom had lost &ge; 9 kg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms and signs present in 5 percent or less included: paresthesias (5 percent), hepatomegaly (4 percent), splenomegaly (1 percent), lymphadenopathy (1 percent), and fever (0.7 percent). Pleural effusion and diffuse pulmonary involvement due to plasma cell infiltration are rare and usually occur in advanced disease. As the use of \"routine\" blood work has become more common, patients are being diagnosed earlier in the disease course.",
"   </p>",
"   <p>",
"    Extramedullary plasmacytomas (EP) are seen in approximately 7 percent of patients with MM at the time of diagnosis, and an additional 6 percent of patients will develop EP later in the disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/24,29\">",
"     24,29",
"    </a>",
"    ]. EP can present as large, purplish, subcutaneous masses (",
"    <a class=\"graphic graphic_picture graphicRef79555 \" href=\"mobipreview.htm?31/21/32082\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83143 \" href=\"mobipreview.htm?25/14/25831\">",
"     image 1",
"    </a>",
"    ). Plane xanthomas involving the creases of the palms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soles may represent a paraneoplastic phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/30\">",
"     30",
"    </a>",
"    ]. Cutaneous spicules, composed in part of the monoclonal protein, may rarely occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16662?source=see_link\">",
"     \"Diagnosis and management of solitary extramedullary plasmacytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link\">",
"     \"Cutaneous manifestations of internal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normocytic, normochromic anemia (hemoglobin &le;12",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is present in 73 percent at diagnosis and in 97 percent at some time during the course of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. This anemia can be related to bone marrow replacement, kidney damage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    can be due to dilution in the case of a large M-protein. Anemia commonly results in complaints of fatigue and pallor seen on physical examination.",
"   </p>",
"   <p>",
"    Macrocytosis (mean corpuscular volume &gt;100 fL) was present in 9 percent of 1027 patients studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. In this study, 53 patients (11 percent) with a MCV &gt;100 fL had a vitamin B12 level &lt;200",
"    <span class=\"nowrap\">",
"     ng/L.",
"    </span>",
"    This finding is similar to a prevalence of vitamin B12 deficiency of 14 percent seen in a separate study of 664 consecutive patients with plasma cell dyscrasias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/26\">",
"     26",
"    </a>",
"    ]. While the mechanism for low vitamin B12 levels in these patients is not known, investigations must be done to rule out pernicious anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bone pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone pain, particularly in the back or chest, and less often in the extremities, is present at the time of diagnosis in approximately 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. The pain is usually induced by movement and does not occur at night except with change of position. The patient's height may be reduced by several inches because of vertebral collapse. Plasmacytomas of the ribs occur and can present either as expanding costal lesions or soft tissue masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum creatinine concentration is increased in almost one-half of patients at diagnosis (and is &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in approximately 20 percent); renal failure may be the presenting manifestation of MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8,27\">",
"     8,27",
"    </a>",
"    ]. Two major causes of renal insufficiency in patients with MM are light chain cast nephropathy (also called myeloma kidney) and hypercalcemia. Patients who do not secrete light chains are not at risk for myeloma kidney. Other causes of renal failure in a patient with myeloma include concurrent light chain (AL) amyloidosis, light chain deposition disease, and drug-induced renal damage. Renal disease in MM is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is found in 28 percent of one series of patients with MM at the time of diagnosis; serum calcium was &ge;11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.75",
"    <span class=\"nowrap\">",
"     mmol/liter)",
"    </span>",
"    in 13 percent and can require emergent treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. The ionized calcium should be measured if the patient has a high serum calcium level but no symptoms of hypercalcemia. Elevation of the serum calcium may be due to binding of the monoclonal protein with calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Hypercalcemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link&amp;anchor=H2#H2\">",
"     \"Hypercalcemia of malignancy\", section on 'Osteolytic metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, severe hypercalcemia can act as an unmeasured cation and thereby result in a low anion gap. A decreased anion gap may also be due to the presence of a cationic IgG molecule. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36533?source=see_link\">",
"     \"Serum anion gap in conditions other than metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiculopathy, usually in the thoracic or lumbosacral area, is the most common neurologic complication of multiple myeloma. It can result from compression of the nerve by a paravertebral plasmacytoma or rarely by the collapsed bone itself.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cord compression &mdash; Spinal cord compression from an extramedullary plasmacytoma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83141 \" href=\"mobipreview.htm?13/58/14245\">",
"       image 2",
"      </a>",
"      ) or a bone fragment due to fracture of a vertebral body (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83142 \" href=\"mobipreview.htm?43/20/44357\">",
"       image 3",
"      </a>",
"      )occurs in approximately 5 percent of patients; it should be suspected in patients presenting with severe back pain along with weakness or paresthesias of the lower extremities, or bladder or bowel dysfunction or incontinence.",
"      <br/>",
"      <br/>",
"      This set of symptoms constitutes a",
"      <strong>",
"       medical emergency",
"      </strong>",
"      ; magnetic resonance imaging (MRI) or computed tomographic myelography of the entire spine must be performed immediately, with appropriate follow-up treatment by chemotherapy, radiotherapy, or neurosurgery to avoid permanent paraplegia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"       \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link\">",
"       \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral neuropathy &mdash; Peripheral neuropathy is uncommon in MM at the time of initial diagnosis and, when present, is usually due to amyloidosis. An exception to this general rule occurs in the infrequent subset of patients with POEMS syndrome (osteosclerotic myeloma) in which neuropathy occurs in nearly 100 percent of patients. The pathogenesis of the neuropathy is uncertain but a paraneoplastic mechanism may be important; this issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"       \"POEMS syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link&amp;anchor=H5#H5\">",
"       \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Association with plasma cell dyscrasias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CNS involvement &mdash; Intracranial plasmacytomas are rare and almost always represent extensions of myelomatous lesions of the skull or plasmacytomas involving the clivus or base of the skull. Leptomeningeal myelomatosis along with abnormal cerebrospinal fluid findings is uncommon but is being recognized more frequently, especially in advanced stages of the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/32-36\">",
"       32-36",
"      </a>",
"      ]. When found it denotes a poor prognosis with survival historically measured in months despite treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/36\">",
"       36",
"      </a>",
"      ]. Survival appears to have improved slightly since the incorporation of immunomodulatory drugs and proteasome inhibitors into first line therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Rare cases of encephalopathy due to hyperviscosity or high blood levels of ammonia, in the absence of liver involvement, have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/38-41\">",
"       38-41",
"      </a>",
"      ]. Myeloma cell lines developed from such patients produce elevated amounts of ammonia, although the mechanism is unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/42\">",
"       42",
"      </a>",
"      ]. Ammonia levels and the patient's state of consciousness return to normal if and when the underlying myeloma responds to chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MM are at increased risk for infection due to a combination of immune dysfunction and physical factors. Immune dysfunction results from impaired lymphocyte function, suppression of normal plasma cell function, and hypogammaglobulinemia. Physical factors include hypoventilation secondary to pathologic fractures and pain involving the rib cage and spine. Streptococcus pneumoniae and gram-negative organisms are the most frequent pathogens.",
"   </p>",
"   <p>",
"    Further details of immunodeficiency due to MM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monoclonal proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a monoclonal (M) protein in the serum or urine is a major criterion for the diagnosis of MM. The vast majority (97 percent) of patients with MM will have an M-protein produced and secreted by the malignant plasma cells, which can be detected by protein electrophoresis of the serum (SPEP)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    of an aliquot of urine (UPEP) from a 24-hour collection combined with immunofixation of the serum and urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The M-protein usually presents as a single narrow peak, like a church spire, in the gamma, beta, or alpha-2 region of the densitometer tracing (",
"    <a class=\"graphic graphic_figure graphicRef67685 \" href=\"mobipreview.htm?21/3/21566\">",
"     figure 1",
"    </a>",
"    ) or as a dense, discrete band on the agarose gel (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62500 \" href=\"mobipreview.htm?6/58/7087\">",
"     image 4",
"    </a>",
"    ). Infrequently, two M proteins are present (biclonal gammopathy) (",
"    <a class=\"graphic graphic_figure graphicRef54186 \" href=\"mobipreview.htm?29/1/29727\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum immunofixation confirms the presence of an M-protein and determines its type (",
"    <a class=\"graphic graphic_figure graphicRef55916 \" href=\"mobipreview.htm?4/39/4735\">",
"     figure 3",
"    </a>",
"    ). The malignant plasma cells can produce immunoglobulin heavy chains plus light chains, light chains alone, or neither with the following frequencies on serum immunofixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgG &mdash; 52 percent",
"     </li>",
"     <li>",
"      IgA &mdash; 21 percent",
"     </li>",
"     <li>",
"      Kappa or lambda light chain only (Bence Jones) &mdash; 16 percent",
"     </li>",
"     <li>",
"      IgD &mdash; 2 percent",
"     </li>",
"     <li>",
"      Biclonal &mdash; 2 percent",
"     </li>",
"     <li>",
"      IgM &mdash; 0.5 percent",
"     </li>",
"     <li>",
"      Negative &mdash; 6.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Kappa is the predominant light chain isotype compared with lambda, by a factor of 2 to 1 with the exception that lambda light chains are more common in IgD myeloma (",
"    <a class=\"graphic graphic_figure graphicRef56523 \" href=\"mobipreview.htm?1/57/1951\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Typical pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum protein electrophoresis (SPEP) will demonstrate a localized band or peak in 82 percent of patients with myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. Addition of serum protein immunofixation increases the sensitivity to 93 percent. If, in addition, either the serum free light chain assay or urine monoclonal protein studies (urine protein electrophoresis and urine immunofixation) are done, the sensitivity increases to 97 percent or more. Patients who lack detectable M protein by any of these tests are considered to have \"non-secretory myeloma.\" Among the 20 percent with no localized band on SPEP, hypogammaglobulinemia is seen in about one-half (due in part to suppression of normal gamma globulin production) and no apparent abnormality in the remainder.",
"   </p>",
"   <p>",
"    The level of one or both of the major uninvolved immunoglobulins (ie, IgM and IgA in the case of IgG myeloma) is reduced in 91 percent of patients overall, and both are reduced in 73 percent. Normal levels of the uninvolved immunoglobulins were present at diagnosis in 3, 8, 12, and 13 percent of our patients with IgA, nonsecretory, IgG, and light chain myeloma, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. In one study, patients with myeloma had lower median levels of IgE (11",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    than normal subjects (38",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Light chain myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 20 percent of myeloma is characterized by only a light chain in the serum or urine, lacking expression of the immunoglobulin heavy chain. These patients are detected readily by UPEP and urine immunofixation. The incidence of renal failure is much higher in light-chain myeloma, as the serum creatinine is &ge;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in about one-third of these patients at presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Non-secretory myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 3 percent of patients with MM have no M-protein in the serum or urine on immunofixation at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. Free light chain (FLC) assays can be used to detect monoclonal protein in the absence of M protein with the above studies. In approximately 60 percent of patients with myeloma who have a normal serum and urine immunofixation, monoclonal free light chains can be detected in the serum using FLC assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The FLC assay measures serum kappa and lambda light chain levels, which can then be expressed as a FLC kappa to lambda ratio. Patients without proliferative disorders of plasma cells or B-lymphocytes have normal FLC ratios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/47\">",
"     47",
"    </a>",
"    ]. In comparison, patients with plasma cell disorders will have greater than expected proportions of kappa or lambda light chains resulting in an abnormal ratio. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"     \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with myeloma who have normal serum and urine immunofixation and normal serum free light chain assay are considered to have nonsecretory myeloma. Of these, the majority (approximately 85 percent) will have M-protein that can be detected in the cytoplasm of the neoplastic plasma cells by immunochemistry, but have impaired secretion of this protein. The other 15 percent do not have immunoglobulin detectable in the plasma cells (ie, non-producer myeloma).",
"   </p>",
"   <p>",
"    Nonsecretory myeloma remains nonsecretory in most patients (76 percent), even with extended follow-up. Patients with nonsecretory MM are not at risk for myeloma kidney as long as light chains cannot be detected in the urine, but they are at risk for other complications of MM.",
"   </p>",
"   <p>",
"    Patients with non-secretory myeloma need to be monitored mainly on the basis of imaging tests and bone marrow studies, as well as the free light chain ratio if initially abnormal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607174\">",
"    <span class=\"h3\">",
"     Oligo-secretory myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 10 percent of patients with MM have oligo-secretory myeloma at diagnosis, defined as absence of measurable disease in serum or urine by the following parameters:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum M protein &lt;1",
"      <span class=\"nowrap\">",
"       gram/dL,",
"      </span>",
"      and",
"     </li>",
"     <li>",
"      Urine M protein &lt;200",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring of these patients is difficult using the standard serum and urine electrophoretic tests since it will be difficult to determine if small variations are real or due to expected laboratory variability. In most of these patients, the serum free light chain (FLC) assay can be used to monitor the disease, provided that the serum FLC ratio is abnormal and the involved (affected) FLC level is &ge;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/48\">",
"     48",
"    </a>",
"    ]. As with non-secretory myeloma, patients with oligo-secretory disease may also need to be monitored by imaging and bone marrow studies, particularly if the baseline FLC levels are unmeasurable (&lt;10",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    or if there is concern about the reliability of the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Laboratory artifacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating monoclonal proteins may interfere with one or more laboratory tests performed on liquid-based automated analyzers, either by precipitating during the analysis, or by virtue of their specific binding properties. The most common artifacts are a low value for HDL cholesterol, a high value for bilirubin, as well as altered measurement of inorganic phosphate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link&amp;anchor=H5#H5\">",
"     \"Recognition of monoclonal proteins\", section on 'Interference with laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not a laboratory artifact, monoclonal protein can increase the serum viscosity and erythrocyte sedimentation rate (ESR). The ESR is &gt;20",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    in 84 percent, and &gt;100",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    in one-third of patients with MM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, patients with MM frequently present with renal insufficiency due to cast nephropathy. Alternatively, kidney disease associated with MM can be due to amyloidosis or light chain deposition disease. Care must be taken in interpreting the urinalysis results. Urine dipstick examinations primarily detect albumin, not light chains, which can be detected by sulfosalicylic acid or a 24-hour urine collection including electrophoresis and immunofixation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings on urinalysis in MM depend upon the etiology of the kidney damage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloma cast nephropathy is characterized by the presence of large, waxy, laminated casts in the distal and collecting tubules; the casts are mainly composed of precipitated monoclonal light chains (",
"      <a class=\"graphic graphic_picture graphicRef57572 graphicRef70405 graphicRef82327 \" href=\"mobipreview.htm?16/0/16394\">",
"       picture 2A-C",
"      </a>",
"      ). The urine dipstick is typically negative for protein, since most of the proteinuria is comprised of urinary monoclonal protein (Bence Jones proteinuria) rather than albumin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22551?source=see_link\">",
"       \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to myeloma cast nephropathy, renal involvement in other related plasma cell disorders, namely AL amyloidosis and light chain deposition disease, typically present with a markedly positive dipstick for protein, since most of the urinary protein is comprised of albumin (nephrotic syndrome). Bence Jones proteinuria is minimal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cast nephropathy and amyloidosis rarely occur in the same patients because the biochemical characteristics of the individual monoclonal light chain are an important determinant of the type of renal disease that may be seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Peripheral smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent findings on peripheral smear are rouleaux formation (&gt;50 percent), leukopenia (20 percent), and thrombocytopenia (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. Rouleaux formation is the phenomenon when red cells take on the appearance of a stack of coins in diluted suspensions of blood and is seen in patients with elevated serum protein levels (",
"    <a class=\"graphic graphic_picture graphicRef74369 \" href=\"mobipreview.htm?27/33/28183\">",
"     picture 3",
"    </a>",
"    ). A leukoerythroblastic reaction is uncommonly seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the peripheral blood smear\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monoclonal plasma cells are rarely seen in the peripheral smear in patients with myeloma; a detectable absolute peripheral blood plasma cell count &ge;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (&ge;0.1 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    is found in approximately 10 percent (",
"    <a class=\"graphic graphic_picture graphicRef63684 \" href=\"mobipreview.htm?19/27/19888\">",
"     picture 4",
"    </a>",
"    ). Plasma cell leukemia, a rare, yet aggressive form of MM characterized by high levels of plasma cells circulating in the peripheral blood should be considered whenever circulating plasma cells are readily detected on conventional complete blood count evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16039?source=see_link\">",
"     \"Plasma cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Circulating monoclonal plasma cells can be detected using a slide-based immunofluorescence assay, a two-color immunoassay technique (ELISPOT), or flow cytometry by gating on",
"    <span class=\"nowrap\">",
"     CD38+/CD45-",
"    </span>",
"    cells. Using these sensitive techniques, circulating monoclonal plasma cells can be identified in the majority of patients with MM; the absolute percentage depends upon the sensitivity of the test used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link&amp;anchor=H12#H12\">",
"     \"Staging and prognostic studies in multiple myeloma\", section on 'Circulating plasma cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bone marrow aspirate and biopsy are a key component to the diagnosis of MM (",
"    <a class=\"graphic graphic_picture graphicRef61145 \" href=\"mobipreview.htm?33/12/33990\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72153 \" href=\"mobipreview.htm?27/45/28372\">",
"     picture 6",
"    </a>",
"    ). The bone marrow of the vast majority of patients contains 10 percent or more clonal plasma cells. However, due to patchy bone marrow involvement, bone marrow aspirate and biopsy may show less than 10 percent plasma cells in approximately 4 percent of patients. As an example, in the Mayo Clinic series, plasma cells constituted more than 10 percent of all nucleated cells in 96 percent of patients, but this value ranged from less than 5 percent to almost 100 percent, with a median value of 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diagnosis of MM can be made in patients with less than 10 percent clonal plasma cells on biopsy if other diagnostic criteria are fulfilled",
"    <strong>",
"     and",
"    </strong>",
"    after histopathologic confirmation of a soft tissue or bony plasmacytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/10\">",
"     10",
"    </a>",
"    ]. Since bone marrow involvement may be more focal than diffuse, some patients may require bone marrow",
"    <span class=\"nowrap\">",
"     aspirate/biopsy",
"    </span>",
"    from several different sites or a guided biopsy of a focal lesion diagnosed by either MRI or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    (integrated positron emission tomography and computed tomography) scan in order to establish the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphological features of plasma cells can differ depending upon their maturity and, at times, they may be morphologically indistinguishable from myeloblasts. Mature plasma cells are oval with abundant basophilic cytoplasm. The nucleus is round and eccentrically located with a marked perinuclear hof, or cytoplasmic clearing (",
"    <a class=\"graphic graphic_picture graphicRef63684 \" href=\"mobipreview.htm?19/27/19888\">",
"     picture 4",
"    </a>",
"    ). The nucleus contains \"clock-face\" or \"spoke wheel\" chromatin without nucleoli. Immature plasma cells have dispersed nuclear chromatin, prominent nucleoli and a high nuclear to cytoplasmic ratio.",
"   </p>",
"   <p>",
"    The cytoplasm of myeloma cells may contain condensed or crystallized cytoplasmic immunoglobulin resulting in the following unusual findings, which are not limited to MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple pale bluish-white, grape-like accumulations (eg, Mott cells, Morula cells)",
"     </li>",
"     <li>",
"      Cherry-red refractive round bodies (eg, Russell bodies)",
"     </li>",
"     <li>",
"      Vermilion staining glycogen-rich IgA (eg, Flame cells)",
"     </li>",
"     <li>",
"      Overstuffed fibrils (eg, Gaucher-like cells, thesaurocytes)",
"     </li>",
"     <li>",
"      Crystalline rods",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemical staining, immunofluorescent studies, and flow cytometry detect either kappa or lambda light chains, but not both, in the cytoplasm of bone marrow plasma cells in patients with myeloma; surface immunoglobulin is absent. The normal",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    ratio in the bone marrow is 2:1. A ratio of more than 4:1 or less than 1:2 is considered to meet the definition of kappa or lambda monoclonality, respectively. This finding distinguishes the monoclonal gammopathies from reactive plasmacytosis due to autoimmune diseases, metastatic carcinoma, chronic liver disease, acquired immunodeficiency syndrome (AIDS), or chronic infection, in which the plasma cells show reactivity for both light chain types and the",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    ratio is within the normal range. A CD138 stain can identify plasma cells and aid in the accurate determination of percentage involved.",
"   </p>",
"   <p>",
"    Much like normal plasma cells, myeloma cells express CD79a, VS38c, CD138, and CD38 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast to normal plasma cells, myeloma cells infrequently express CD19. Approximately 70 percent of myeloma cells will express CD56, which is typically negative in normal plasma cells and in plasma cell leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16039?source=see_link\">",
"     \"Plasma cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cytogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single cytogenetic abnormality that is typical or diagnostic of MM. The majority of myeloma tumors have genetic abnormalities that can be detected with sensitive molecular genetic techniques, such as interphase fluorescent in situ hybridization (FISH). In contrast, only 20 to 30 percent of patients will have cytogenetic abnormalities detected in bone marrow plasma cells by conventional karyotyping, due to a low number of metaphases in myeloma cells in such specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The genetic changes found in MM are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27977?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathobiology of multiple myeloma\", section on 'Cytogenetic abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link&amp;anchor=H9#H9\">",
"     \"Staging and prognostic studies in multiple myeloma\", section on 'Fluorescent in situ hybridization (FISH)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A metastatic bone survey with plain radiographs including the humeri and femoral bones is a key component to the evaluation of a patient suspected of having MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/52\">",
"     52",
"    </a>",
"    ]. Computerized tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are more sensitive than plain radiographs at detecting bone involvement; however, the clinical importance of asymptomatic bone lesions detected by these imaging modalities alone is not clear.",
"   </p>",
"   <p>",
"    We reserve CT, MRI, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    for select patients such as those with bone pain without an abnormality on skeletal survey, patients in whom there is any uncertainty about the extent of bone disease, patients with compression fractures, or those with neurological deficit that may be due to spinal cord compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, either MRI or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan including the pelvis and lumbar spine should be performed routinely before making the diagnosis of solitary plasmacytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/54\">",
"     54",
"    </a>",
"    ]. A baseline MRI scan of the pelvis and spine may also be useful for risk stratification in patients with smoldering MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/55\">",
"     55",
"    </a>",
"    ]. Our approach is consistent with the guidelines proposed by the International Myeloma Working Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/53\">",
"     53",
"    </a>",
"    ]. Technetium-99m bone scanning (which primarily detects osteoblastic activity) is inferior to conventional roentgenography for the detection of lytic lesions and should not be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Skeletal surveys",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skeletal survey for patients with MM includes a posteroanterior view of the chest, anteroposterior and lateral views of the cervical spine, thoracic spine, lumbar spine, humeri and femora, anteroposterior and lateral views of the skull and anteroposterior view of the pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/53\">",
"     53",
"    </a>",
"    ]. Symptomatic areas are also imaged.",
"   </p>",
"   <p>",
"    Conventional skeletal surveys reveal punched-out lytic lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78569 \" href=\"mobipreview.htm?3/0/3076\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83023 \" href=\"mobipreview.htm?39/41/40595\">",
"     image 6",
"    </a>",
"    ), diffuse osteopenia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83026 \" href=\"mobipreview.htm?33/48/34565\">",
"     image 7",
"    </a>",
"    ), or fractures in nearly 80 percent of patients with MM at the time of diagnosis (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"mobipreview.htm?21/17/21787\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8,57,58\">",
"     8,57,58",
"    </a>",
"    ]. Focal lytic lesions are found in nearly 60 percent; osteoporosis, pathologic fractures, or compression fractures of the spine each occur in approximately 20 percent of patients. The most frequent sites of involvement include areas with active hematopoiesis, such as the vertebral bodies, skull, thoracic cage, pelvis, and proximal humeri and femora. Osteosclerotic lesions (ie, areas of intense increased bone density) are rare. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'POEMS syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"     \"POEMS syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT), magnetic resonance imaging (MRI), and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans are helpful in patients who have bone pain but no abnormalities on routine roentgenograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/56,59-72\">",
"     56,59-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI can detect diffuse and focal bone marrow lesions in patients with MM without osteopenia or focal osteolytic lesions on standard metastatic bone surveys and bone surveys can detect lesions not found on MRI of the axial skeleton. In one study in which 611 patients with myeloma had both MRI imaging (limited to the axial bone marrow) as well as a standard metastatic bone survey, MRI detected focal lesions in 52 percent of those with negative bone surveys, while bone surveys detected focal lesions in 20 percent of those with a negative MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/66\">",
"     66",
"    </a>",
"    ]. Significantly higher proportions of patients had focal lesions detected on MRI in the spine, pelvis, and sternum, while bone surveys outperformed MRI for lesions in the ribs and long bones.",
"   </p>",
"   <p>",
"    Up to half of smoldering (asymptomatic) MM patients with normal plain films may demonstrate tumor-related lesions on MRI of the lower spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. MRI may also be of prognostic value in such patients in determining risk of progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/65,73\">",
"     65,73",
"    </a>",
"    ]. As an example, the importance of focal lesions identified on whole-body MRI was investigated in 149 patients with asymptomatic (smoldering) myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/73\">",
"     73",
"    </a>",
"    ]. On multivariate analysis, the presence of more than one focal lesion or the presence of diffuse marrow involvement were significantly associated with an increased likelihood of progression to symptomatic multiple myeloma.",
"   </p>",
"   <p>",
"    Among patients with moderate to advanced renal failure (dialysis- dependent or estimated GFR &lt;30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should be avoided if possible. This issue, as well as the role of hemodialysis after the procedure if gadolinium-based imaging must be performed, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning using fluorine-18-labeled FDG appears to correlate with areas of active lytic bone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/69-72,74\">",
"     69-72,74",
"    </a>",
"    ]. In one small series,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning detected some lesions missed by other techniques; however, false positive as well as false negative results were also reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/71\">",
"     71",
"    </a>",
"    ]. The specificity of myeloma lesions is higher with a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which suggests an active osteolytic lesion at the site of increased tracer uptake.",
"   </p>",
"   <p>",
"    The administration of radiocontrast media, usually in conjunction with a CT scan, can lead to a usually reversible form of acute kidney injury that begins soon after the contrast is administered, called contrast-induced nephropathy. Patients with multiple myeloma are at increased risk from a contrast study, although the incidence of acute renal failure appears to be less than 1.5 percent with the use of modern contrast agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/75\">",
"     75",
"    </a>",
"    ]. Patients with near-normal renal function are at relatively low risk and few precautions are necessary other than avoidance of volume depletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having MM should initially undergo a complete history and physical examination. The history should pay specific attention to complaints of bone pain, constitutional symptoms, neurological symptoms, and infections. The physical examination should include a detailed neurologic exam.",
"   </p>",
"   <p>",
"    In addition, we perform the following laboratory studies as an initial screen to look for MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete blood count and differential with examination of the peripheral blood smear.",
"     </li>",
"     <li>",
"      A chemistry screen that includes measurements of serum calcium, creatinine, albumin, lactate dehydrogenase, beta-2 microglobulin, and C-reactive protein. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link\">",
"       \"Staging and prognostic studies in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum free monoclonal light chain (FLC) analysis.",
"     </li>",
"     <li>",
"      A serum protein electrophoresis (SPEP) with immunofixation and quantitation of immunoglobulins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A routine urinalysis and a 24-hour urine collection for electrophoresis (UPEP) and immunofixation. Serum free FLC analysis may be used in place of a 24-hour urine collection in conjunction with SPEP and immunofixation for screening purposes only [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/81\">",
"       81",
"      </a>",
"      ]. However, if a plasma cell proliferative disorder is identified, the UPEP and immunofixation are necessary. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum viscosity should be measured if the M-protein concentration is high (ie, &gt;5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      or there are symptoms suggestive of hyperviscosity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone marrow aspiration and biopsy with immunophenotyping, conventional cytogenetics, and fluorescence in situ hybridization (FISH). Although a bone marrow evaluation is indicated for all patients with MM at diagnosis, it may be deferred for persons that are clinically suspected of having MGUS with a small monoclonal protein (less than 1.5",
"      <span class=\"nowrap\">",
"       g/100",
"      </span>",
"      mL), minimal or no abnormalities in serum free light chains, and no end organ damage.",
"     </li>",
"     <li>",
"      A metastatic bone survey with plain radiographs including the humeri and femoral bones should be performed in all patients. If patients have a normal bone survey in the setting of bone pain, or have neurological deficits that may be due to spinal cord compression, additional imaging such as MRI, CT, or",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      should be performed to rule out myeloma bone disease. MRI and",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      are useful in patients in whom there is uncertainty about the extent of bone disease, and the role of these imaging modalities is evolving.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Mayo Clinic and the International Myeloma Working Group criteria for the diagnosis of symptomatic MM emphasize the importance of end organ damage in making the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef57627 \" href=\"mobipreview.htm?41/38/42603\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/77,78,82,83\">",
"     77,78,82,83",
"    </a>",
"    ]. The following three criteria must be met for the diagnosis of symptomatic MM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of an M-protein in serum (",
"      <a class=\"graphic graphic_figure graphicRef67685 \" href=\"mobipreview.htm?21/3/21566\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55916 \" href=\"mobipreview.htm?4/39/4735\">",
"       figure 3",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine (",
"      <a class=\"graphic graphic_figure graphicRef55073 \" href=\"mobipreview.htm?7/20/7503\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75044 \" href=\"mobipreview.htm?42/51/43824\">",
"       figure 6",
"      </a>",
"      ). Note: no specific level of M-protein is used as a cutoff value since approximately 40 percent of patients with symptomatic MM will have an M-protein of less than 3",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      Also note that, in true non-secretory MM (approximately 3 percent of MM), an M protein will not be detectable in the serum or urine with immunofixation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link\">",
"       \"Recognition of monoclonal proteins\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Presence of 10 percent or more clonal bone marrow plasma cells. Note: approximately 4 percent of patients may have fewer than 10 percent bone marrow plasma cells since marrow involvement may be focal, rather than diffuse. Repeat bone marrow biopsy should be considered in such patients. A diagnosis of MM can be made, if other diagnostic criteria are fulfilled, after histopathologic confirmation of a soft tissue or bony plasmacytoma.",
"     </li>",
"     <li>",
"      Presence of related organ or tissue impairment (often recalled by the acronym CRAB) which can include increased plasma",
"      <strong>",
"       c",
"      </strong>",
"      alcium level,",
"      <strong>",
"       r",
"      </strong>",
"      enal insufficiency,",
"      <strong>",
"       a",
"      </strong>",
"      nemia, and lytic",
"      <strong>",
"       b",
"      </strong>",
"      one lesions typically detected by radiographic survey. Note: In order to be included as diagnostic criteria, changes in the above factors must be felt to be related to the underlying plasma cell proliferative disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H2#H2\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Verification of the diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Connective tissue disorders, metastatic carcinoma, lymphoma, and leukemia may share some of the features of MM and must be excluded in the differential diagnosis. In addition, MM must be differentiated from monoclonal gammopathy of undetermined significance (MGUS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/84,85\">",
"     84,85",
"    </a>",
"    ] and smoldering multiple myeloma (SMM) (",
"    <a class=\"graphic graphic_table graphicRef57627 \" href=\"mobipreview.htm?41/38/42603\">",
"     table 2",
"    </a>",
"    ), (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Differential diagnosis'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic criteria for MM are evolving as we increase our understanding of the pathobiology of plasma cell dyscrasias and identify better biomarkers of aggressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/87\">",
"     87",
"    </a>",
"    ]. The traditional diagnostic criteria described above rely heavily on the clinician to judge the presence of end organ damage and do not allow for the diagnosis of malignancy prior to the development of end organ damage. Efforts are underway to identify patients without end organ disease who will inevitably progress. As an example, patients without end organ damage who have 60 percent or more clonal bone marrow plasma cells almost inevitably progress to overt MM within two years (median time to progression is seven months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/88\">",
"     88",
"    </a>",
"    ]. Therefore, most experts now agree that such patients are best considered as having MM even in the absence of end-organ damage.",
"   </p>",
"   <p>",
"    Other biomarkers that predict a high likelihood of progression are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/87\">",
"     87",
"    </a>",
"    ]: high involved over uninvolved free light chain ratio (&ge;100); high levels of circulating plasma cells; absence (&lt;5 percent) of normal plasma cells by immunophenotyping; high bone marrow plasma cell proliferative rate by S-phase assessment on multiparametric flow cytometry; deletion 17p on cytogenetic studies; &ge;3 focal lesions on MRI studies; significant increases in monoclonal protein or light chain levels over time; and an unexplained decrease in creatinine clearance by &ge;25 percent accompanied by a rise in urinary M protein or serum free light chain levels. Identification of the optimal cut offs and validation of these biomarkers are needed before these can be fully integrated into the diagnostic criteria. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish MM both from benign causes, which can present with similar manifestations and from other plasma cell dyscrasias for the purposes of prognosis and treatment. The diagnostic approaches to patients with hypercalcemia or acute renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main conditions to consider in the differential diagnosis of MM are monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/86\">",
"     86",
"    </a>",
"    ], Waldenstr&ouml;m macroglobulinemia, solitary plasmacytoma, primary amyloidosis (AL), POEMS syndrome, and metastatic carcinoma. Distinguishing features of these conditions are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Monoclonal gammopathy of undetermined significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal gammopathy of undetermined significance (MGUS) is diagnosed in persons who meet the following three criteria (",
"    <a class=\"graphic graphic_table graphicRef57627 \" href=\"mobipreview.htm?41/38/42603\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum monoclonal protein (whether IgA, IgG, or IgM) &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Clonal bone marrow plasma cells &lt;10 percent",
"     </li>",
"     <li>",
"      Absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency (end-organ damage) that can be attributed to the plasma cell proliferative disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MGUS carries a risk of progression to MM of approximately 1 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/85\">",
"     85",
"    </a>",
"    ]. Differentiation of MGUS from MM can be difficult and is primarily based on presence or absence of related end-organ damage. In comparison to overt MM or plasma cell leukemia, most patients with MGUS or SMM have few or no circulating monoclonal plasma cells. The use of other clinical and laboratory factors to differentiate between these two entities is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Multiple myeloma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Smoldering multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoldering multiple myeloma (SMM), also called asymptomatic multiple myeloma, is diagnosed in persons who meet the following criteria (",
"    <a class=\"graphic graphic_table graphicRef57627 \" href=\"mobipreview.htm?41/38/42603\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/78,86\">",
"     78,86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum monoclonal protein &ge;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;10 to &lt;60 percent bone marrow clonal plasma cells",
"     </li>",
"     <li>",
"      Absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency (end-organ damage) that can be attributed to the plasma cell proliferative disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SMM is distinguished from MM based upon the lack of end-organ damage and from MGUS based on the size of the M protein and the percent plasma cells in the bone marrow. The risk of progression of SMM to overt MM or amyloidosis is approximately 10 percent per year in the first five years, 3 percent per year in the next five years, and 1 to 2 percent per year thereafter, resulting in a cumulative probability of progression to MM or amyloidosis of 73 percent at 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. These values for disease progression in SMM are considerably higher than the above-noted rate of progression of MGUS to MM of 1 percent per year, necessitating that patients with SMM be followed more frequently (eg, once every three to four months, at least initially).",
"   </p>",
"   <p>",
"    Patients with SMM should have less than 60 percent bone marrow clonal plasma cells. Patients who have 60 percent or more clonal bone marrow plasma cells rarely present without end-organ damage attributable to the plasma cell disorder, and even if they do present as such, they almost inevitably progress to overt multiple myeloma within two years (median time to progression is seven months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/88\">",
"     88",
"    </a>",
"    ]. Therefore, such patients are best considered as having multiple myeloma even in the absence of end-organ damage.",
"   </p>",
"   <p>",
"    Risk factors for progression include the serum monoclonal protein level, the proportion of plasma cells in the bone marrow, the serum free light chain ratio, and MRI of the spine and pelvis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large retrospective study from the Mayo Clinic evaluated the added value of incorporating the free light chain (FLC) ratio into a prognostic score for patients with SMM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/93\">",
"       93",
"      </a>",
"      ]. The following three risk factors each had significant prognostic value: bone marrow plasma cells more than 10 percent; serum M protein more than 30",
"      <span class=\"nowrap\">",
"       g/L;",
"      </span>",
"      and abnormal FLC ratio less than 0.125 or more than 8. The probability of progression at five years was 25, 51, and 76 percent for patients who had one, two, or three of these risk factors, respectively. Based on this study, a baseline serum free light chain assay for risk-stratification is recommended at diagnosis in patients with SMM.",
"     </li>",
"     <li>",
"      The presence of more than one focal lesion or the presence of diffuse marrow involvement on MRI are significantly associated with an increased likelihood of progression to symptomatic multiple myeloma (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Radiographic studies'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there are doubts about the differentiation of",
"    <span class=\"nowrap\">",
"     MGUS/SMM",
"    </span>",
"    from myeloma, and whether to begin chemotherapy immediately, one should withhold treatment and reevaluate in two or three months. Patients with SMM may remain stable for prolonged periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/86,94\">",
"     86,94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Waldenstr&ouml;m macroglobulinemia and IgM multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waldenstr&ouml;m macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating lymphoplasmacytic lymphoma (LPL) in the bone marrow with an IgM monoclonal gammopathy in the blood. Patients may present with symptoms related to the infiltration of the hematopoietic tissues or the effects of monoclonal IgM in the blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, the distinction between Waldenstr&ouml;m macroglobulinemia and multiple myeloma is straightforward since the clinical features are different, and the type of M protein seen in Waldenstr&ouml;m macroglobulinemia is unique (IgM). The lymphoplasmacytic lymphoma seen in the bone marrow of patients with WM can be distinguished from plasma cells seen in the bone marrow of patients with MM by the absence of CD56 and the presence of a substantial small lymphocytic component that expresses a clonal surface immunoglobulin, CD19, and CD20. Some patients with MM and t(11;14) may have lymphoplasmacytic or small mature plasma cell morphology, along with CD20 expression that may resemble Waldenstr&ouml;m macroglobulinemia. However, the t(11;14) translocation is not seen in WM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link&amp;anchor=H9#H9\">",
"     \"Staging and prognostic studies in multiple myeloma\", section on 'Fluorescent in situ hybridization (FISH)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classic MM with an IgM paraprotein (IgM multiple myeloma) is extremely rare, comprising only 0.5 percent of the Mayo Clinic series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"     8",
"    </a>",
"    ]. The Mayo Clinic criteria for diagnosis of IgM myeloma (and its differentiation from Waldenstr&ouml;m macroglobulinemia) require presence of either lytic bone lesions felt secondary to the plasma cell disorder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of the t(11;14) translocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/95\">",
"     95",
"    </a>",
"    ]. The criteria are conservative and designed to emphasize specificity over sensitivity, and ensure that patients with Waldenstr&ouml;m macroglobulinemia are not misclassified and treated as myeloma patients based on less reliable and subjective measures such as CD20 expression or morphology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Solitary plasmacytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmacytomas are tumors composed of plasma cells of variable maturity, which are histologically identical to those seen in MM. If they occur solely in the bone, they are designated solitary plasmacytoma of bone. If they arise outside bone in soft tissues, they are called solitary extramedullary plasmacytoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44535?source=see_link\">",
"     \"Diagnosis and management of solitary plasmacytoma of bone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16662?source=see_link\">",
"     \"Diagnosis and management of solitary extramedullary plasmacytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To make the diagnosis of solitary plasmacytoma, the following four criteria must be met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopsy-proven solitary lesion of the bone or soft tissue that demonstrates clonal plasma cells.",
"     </li>",
"     <li>",
"      Normal bone marrow with no evidence of clonal plasma cells.",
"     </li>",
"     <li>",
"      Skeletal survey and MRI of the spine and pelvis are normal except for the primary solitary lesion.",
"     </li>",
"     <li>",
"      Absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Note that patients who have a biopsy-proven solitary medullary or extramedullary lesion with evidence of clonal plasma cells in the bone marrow are usually treated in a similar fashion to those with solitary plasmacytoma, but technically are considered to have either &ldquo;solitary plasmacytoma with associated MGUS&rdquo; if clonal bone marrow plasma cells are &lt;10 percent, or multiple myeloma (typically Durie-Salmon stage 1) if clonal bone marrow plasma cells are &ge;10 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link\">",
"     \"Staging and prognostic studies in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with MM, AL (amyloid light chain) amyloidosis (previously referred to as primary amyloidosis) and light chain deposition disease are plasma cell proliferative disorders associated with the overproduction of monoclonal light chains. However, patients with primary amyloidosis or light chain deposition disease develop tissue deposits of amyloid fibrils or non-fibrillar material that can produce the nephrotic syndrome, heart failure, hepatomegaly, and other findings that are not seen in MM.",
"   </p>",
"   <p>",
"    In contrast to patients with MM, patients with AL amyloidosis usually demonstrate less than 20 percent bone marrow plasma cells, no lytic bone lesions on imaging, and a modest amount of Bence Jones proteinuria. The diagnosis of primary amyloidosis is established by demonstrating amyloid on a biopsy of affected tissue, such as abdominal fat, bone marrow, rectum, or kidney. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, MM can develop in patients with primary amyloidosis. In a series of 1596 patients with primary amyloidosis seen at the Mayo Clinic between 1960 and 1994, only 6 (0.4 percent) showed delayed progression (at 10 to 81 months) to overt MM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/13/35034/abstract/96\">",
"     96",
"    </a>",
"    ]. This usually occurs in patients without cardiac or hepatic amyloid who live long enough to develop MM. On the other hand, the development of dipstick-positive proteinuria, hypoalbuminemia, and edema or heart failure in a patient with known MM suggests superimposed amyloidosis or light chain deposition disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     POEMS syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;POEMS syndrome (osteosclerotic myeloma:",
"    <strong>",
"     P",
"    </strong>",
"    olyneuropathy,",
"    <strong>",
"     O",
"    </strong>",
"    rganomegaly,",
"    <strong>",
"     E",
"    </strong>",
"    ndocrinopathy,",
"    <strong>",
"     M",
"    </strong>",
"    onoclonal protein,",
"    <strong>",
"     S",
"    </strong>",
"    kin changes) is a monoclonal plasma cell disorder accompanied by symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of peripheral neuropathy, osteosclerotic lesions, Castleman's disease, organomegaly, endocrinopathy (excluding diabetes mellitus or hypothyroidism), edema, typical skin changes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    papilledema. These patients typically have elevated serum VEGF (vascular endothelial growth factor) levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"     \"POEMS syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polyneuropathy is uncommon in classical MM, and when present is usually due to the presence of amyloidosis. The presence of anemia, hypercalcemia, renal failure, pathologic fractures, and a high percent of plasma cells in the bone marrow all serve to distinguish classical MM from POEMS syndrome.",
"   </p>",
"   <p>",
"    In rare instances, MM may be associated with the presence of diffuse osteosclerotic bone lesions. Such patients have the typical clinical and laboratory features of MM and do not have the other characteristics of POEMS syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Metastatic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of lytic bone lesions in a patient with a monoclonal gammopathy suggests the possibility of MM. However, metastatic carcinoma (eg, kidney, breast, non-small cell lung cancer) can produce lytic lesions, and a subset of patients presenting in this way will have metastatic cancer with an associated, unrelated monoclonal gammopathy (eg, MGUS). Persons presenting with lytic bone lesions, constitutional symptoms, a small M component, and fewer than 10 percent clonal plasma cells in the bone marrow, are more likely to have metastatic carcinoma with an unrelated MGUS rather than multiple myeloma. This can be confirmed with a biopsy of the bone lesion.",
"   </p>",
"   <p>",
"    Similarly, for patients with lytic lesions in whom no M-protein is found in the serum or urine, metastatic carcinoma should be excluded before the diagnosis of nonsecretory myeloma is seriously considered, by performing a biopsy of one of the lytic lesions (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"mobipreview.htm?21/17/21787\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma is a heterogeneous disease with some patients progressing rapidly despite treatment and others not requiring therapy for a number of years. Distinction between these two groups is important so that treatment can be initiated in appropriate patients and postponed in those who do not need it. The prognosis of MM is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=see_link\">",
"     \"Staging and prognostic studies in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/26/29090?source=see_link\">",
"       \"Patient information: Multiple myeloma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple myeloma (MM) is characterized by the neoplastic proliferation of immunoglobulin-producing plasma cells. Most patients with MM present with signs or symptoms related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. Common presentations include anemia, bone pain, elevated creatinine or serum protein, fatigue, and hypercalcemia. Less common, but emergent presentations include spinal cord compression and severe hypercalcemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with suspected myeloma or related disorders, appropriate initial screening tests include a serum protein electrophoresis along with immunofixation, and a serum free light chain assay. A 24-hour urine collection for electrophoresis and immunofixation must be done if a diagnosis of multiple myeloma is made. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation to confirm the diagnosis of MM includes a bone marrow aspiration and biopsy, a metastatic bone survey, a complete blood count with differential and a chemistry screen. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are some exceptions, the diagnosis of symptomatic MM is usually made by meeting the following three criteria (",
"      <a class=\"graphic graphic_table graphicRef57627 \" href=\"mobipreview.htm?41/38/42603\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Presence of an M-protein in serum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine",
"     </li>",
"     <li>",
"      Presence of 10 percent or more clonal bone marrow plasma cells or a biopsy proven plasmacytoma",
"     </li>",
"     <li>",
"      Presence of related organ or tissue impairment that can be attributed to the plasma cell proliferative disorder (eg, increased calcium, renal insufficiency, anemia, lytic bone lesions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltration with malignant plasma cells may be focal, requiring",
"      <span class=\"nowrap\">",
"       aspiration/biopsy",
"      </span>",
"      at multiple sites. Imaging with MRI",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PET scan can be helpful in locating focal disease. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Bone marrow examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Radiographic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for MM includes monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), Waldenstr&ouml;m macroglobulinemia, solitary plasmacytoma, AL amyloidosis, POEMS syndrome, and metastatic carcinoma. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/1\">",
"      Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM 2007; 100:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/3\">",
"      Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/4\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/5\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/6\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer 2004; 101:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/7\">",
"      Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010; 85:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/8\">",
"      Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/9\">",
"      Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010; 116:5501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/10\">",
"      Huang SY, Yao M, Tang JL, et al. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer 2007; 110:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/11\">",
"      Blad&eacute; J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998; 30:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/12\">",
"      Lynch HT, Sanger WG, Pirruccello S, et al. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2001; 93:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/13\">",
"      Lynch HT, Watson P, Tarantolo S, et al. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 2005; 23:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/14\">",
"      Lynch HT, Ferrara K, Barlogie B, et al. Familial myeloma. N Engl J Med 2008; 359:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/15\">",
"      Camp NJ, Werner TL, Cannon-Albright LA. Familial myeloma. N Engl J Med 2008; 359:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/16\">",
"      Jain M, Ascensao J, Schechter GP. Familial myeloma and monoclonal gammopathy: a report of eight African American families. Am J Hematol 2009; 84:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/17\">",
"      Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009; 114:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/18\">",
"      Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009; 114:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/19\">",
"      Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 1999; 85:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/20\">",
"      Maldonado JE, Kyle RA. Familial myeloma. Report of eight families and a study of serum proteins in their relatives. Am J Med 1974; 57:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/21\">",
"      Deshpande HA, Hu XP, Marino P, et al. Anticipation in familial plasma cell dyscrasias. Br J Haematol 1998; 103:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/22\">",
"      Grosbois B, Jego P, Attal M, et al. Familial multiple myeloma: report of fifteen families. Br J Haematol 1999; 105:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/23\">",
"      Sobol H, Vey N, Sauvan R, et al. Re: familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2002; 94:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/24\">",
"      Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/25\">",
"      Satta R, Casu G, Dore F, et al. Follicular spicules and multiple ulcers: cutaneous manifestations of multiple myeloma. J Am Acad Dermatol 2003; 49:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/26\">",
"      Baz R, Alemany C, Green R, Hussein MA. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer 2004; 101:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/27\">",
"      Winearls CG. Acute myeloma kidney. Kidney Int 1995; 48:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/28\">",
"      Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 2012; 44:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/29\">",
"      Blad&eacute; J, Fern&aacute;ndez de Larrea C, Rosi&ntilde;ol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011; 29:3805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/30\">",
"      Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 2011; 118:3777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/31\">",
"      Annesley TM, Burritt MF, Kyle RA. Artifactual hypercalcemia in multiple myeloma. Mayo Clin Proc 1982; 57:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/32\">",
"      Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999; 62:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/33\">",
"      Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/34\">",
"      Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. Arch Neurol 2004; 61:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/35\">",
"      Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004; 127:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/36\">",
"      Chamberlain MC, Glantz M. Myelomatous meningitis. Cancer 2008; 112:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/37\">",
"      Gozzetti A, Cerase A, Lotti F, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer 2012; 118:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/38\">",
"      Chang H, Bartlett ES, Patterson B, et al. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol 2005; 129:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/39\">",
"      Kwan L, Wang C, Levitt L. Hyperammonemic encephalopathy in multiple myeloma. N Engl J Med 2002; 346:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/40\">",
"      Matsuzaki H, Hata H, Sonoki T, et al. Serum amino acid disturbance in multiple myeloma with hyperammonemia. Int J Hematol 1995; 61:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/41\">",
"      Talamo G, Cavallo F, Zangari M, et al. Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol 2007; 82:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/42\">",
"      Otsuki T, Yamada O, Sakaguchi H, et al. In vitro excess ammonia production in human myeloma cell lines. Leukemia 1998; 12:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/43\">",
"      Blad&eacute; J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994; 12:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/44\">",
"      Matta GM, Battaglio S, Dibello C, et al. Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. Clin Cancer Res 2007; 13:5348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/45\">",
"      Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/46\">",
"      Singhal S, Vickrey E, Krishnamurthy J, et al. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009; 114:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/47\">",
"      Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/48\">",
"      Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma. N Engl J Med 2012; 367:580.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/50\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/51\">",
"      Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/52\">",
"      D'Sa S, Abildgaard N, Tighe J, et al. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007; 137:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/53\">",
"      Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/54\">",
"      Kim PJ, Hicks RJ, Wirth A, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys 2009; 74:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/55\">",
"      Blad&eacute; J, Dimopoulos M, Rosi&ntilde;ol L, et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010; 28:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/56\">",
"      Tryciecky EW, Gottschalk A, Ludema K. Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med 1997; 27:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/57\">",
"      Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/58\">",
"      Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/59\">",
"      Angtuaco EJ, Fassas AB, Walker R, et al. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004; 231:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/60\">",
"      Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med 1985; 145:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/61\">",
"      Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997; 90:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/62\">",
"      Mahnken AH, Wildberger JE, Gehbauer G, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002; 178:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/63\">",
"      Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008; 190:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/64\">",
"      Baur A, St&auml;bler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002; 95:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/65\">",
"      Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999; 104:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/66\">",
"      Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/67\">",
"      B&auml;uerle T, Hillengass J, Fechtner K, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 2009; 252:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/68\">",
"      Ailawadhi S, Abdelhalim AN, Derby L, et al. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer 2010; 116:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/69\">",
"      Durie BG, Nguyen K, Joselson M, et al. Technetium-99-MIBI scanning in multiple myeloma: Comparison with PET (FDG) scanning. Cancer Res Ther Control 1998; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/70\">",
"      el-Shirbiny AM, Yeung H, Imbriaco M, et al. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 1997; 38:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/71\">",
"      Bredella MA, Steinbach L, Caputo G, et al. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005; 184:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/72\">",
"      Shortt CP, Gleeson TG, Breen KA, et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 2009; 192:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/73\">",
"      Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/74\">",
"      van Lammeren-Venema D, Regelink JC, Riphagen II, et al. &sup1;���F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer 2012; 118:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/75\">",
"      McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/76\">",
"      Pahade JK, LeBedis CA, Raptopoulos VD, et al. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol 2011; 196:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/77\">",
"      Smith A, Wisloff F, Samson D, et al. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/78\">",
"      International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/79\">",
"      Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/80\">",
"      Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117:4701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/81\">",
"      Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/82\">",
"      Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/83\">",
"      Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstr&ouml;m macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/84\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/85\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/86\">",
"      Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/87\">",
"      Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol 2012; 9:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/88\">",
"      Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/89\">",
"      Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/90\">",
"      Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/91\">",
"      Witzig TE, Gertz MA, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996; 88:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/92\">",
"      Rosi&ntilde;ol L, Blad&eacute; J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003; 123:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/93\">",
"      Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/94\">",
"      Kyle RA. \"Benign\" monoclonal gammopathy--after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/95\">",
"      Schuster SR, Rajkumar SV, Dispenzieri A, et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol 2010; 85:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/13/35034/abstract/96\">",
"      Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998; 82:1501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6649 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35034=[""].join("\n");
var outline_f34_13_35034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bone pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Typical pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Light chain myeloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Non-secretory myeloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H607174\">",
"      - Oligo-secretory myeloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Laboratory artifacts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cytogenetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RADIOGRAPHIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Skeletal surveys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Smoldering multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Waldenstr&ouml;m macroglobulinemia and IgM multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Solitary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Metastatic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6649|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/14/25831\" title=\"diagnostic image 1\">",
"      Plasmacytoma CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/58/14245\" title=\"diagnostic image 2\">",
"      Extradural plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/20/44357\" title=\"diagnostic image 3\">",
"      Lytic bone disease and PET positive scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/58/7087\" title=\"diagnostic image 4\">",
"      Immunoglobin pattern MM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/0/3076\" title=\"diagnostic image 5\">",
"      MM lytic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/41/40595\" title=\"diagnostic image 6\">",
"      Lytic lesions in the radius",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/48/34565\" title=\"diagnostic image 7\">",
"      Multiple myeloma effect on vertebral bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6649|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/3/21566\" title=\"figure 1\">",
"      Monoclonal pattern on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/1/29727\" title=\"figure 2\">",
"      Biclonal gammopathy on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/39/4735\" title=\"figure 3\">",
"      Monoclonal pattern immunofixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/57/1951\" title=\"figure 4\">",
"      Free light chains serum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/20/7503\" title=\"figure 5\">",
"      Bence Jones protein UPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43824\" title=\"figure 6\">",
"      Bence Jones protein immunofix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6649|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/21/32082\" title=\"picture 1\">",
"      Extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/40/41603\" title=\"picture 2A\">",
"      Myeloma cast I-light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/30/33253\" title=\"picture 2B\">",
"      Myeloma cast II- light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/60/13248\" title=\"picture 2C\">",
"      Myeloma kidney-immunofluorescence microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/33/28183\" title=\"picture 3\">",
"      Rouleaux in myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/27/19888\" title=\"picture 4\">",
"      Plasma cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/12/33990\" title=\"picture 5\">",
"      Multiple myeloma marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/45/28372\" title=\"picture 6\">",
"      Flame cell myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/17/21787\" title=\"table 1\">",
"      Typical radiographic response in bone to select tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/38/42603\" title=\"table 2\">",
"      Diagnostic criteria for myeloma MGUS and SMM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16662?source=related_link\">",
"      Diagnosis and management of solitary extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44535?source=related_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22551?source=related_link\">",
"      Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/26/29090?source=related_link\">",
"      Patient information: Multiple myeloma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16039?source=related_link\">",
"      Plasma cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36533?source=related_link\">",
"      Serum anion gap in conditions other than metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10618?source=related_link\">",
"      Staging and prognostic studies in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_13_35035="Autoimmune disorders with adrenal insufficiency";
var content_f34_13_35035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of other autoimmune diseases in 365 patients with autoimmune adrenal insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Thyroid disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothyroidism",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nontoxic goiter",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperthyroidism",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Gonadal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ovarian",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Testicular",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 1 diabetes mellitus",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoparathyroidism",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pernicious anemia",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"       <td class=\"centered\">",
"        53",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Compiled from multiple reports.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35035=[""].join("\n");
var outline_f34_13_35035=null;
var title_f34_13_35036="Differential glomerular disease";
var content_f34_13_35036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of glomerular disease according to clinical features",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mild glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Active urine sediment without renal insufficiency or nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Less than 15 years of age - Mild postinfectious glomerulonephritis, IgA nephropathy, thin basement membrane disease, hereditary nephritis, Henoch-Sch&ouml;nlein purpura, mesangial proliferative glomerulonephritis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          15 to 40 years of age - IgA nephropathy, thin basement membrane disease, lupus, hereditary nephritis, mesangial proliferative glomerulonephritis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Greater than 40 years of age - IgA nephropathy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Moderate to severe glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Active urine sediment with renal insufficiency and variable proteinuria, which can include nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Less than 15 years of age - Postinfectious glomerulonephritis, membranoproliferative glomerulonephritis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          15 to 40 years of age - Postinfectious glomerulonephritis, lupus, rapidly progressive glomerulonephritis, fibrillary glomerulonephritis, membranoproliferative glomerulonephritis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Greater than 40 years of age - Rapidly progressive glomerulonephritis, vasculitis (including mixed cryoglobulinemia), fibrillary glomerulonephritis, postinfectious glomerulonephritis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Heavy proteinuria, bland sediment although some hematuria allowed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Less than 15 years of age - Minimal change disease, focal glomerulosclerosis, mesangial proliferative glomerulonephritis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          15 to 40 years of age - Focal glomerulosclerosis, minimal change disease, membranous nephropathy (including lupus), diabetic nephropathy, preeclampsia, postinfectious glomerulonephritis (later stage)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Greater than 40 years of age - Focal glomerulosclerosis, membranous nephropathy, diabetic nephropathy, minimal change disease, IgA nephropathy, primary amyloidosis or the related disorder light chain deposition disease (which can account for 15 to 20 percent of cases in patients over the age of 60), benign nephrosclerosis, postinfectious glomerulonephritis (later stage)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35036=[""].join("\n");
var outline_f34_13_35036=null;
var title_f34_13_35037="Mechanisms of glucocorticoid insensitivity in severe asthma";
var content_f34_13_35037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F88276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F88276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanisms implicated in glucocorticoid insensitivity in severe asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A number of factors including infection, oxidative stress (either directly or indirectly from cigarette smoking), allergen exposure (leading to Th2 cytokine expression), inflammation (eg, IL-17 production from Th17 and other cells), and a lack of vitamin D3 can modulate glucocorticoid function and have been shown to be important in patients with glucocorticoid resistant asthma. Drugs that target these abnormal processes or signalling pathways may prove of benefit in severe asthma.",
"    <div class=\"footnotes\">",
"     IL: interleukin; LPS: lipopolysaccharide; ROS: reactive oxygen species; TH17: IL-17-producing T helper lymphocytes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35037=[""].join("\n");
var outline_f34_13_35037=null;
var title_f34_13_35038="Muscle biopsy DM IF";
var content_f34_13_35038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vascular involvement in DM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 195px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Muscle biopsy in a patient with dermatomyositis showing vascular C5b-9 deposition in the perimysial blood vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35038=[""].join("\n");
var outline_f34_13_35038=null;
var title_f34_13_35039="Hidradenitis suppurativa draining inflammatory nodule";
var content_f34_13_35039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hidradenitis suppurativa draining inflammatory nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows an inflammatory draining nodule. The patient was diagnosed with hidradenitis suppurativa in the groin, the nodule is medial to left inguinal crease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_13_35039=[""].join("\n");
var outline_f34_13_35039=null;
